S3-Leitlinie Diagnostik und Therapie des Hepatozellulären Karzinoms – Langversion

Michael Bitzer; Sabrina Groß; Jörg Albert; Susanne Blödt; Judit Boda-Heggemann; Katrin Borucki; Thomas Brunner; Reiner Caspari; Frank Dombrowski; Matthias Evert; Markus Follmann; Paul Freudenberger; Cihan Gani; Jamila Gebert; Andreas Geier; Eleni Gkika; Martin Götz; Thomas Helmberger; Ralf-Thorsten Hoffmann; Peter Huppert; David Krug; Christian La Fougère; Hauke Lang; Thomas Langer; Philipp Lenz; Tom Lüdde; Andreas Mahnken; Silvio Nadalin; Hoa Huu Phuc Nguyen; Monika Nothacker; Johann Ockenga; Karl Oldhafer; Julia Ott; Philipp Paprottka; Philippe Pereira; Thorsten Persigehl; Ruben Plentz; Jürgen Pohl; Heinrich Recken; Peter Reimer; Jutta Riemer; Kristina Ringe; Elke Roeb; Jörn Rüssel; Barbara Schellhaas; Peter Schirmacher; Hans Jürgen Schlitt; Irene Schmid; Kerstin Schütte; Andreas Schuler; Daniel Seehofer; Marianne Sinn; Andreas Stengel; Nadine Steubesand; Christoph Stoll; Andrea Tannapfel; Anne Taubert; Jörg Trojan; Ingo van Thiel; Martin Utzig; Arndt Vogel; Thomas Vogl; Frank Wacker; Oliver Waidmann; Heiner Wedemeyer; Henning Wege; Gregor Wenzel; Dane Wildner; Marcus-Alexander Wörns; Peter Galle; Nisar Malek

doi:10.1055/a-2460-6298

Zeitschrift für Gastroenterologie, Inhaltsverzeichnis

Z Gastroenterol 2025; 63(03): e159-e260
DOI: 10.1055/a-2460-6298

Leitlinie

S3-Leitlinie Diagnostik und Therapie des Hepatozellulären Karzinoms – Langversion

Version 5.1 – August 2024 – AWMF-Registernummer:032-053OL

Autor*innen

Michael Bitzer

¹Abteilung für Gastroenterologie, Gastrointestinale Onkologie, Hepatologie, Infektiologie und Geriatrie, Eberhard-Karls Universität, Tübingen
Sabrina Groß

¹Abteilung für Gastroenterologie, Gastrointestinale Onkologie, Hepatologie, Infektiologie und Geriatrie, Eberhard-Karls Universität, Tübingen
Jörg Albert

²Katharinenhospital, Klinik für Allgemeine Innere Medizin, Gastroenterologie, Hepatologie, Infektiologie und Pneumologie, Stuttgart
Susanne Blödt

³Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e. V. (AWMF), Berlin
Judit Boda-Heggemann

⁴Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Mannheim
Katrin Borucki

⁵Otto-von-Guericke-Universität Magdeburg, Medizinische Fakultät, Institut für Klinische Chemie und Pathobiochemie
Thomas Brunner

⁶Universitätsklinik für Strahlentherapie-Radioonkologie, Medizinische Universität Graz
Reiner Caspari

⁷Klinik Niederrhein Erkrankungen des Stoffwechsels der Verdauungsorgane und Tumorerkrankungen, Bad Neuenahr-Ahrweiler
Frank Dombrowski

⁸Institut für Pathologie, Universität Greifswald
Matthias Evert

⁹Institut für Pathologie, Universität Regensburg
Markus Follmann

¹⁰Office des Leitlinienprogrammes Onkologie, Deutsche Krebsgesellschaft e.V., Berlin
Paul Freudenberger

¹¹Clinical Guideline Services GmbH (CGS), Berlin/Kiel
Cihan Gani

¹²Klinik für Radioonkologie, Universitätsklinikum Tübingen
Jamila Gebert

¹Abteilung für Gastroenterologie, Gastrointestinale Onkologie, Hepatologie, Infektiologie und Geriatrie, Eberhard-Karls Universität, Tübingen
Andreas Geier

¹³Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg
Eleni Gkika

¹⁴Klinik für Strahlenheilkunde, Department für Radiologische Diagnostik und Therapie, Universitätsklinikum Freiburg
Martin Götz

¹⁵Medizinische Klinik IV – Gastroenterologie/Onkologie, Klinikverbund Südwest, Böblingen
Thomas Helmberger

¹⁶Institut für Radiologie, Neuroradiologie und minimal invasive Therapie, München Klinik Bogenhausen
Ralf-Thorsten Hoffmann

¹⁷Institut und Poliklinik für Diagnostische und Interventionelle Radiologie, Universitätsklinikum Dresden
Peter Huppert

¹⁸Radiologisches Zentrum, Max Grundig Klinik, Bühlerhöhe
David Krug

¹⁹Strahlentherapie Campus Kiel, Universitätsklinikum Schleswig-Holstein
Christian La Fougère

²⁰Nuklearmedizin und Klinische Molekulare Bildgebung, Eberhard-Karls Universität, Tübingen
Hauke Lang

²¹Klinik für Allgemein-, Viszeral- und Transplantationschirurgie, Johannes Gutenberg-Universität, Mainz
Thomas Langer

¹⁰Office des Leitlinienprogrammes Onkologie, Deutsche Krebsgesellschaft e.V., Berlin
Philipp Lenz

²²Zentrale Einrichtung Palliativmedizin, Universitätsklinikum Münster
Tom Lüdde

²³Medizinische Klinik für Gastroenterologie, Hepatologie und Infektiologie, Universitätsklinikum Düsseldorf
Andreas Mahnken

²⁴Klinik für Diagnostische und Interventionelle Radiologie, Universitätsklinikum Marburg
Silvio Nadalin

²⁵Klinik für Allgemein-, Viszeral- und Transplantationschirurgie, Eberhard-Karls Universität, Tübingen
Hoa Huu Phuc Nguyen

²⁶MVZ Katholisches Klinikum Bochum
Monika Nothacker

³Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e. V. (AWMF), Berlin
Johann Ockenga

²⁷Medizinische Klinik II, Gesundheit Nord, Klinikverbund Bremen
Karl Oldhafer

²⁸Klinik für Leber-, Gallenwegs- und Pankreaschirurgie, Asklepios Klinik Barmbek
Julia Ott

¹Abteilung für Gastroenterologie, Gastrointestinale Onkologie, Hepatologie, Infektiologie und Geriatrie, Eberhard-Karls Universität, Tübingen
Philipp Paprottka

²⁹Sektion für Interventionelle Radiologie, Klinikum rechts der Isar, Technische Universität München
Philippe Pereira

³⁰Zentrum für Radiologie, Minimal-invasive Therapien und Nuklearmedizin, SLK-Klinken Heilbronn
Thorsten Persigehl

³¹Institut für Diagnostische und Interventionelle Radiologie, Universitätsklinikum Köln
Ruben Plentz

³²Digestive Diseases and Nutrition, Gastroenterology, University of Kentucky
Jürgen Pohl

³³Abteilung für Gastroenterologie, Asklepios Klinik Altona
Heinrich Recken

³⁴Hamburger Fern-Hochschule
Peter Reimer

³⁵Institut für Diagnostische und Interventionelle Radiologie, Städtisches Klinikum Karlsruhe
Jutta Riemer

³⁶Lebertransplantierte e.V.
Kristina Ringe

³⁷Institut für Diagnostische und Interventionelle Radiologie, Medizinische Hochschule Hannover
Elke Roeb

³⁸Medizinische Klinik II Pneumologie, Nephrologie und Gastroenterologie, Universitätsklinikum Gießen
Jörn Rüssel

³⁹Medizinische Klinik IV Hämatologie und Onkologie, Universitätsklinikum Halle (Saale)
Barbara Schellhaas

⁴⁰Medizinische Klinik I Gastroenterologie, Pneumologie und Endokrinologie, Friedrich-Alexander-Universität, Erlangen
Peter Schirmacher

⁴¹Allgemeine Pathologie und pathologische Anatomie, Universitätsklinikum Heidelberg
Hans Jürgen Schlitt

⁴²Klinik und Poliklinik für Chirurgie, Universitätsklinikum Regensburg
Irene Schmid

⁴³Kinderklinik und Kinderpoliklinik im Dr. von Haunerschen Kinderspital, LMU München
Kerstin Schütte

⁴⁴Klinik für Innere Medizin und Gastroenterologie, Niels-Stensen-Kliniken, Marienhospital Osnabrück
Andreas Schuler

⁴⁵Medizinische Klinik, Gastroenterologie, Alb-Fils-Kliniken, Geislingen an der Steige
Daniel Seehofer

⁴⁶Klinik und Poliklinik für Viszeral-, Transplantations-, Thorax- und Gefäßchirurgie, Universitätsklinikum Leipzig
Marianne Sinn

⁴⁷II. Medizinische Klinik und Poliklinik (Onkologie, Hämatologie, Knochenmarktransplantation mit Abteilung für Pneumologie), Universitätsklinikum Hamburg-Eppendorf
Andreas Stengel

⁴⁸Innere Medizin VI – Psychosomatische Medizin und Psychotherapie, Eberhard-Karls Universität, Tübingen
Nadine Steubesand

¹¹Clinical Guideline Services GmbH (CGS), Berlin/Kiel
Christoph Stoll

⁴⁹Klinik Herzoghöhe Bayreuth
Andrea Tannapfel

⁵⁰Institut für Pathologie, Ruhr-Universität Bochum
Anne Taubert

⁵¹Klinische Sozialarbeit, Universitätsklinikum Heidelberg
Jörg Trojan

⁵²Medizinische Klinik 1: Gastroenterologie und Hepatologie, Pneumologie und Allergologie, Endokrinologie und Diabetologie sowie Ernährungsmedizin, Goethe-Universität, Frankfurt
Ingo van Thiel

⁵³Deutsche Leberhilfe e.V.
Martin Utzig

⁵⁴Abteilung Zertifizierung, Deutsche Krebsgesellschaft e.V., Berlin
Arndt Vogel

⁵⁵Institute of Medical Science, University of Toronto
Thomas Vogl

⁵⁶Institut für Diagnostische und Interventionelle Radiologie, Goethe-Universität, Frankfurt
Frank Wacker

³⁷Institut für Diagnostische und Interventionelle Radiologie, Medizinische Hochschule Hannover
Oliver Waidmann

⁵⁷Onkologie Bethanien, Frankfurt am Main
Heiner Wedemeyer

⁵⁸Klinik für Gastroenterologie, Hepatologie, Infektiologie und Endokrinologie, Medizinische Hochschule Hannover
Henning Wege

⁵⁹Klinik für Allgemeine Innere Medizin, Onkologie/Hämatologie, Gastroenterologie und Infektiologie, Klinikum Esslingen
Gregor Wenzel

¹⁰Office des Leitlinienprogrammes Onkologie, Deutsche Krebsgesellschaft e.V., Berlin
Dane Wildner

⁶⁰Innere Medizin, Krankenhäuser Nürnberger Land GmbH, Standort Lauf
Marcus-Alexander Wörns

⁶¹Klinik für Gastroenterologie, Hämatologie und internistische Onkologie und Endokrinologie, Klinikum Dortmund
Peter Galle

⁶²1. Medizinische Klinik und Poliklinik, Gastroenterologie, Hepatologie, Nephrologie, Rheumatologie, Infektiologie, Johannes Gutenberg-Universität, Mainz
Nisar Malek

¹Abteilung für Gastroenterologie, Gastrointestinale Onkologie, Hepatologie, Infektiologie und Geriatrie, Eberhard-Karls Universität, Tübingen

Abstract

Volltext

Referenzen

Literatur
1 Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53 (03) 1020-1022 https://pubmed.ncbi.nlm.nih.gov/21374666/
2 The Global Cancer Observatory. 2021 https://gco.iarc.fr/
3 Zentrum für Krebsregisterdaten. 2021 https://www.krebsdaten.de/
4 EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018; 69: 182-236 https://www.sciencedirect.com/science/article/pii/S0168827818302150
5 Sangiovanni A, Prati GM, Fasani P. et al. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology 2006; 43: 1303-1310
6 Ioannou GN, Splan MF, Weiss NS. et al. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2007; 5: 938-945, 945.e1-4
7 Kanwal F, Kramer JR, Asch SM. et al. Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents. Hepatology 2020; 71: 44-55
8 Kanwal F, Kramer JR, Mapakshi S. et al. Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. Gastroenterology 2018; 155: 1828-1837.e2 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279617/pdf/nihms-1504451.pdf
9 EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64: 1388-1402 https://pubmed.ncbi.nlm.nih.gov/27062661/
10 Frenette CT, Isaacson AJ, Bargellini I. et al. A Practical Guideline for Hepatocellular Carcinoma Screening in Patients at Risk. Mayo Clin Proc Innov Qual Outcomes 2019; 3: 302-310 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713857/pdf/main.pdf
11 Cucchetti A, Cescon M, Erroi V. et al. Cost-effectiveness of liver cancer screening. Best Pract Res Clin Gastroenterol 2013; 27: 961-972
12 Brouwer WP, van der Meer AJP, Boonstra A. et al. Prediction of long-term clinical outcome in a diverse chronic hepatitis B population: Role of the PAGE-B score. J Viral Hepat 2017; 24: 1023-1031
13 Papatheodoridis G, Dalekos G, Sypsa V. et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol 2016; 64: 800-806 https://www.sciencedirect.com/science/article/pii/S0168827815007953?via%3Dihub
14 Papatheodoridis GV, Lampertico P, Manolakopoulos S. et al. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 2010; 53: 348-356
15 Yuen MF, Tanaka Y, Fong DY. et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 2009; 50: 80-88 https://www.sciencedirect.com/science/article/pii/S0168827808005655?via%3Dihub
16 Yang HI, Yuen MF, Chan HL. et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol 2011; 12: 568-574 https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70077-8/fulltext
17 Wong VW, Chan SL, Mo F. et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol 2010; 28: 1660-1665
18 Yip TC, Wong GL, Wong VW. et al. Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B. J Hepatol 2020; 72: 847-854 https://www.sciencedirect.com/science/article/abs/pii/S0168827819307172?via%3Dihub
19 Marrero JA, Kulik LM, Sirlin CB. et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2018; 68: 723-750
20 Mittal S, El-Serag HB, Sada YH. et al. Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans is Associated With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2016; 14: 124-131.e1 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4690789/pdf/nihms709433.pdf
21 EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015; 63: 237-264
22 Thomas J, Kendall B, Dalais C. et al. Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Eur J Cancer 2022; 173: 250-262 https://pubmed.ncbi.nlm.nih.gov/35944373/
23 Loosen S, Kostev K, Keitel V. et al. An elevated FIB-4 score predicts liver cancer development: A longitudinal analysis from 29,999 patients with NAFLD. J Hepatol 2022; 76 (01) 247-248 https://pubmed.ncbi.nlm.nih.gov/34520785/
24 Castera L, Friedrich-Rust M, Loomba R. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2019; 156: 1264-1281.e4 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505052/pdf/nihms-1567724.pdf
25 Roeb E, Steffen HM, Bantel H. et al. [S2k Guideline non-alcoholic fatty liver disease]. Z Gastroenterol 2015; 53: 668-723
26 Roeb E, Geier A. Nonalcoholic steatohepatitis (NASH) – current treatment recommendations and future developments. Z Gastroenterol 2019; 57: 508-517
27 Angulo P, Hui JM, Marchesini G. et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-854
28 Tanwar S, Trembling PM, Hogan BJ. et al. Biomarkers of Hepatic Fibrosis in Chronic Hepatitis C: A Comparison of 10 Biomarkers Using 2 Different Assays for Hyaluronic Acid. J Clin Gastroenterol 2017; 51: 268-277 https://www.ingentaconnect.com/content/wk/jcga/2017/00000051/00000003/art00015;jsessionid=4j79pxsus6e3.x-ic-live-03
29 Kanwal F, Kramer J, Asch SM. et al. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Gastroenterology 2017; 153: 996-1005.e1 https://pubmed.ncbi.nlm.nih.gov/28642197/
30 Masuzaki R, Tateishi R, Yoshida H. et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology 2009; 49: 1954-1961
31 El-Serag HB, Kanwal F, Richardson P. et al. Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology 2016; 64: 130-137
32 Ioannou GN, Beste LA, Green PK. et al. Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores. Gastroenterology 2019; 157: 1264-1278.e4 https://www.sciencedirect.com/science/article/abs/pii/S001650851941130X?via%3Dihub
33 Omata M, Cheng AL, Kokudo N. et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 2017; 11: 317-370 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491694/pdf/12072_2017_Article_9799.pdf
34 Younes R, Bugianesi E. Should we undertake surveillance for HCC in patients with NAFLD?. J Hepatol 2018; 68: 326-334 https://www.journal-of-hepatology.eu/article/S0168-8278(17)32353-X/fulltext
35 Simeone JC, Bae JP, Hoogwerf BJ. et al. Clinical course of nonalcoholic fatty liver disease: an assessment of severity, progression, and outcomes. Clin Epidemiol 2017; 9: 679-688 https://pubmed.ncbi.nlm.nih.gov/29276410/
36 Fujiwara N, Friedman SL, Goossens N. et al. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol 2018; 68: 526-549 https://www.journal-of-hepatology.eu/article/S0168-8278(17)32328-0/pdf
37 Gellert-Kristensen H, Richardson T, Davey Smith G. et al. Combined Effect of PNPLA3, TM6SF2, and HSD17B13 Variants on Risk of Cirrhosis and Hepatocellular Carcinoma in the General Population. Hepatology 2020; 72 (03) 845-856 https://pubmed.ncbi.nlm.nih.gov/32190914/
38 Raffetti E, Fattovich G, Donato F. Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: a systematic review and meta-analysis. Liver Int 2016; 36: 1239-1251
39 Papatheodoridis GV, Chan HL, Hansen BE. et al. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J Hepatol 2015; 62: 956-967 https://air.unimi.it/retrieve/handle/2434/437611/717191/1-s2.0-S0168827815000045-main.pdf
40 Orci L, Sanduzzi-Zamparelli M, Caballol B. et al. Incidence of Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression. Clin Gastroenterol Hepatol 2022; 20 (02) 283-292.e10 https://pubmed.ncbi.nlm.nih.gov/33965578/
41 Björkström K, Widman L, Hagström H. Risk of hepatic and extrahepatic cancer in NAFLD: A population-based cohort study. Liver Int 2022; 42 (04) 820-828 https://pubmed.ncbi.nlm.nih.gov/35152526/
42 Huang D, Tan D, Ng C. et al. Hepatocellular Carcinoma Incidence in Alcohol-Associated Cirrhosis: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2023; 21 (05) 1169-1177 https://pubmed.ncbi.nlm.nih.gov/35940513/
43 Lithner F, Wetterberg L. Hepatocellular carcinoma in patients with acute intermittent porphyria. Acta Med Scand 1984; 215 (03) 271-274 https://pubmed.ncbi.nlm.nih.gov/6328897/
44 Baravelli C, Sandberg S, Aarsand A. et al. Acute hepatic porphyria and cancer risk: a nationwide cohort study. J Intern Med 2017; 282 (03) 229-240 https://pubmed.ncbi.nlm.nih.gov/28730628/
45 Jang H, Yang H, Ko J. et al. Development of Hepatocellular Carcinoma in Patients with Glycogen Storage Disease: a Single Center Retrospective Study. J Korean Med Sci 2020; 35 (01) e5 https://pubmed.ncbi.nlm.nih.gov/31898434/
46 Bianchi L. Glycogen storage disease I and hepatocellular tumours. Eur J Pediatr 1993; 152 (Suppl. 01) S63-S70 https://pubmed.ncbi.nlm.nih.gov/8391447/
47 de Fost M, Vom Dahl S, Weverling G. et al. Increased incidence of cancer in adult Gaucher disease in Western Europe. Blood Cells Mol Dis 36 (01) 53-58 https://pubmed.ncbi.nlm.nih.gov/16246599/
48 Regenboog M, van Dussen L, Verheij J. et al. Hepatocellular carcinoma in Gaucher disease: an international case series. J Inherit Metab Dis 2018; 41 (05) 819-827 https://pubmed.ncbi.nlm.nih.gov/29423829/
49 Bartlett D, Lloyd C, McKiernan P. et al. Early nitisinone treatment reduces the need for liver transplantation in children with tyrosinaemia type 1 and improves post-transplant renal function. J Inherit Metab Dis 2014; 37 (05) 745-752 https://pubmed.ncbi.nlm.nih.gov/24515874/
50 Poon D, Anderson BO, Chen LT. et al. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009; 10: 1111-1118
51 Chang MH, Chen CJ, Lai MS. et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997; 336: 1855-1859
52 Indolfi G, Easterbrook P, Dusheiko G. et al. Hepatitis B virus infection in children and adolescents. Lancet Gastroenterol Hepatol 2019; 4: 466-476 https://www.sciencedirect.com/science/article/abs/pii/S2468125319300421?via%3Dihub
53 Inoue M, Yoshimi I, Sobue T. et al. Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: a prospective study in Japan. J Natl Cancer Inst 2005; 97: 293-300 https://pubmed.ncbi.nlm.nih.gov/15713964/
54 Bravi F, Tavani A, Bosetti C. et al. Coffee and the risk of hepatocellular carcinoma and chronic liver disease: a systematic review and meta-analysis of prospective studies. Eur J Cancer Prev 2017; 26: 368-377
55 Aleksandrova K, Bamia C, Drogan D. et al. The association of coffee intake with liver cancer risk is mediated by biomarkers of inflammation and hepatocellular injury: data from the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr 2015; 102: 1498-1508 http://spiral.imperial.ac.uk/bitstream/10044/1/29882/11/Am%20J%20Clin%20Nutr-2015-Aleksandrova-1498-508.pdf
56 Setiawan VW, Wilkens LR, Lu SC. et al. Association of coffee intake with reduced incidence of liver cancer and death from chronic liver disease in the US multiethnic cohort. Gastroenterology 2015; 148: 118-25; quiz e15 https://pubmed.ncbi.nlm.nih.gov/25305507/
57 Saab S, Mallam D, Cox GA. et al. Impact of coffee on liver diseases: a systematic review. Liver Int 2014; 34: 495-504
58 Bhurwal A, Rattan P, Yoshitake S. et al. Inverse Association of Coffee with Liver Cancer Development: An Updated Systematic Review and Meta-analysis. J Gastrointestin Liver Dis 2020; 29: 421-428 https://www.jgld.ro/jgld/index.php/jgld/article/download/805/1593
59 Kennedy OJ, Roderick P, Buchanan R. et al. Coffee, including caffeinated and decaffeinated coffee, and the risk of hepatocellular carcinoma: a systematic review and dose-response meta-analysis. BMJ Open 2017; 7: e013739 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5730000/pdf/bmjopen-2016-013739.pdf
60 Filippini T, Malavolti M, Borrelli F. et al. Green tea (Camellia sinensis) for the prevention of cancer. Cochrane Database Syst Rev 2020; 3: Cd005004
61 Singh S, Fujii LL, Murad MH. et al. Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2013; 11: 1573-1584.e1-2 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3900882/pdf/nihms532555.pdf
62 Tseng CH. Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes. Liver Int 2018; 38: 2018-2027
63 Cunha V, Cotrim HP, Rocha R. et al. Metformin in the prevention of hepatocellular carcinoma in diabetic patients: A systematic review. Ann Hepatol 2020; 19: 232-237
64 Harris K, Smith L. Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C. Ann Pharmacother 2013; 47: 1348-1352
65 Inzucchi SE, Lipska KJ, Mayo H. et al. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. Jama 2014; 312: 2668-2675 https://jamanetwork.com/journals/jama/articlepdf/2084896/jrv140019.pdf
66 Zhang X, Harmsen W, Mettler T. et al. Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes. Hepatology 2014; 60 (06) 2008-2016 https://pubmed.ncbi.nlm.nih.gov/24798175/
67 Vandenbulcke H, Moreno C, Colle I. et al. Alcohol intake increases the risk of HCC in hepatitis C virus-related compensated cirrhosis: A prospective study. J Hepatol 2016; 65: 543-551
68 Roeb E, Canbay A, Bantel H. et al. [Not Available]. Z Gastroenterol 2022; 60 (09) 1346-1421 https://pubmed.ncbi.nlm.nih.gov/36100202/
69 Ascha MS, Hanouneh IA, Lopez R. et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51: 1972-1978 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20209604
70 EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. J Hepatol 2018; 69: 154-181
71 Wang ZY, Tao QF, Wang ZH. et al. Antiviral therapy improves post-operative survival outcomes in patients with HBV-related hepatocellular carcinoma of less than 3 cm – A retrospective cohort study. Am J Surg 2020; 219: 717-725 https://www.sciencedirect.com/science/article/abs/pii/S000296101831609X?via%3Dihub
72 Jang JW, Yoo SH, Nam HC. et al. Association of Prophylactic Anti-Hepatitis B Virus Therapy With Improved Long-term Survival in Patients With Hepatocellular Carcinoma Undergoing Transarterial Therapy. Clin Infect Dis 2020; 71: 546-555 https://pubmed.ncbi.nlm.nih.gov/31504352/
73 Yang Y, Wen F, Li J. et al. A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib. Liver Int 2015; 35: 2147-2154
74 Cabibbo G, Celsa C, Calvaruso V. et al. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. J Hepatol 2019; 71: 265-273 https://www.sciencedirect.com/science/article/abs/pii/S0168827819302211?via%3Dihub
75 Dang H, Yeo YH, Yasuda S. et al. Cure With Interferon-Free Direct-Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus-Related Hepatocellular Carcinoma From Both East and West. Hepatology 2020; 71: 1910-1922
76 Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130: 417-422 https://link.springer.com/content/pdf/10.1007%2Fs00432-004-0552-0.pdf
77 Trevisani F, Santi V, Gramenzi A. et al. Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate/advanced cirrhosis?. Am J Gastroenterol 2007; 102: 2448-2457
78 Trevisani F, Santi V, Gramenzi A. et al. Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate/advanced cirrhosis?. Am J Gastroenterol 2007; 102: 2448-2457
79 Fan R, Papatheodoridis G, Sun J. et al. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. J Hepatol 2020; 73 (06) 1368-1378 https://pubmed.ncbi.nlm.nih.gov/32707225/
80 Johnson P, Innes H, Hughes D. et al. Evaluation of the aMAP score for hepatocellular carcinoma surveillance: a realistic opportunity to risk stratify. Br J Cancer 2022; 127 (07) 1263-1269 https://pubmed.ncbi.nlm.nih.gov/35798825/
81 Pocha C, Dieperink E, McMaken KA. et al. Surveillance for hepatocellular cancer with ultrasonography vs computed tomography -- a randomised study. Aliment Pharmacol Ther 2013; 38: 303-312
82 Trinchet JC, Chaffaut C, Bourcier V. et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology 2011; 54: 1987-1997
83 Tzartzeva K, Obi J, Rich NE. et al. Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. Gastroenterology 2018; 154: 1706-1718.e1 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927818/pdf/nihms940431.pdf
84 Song BG, Sinn DH, Chi S. et al. Additional role of liver stiffness measurement in stratifying residual hepatocellular carcinoma risk predicted by serum biomarkers in chronic hepatitis B patients under antiviral therapy. Eur J Gastroenterol Hepatol 2018; 30: 1447-1452
85 Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med 2014; 11: e1001624 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3972088/pdf/pmed.1001624.pdf
86 Feng H, Li B, Li Z. et al. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma. BMC Cancer 2021; 21 (01) 401 https://pubmed.ncbi.nlm.nih.gov/33849479/
87 Ricco G, Cosma C, Bedogni G. et al. Modeling the time-related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma. Cancer Biomark 2020; 29 (02) 189-196 https://pubmed.ncbi.nlm.nih.gov/32623383/
88 Hemken P, Sokoll L, Yang X. et al. Validation of a novel model for the early detection of hepatocellular carcinoma. Clin Proteomics 2019; 16: 2 https://pubmed.ncbi.nlm.nih.gov/30675135/
89 Xu F, Zhang L, He W. et al. The Diagnostic Value of Serum PIVKA-II Alone or in Combination with AFP in Chinese Hepatocellular Carcinoma Patients. Dis Markers 2021; 2021: 8868370 https://pubmed.ncbi.nlm.nih.gov/33628341/
90 Poté N, Cauchy F, Albuquerque M. et al. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion. J Hepatol 2015; 62 (04) 848-854 https://pubmed.ncbi.nlm.nih.gov/25450201/
91 Loglio A, Iavarone M, Facchetti F. et al. The combination of PIVKA-II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on long-term oral therapy. Liver Int 2020; 40 (08) 1987-1996 https://pubmed.ncbi.nlm.nih.gov/32301212/
92 Best J, Bechmann L, Sowa J. et al. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol 2020; 18 (03) 728-735.e4 https://pubmed.ncbi.nlm.nih.gov/31712073/
93 Yang J, Addissie B, Mara K. et al. GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score. Cancer Epidemiol Biomarkers Prev 2019; 28 (03) 531-538 https://pubmed.ncbi.nlm.nih.gov/30464023/
94 Schotten C, Ostertag B, Sowa J. et al. GALAD Score Detects Early-Stage Hepatocellular Carcinoma in a European Cohort of Chronic Hepatitis B and C Patients. Pharmaceuticals (Basel) 2021; 14 (08) https://pubmed.ncbi.nlm.nih.gov/34451832/
95 Huang C, Fang M, Xiao X. et al. Validation of the GALAD model for early diagnosis and monitoring of hepatocellular carcinoma in Chinese multicenter study. Liver Int 2022; 42 (01) 210-223 https://pubmed.ncbi.nlm.nih.gov/34679250/
96 Tayob N, Kanwal F, Alsarraj A. et al. The Performance of AFP, AFP-3, DCP as Biomarkers for Detection of Hepatocellular Carcinoma (HCC): A Phase 3 Biomarker Study in the United States. Clin Gastroenterol Hepatol 2023; 21 (02) 415-423.e4 https://pubmed.ncbi.nlm.nih.gov/35124267/
97 Singal A, Tayob N, Mehta A. et al. GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis. Hepatology 2022; 75 (03) 541-549 https://pubmed.ncbi.nlm.nih.gov/34618932/
98 Chan H, Vogel A, Berg T. et al. Performance evaluation of the Elecsys PIVKA-II and Elecsys AFP assays for hepatocellular carcinoma diagnosis. JGH Open 2022; 6 (05) 292-300 https://pubmed.ncbi.nlm.nih.gov/35601131/
99 Chalasani N, Porter K, Bhattacharya A. et al. Validation of a Novel Multitarget Blood Test Shows High Sensitivity to Detect Early Stage Hepatocellular Carcinoma. Clin Gastroenterol Hepatol 2022; 20 (01) 173-182.e7 https://pubmed.ncbi.nlm.nih.gov/34391922/
100 Loomba R, Lim JK, Patton H. et al. AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review. Gastroenterology 2020; 158: 1822-1830
101 Petrick JL, Thistle JE, Zeleniuch-Jacquotte A. et al. Body Mass Index, Diabetes and Intrahepatic Cholangiocarcinoma Risk: The Liver Cancer Pooling Project and Meta-analysis. Am J Gastroenterol 2018; 113: 1494-1505 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6521884/pdf/nihms-1027973.pdf
102 Loomba R, Adams LA. Advances in non-invasive assessment of hepatic fibrosis. Gut 2020; 69: 1343-1352 https://gut.bmj.com/content/69/7/1343.long
103 Singh S, Allen AM, Wang Z. et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015; 13: 643-654.e1-9 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4208976/pdf/nihms-604814.pdf
104 Sterling RK, Lissen E, Clumeck N. et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-1325
105 Taylor RS, Taylor RJ, Bayliss S. et al. Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Gastroenterology 2020; 158: 1611-1625.e12
106 Rockey DC, Caldwell SH, Goodman ZD. et al. Liver biopsy. Hepatology 2009; 49: 1017-1044
107 Silva MA, Hegab B, Hyde C. et al. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut 2008; 57: 1592-1596 https://gut.bmj.com/content/gutjnl/57/11/1592.full.pdf
108 Müllhaupt B, Durand F, Roskams T. et al. Is tumor biopsy necessary?. Liver Transpl 2011; 17 (Suppl. 02) S14-S25
109 Fuks D, Cauchy F, Fusco G. et al. Preoperative tumour biopsy does not affect the oncologic course of patients with transplantable HCC. J Hepatol 2014; 61: 589-593
110 Paradis V FM. Tumors of the liver and intrahepatic bile ducts. In: WHO Classification of Tumours Editorial Board WHO-Classification of Tumours (5th ed.) Digestive System Tumours. International Agency for Research on Cancer. Lyon: 2019: 215-264
111 Terminology of nodular hepatocellular lesions. Hepatology 1995; 22: 983-993 https://www.sciencedirect.com/science/article/abs/pii/0270913995903240?via%3Dihub
112 Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009; 49: 658-664
113 Burt AD, Alves V, Bedossa P. et al. Data set for the reporting of intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and hepatocellular carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology 2018; 73: 369-385
114 Edmondson HA, Steiner PE. Primary carcinoma of the liver A study of 100 cases among 48900 necropsies. Cancer 1954; 7: 462-503
115 Nzeako UC, Goodman ZD, Ishak KG. Comparison of tumor pathology with duration of survival of North American patients with hepatocellular carcinoma. Cancer 1995; 76: 579-588
116 Di Tommaso L, Franchi G, Park YN. et al. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology 2007; 45: 725-734
117 Di Tommaso L, Destro A, Seok JY. et al. The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. J Hepatol 2009; 50: 746-754
118 Lee YJ, Lee JM, Lee JS. et al. Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis. Radiology 2015; 275: 97-109
119 Chen N, Motosugi U, Morisaka H. et al. Added Value of a Gadoxetic Acid-enhanced Hepatocyte-phase Image to the LI-RADS System for Diagnosing Hepatocellular Carcinoma. Magn Reson Med Sci 2016; 15: 49-59 https://www.jstage.jst.go.jp/article/mrms/15/1/15_2014-0149/_pdf
120 Granito A, Galassi M, Piscaglia F. et al. Impact of gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance on the non-invasive diagnosis of small hepatocellular carcinoma: a prospective study. Aliment Pharmacol Ther 2013; 37: 355-363
121 Haradome H, Grazioli L, Tinti R. et al. Additional value of gadoxetic acid-DTPA-enhanced hepatobiliary phase MR imaging in the diagnosis of early-stage hepatocellular carcinoma: comparison with dynamic triple-phase multidetector CT imaging. J Magn Reson Imaging 2011; 34: 69-78
122 Inoue T, Kudo M, Komuta M. et al. Assessment of Gd-EOB-DTPA-enhanced MRI for HCC and dysplastic nodules and comparison of detection sensitivity versus MDCT. J Gastroenterol 2012; 47: 1036-1047 https://link.springer.com/content/pdf/10.1007%2Fs00535-012-0571-6.pdf
123 Maiwald B, Lobsien D, Kahn T. et al. Is 3-Tesla Gd-EOB-DTPA-enhanced MRI with diffusion-weighted imaging superior to 64-slice contrast-enhanced CT for the diagnosis of hepatocellular carcinoma?. PLoS One 2014; 9: e111935 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223069/pdf/pone.0111935.pdf
124 Park VY, Choi JY, Chung YE. et al. Dynamic enhancement pattern of HCC smaller than 3 cm in diameter on gadoxetic acid-enhanced MRI: comparison with multiphasic MDCT. Liver Int 2014; 34: 1593-1602
125 or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging. Invest Radiol 2010; 45: 96-103 https://www.ncbi.nlm.nih.gov/pubmed/20057319
126 Tsurusaki M, Sofue K, Isoda H. et al. Comparison of gadoxetic acid-enhanced magnetic resonance imaging and contrast-enhanced computed tomography with histopathological examinations for the identification of hepatocellular carcinoma: a multicenter phase III study. J Gastroenterol 2016; 51: 71-79 https://link.springer.com/content/pdf/10.1007%2Fs00535-015-1097-5.pdf
127 Burrel M, Llovet JM, Ayuso C. et al. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology 2003; 38: 1034-1042
128 Di Martino M, De Filippis G, De Santis A. et al. Hepatocellular carcinoma in cirrhotic patients: prospective comparison of US, CT and MR imaging. Eur Radiol 2013; 23: 887-896 https://link.springer.com/content/pdf/10.1007%2Fs00330-012-2691-z.pdf
129 Schellhaas B, Bernatik T, Bohle W. et al. Contrast-Enhanced Ultrasound Algorithms (CEUS-LIRADS/ESCULAP) for the Noninvasive Diagnosis of Hepatocellular Carcinoma – A Prospective Multicenter DEGUM Study. Ultraschall Med 2021; 42 (02) e20 https://pubmed.ncbi.nlm.nih.gov/32717752/
130 Strobel D, Jung E, Ziesch M. et al. Real-life assessment of standardized contrast-enhanced ultrasound (CEUS) and CEUS algorithms (CEUS LI-RADS®/ESCULAP) in hepatic nodules in cirrhotic patients-a prospective multicenter study. Eur Radiol 2021; 31 (10) 7614-7625 https://pubmed.ncbi.nlm.nih.gov/33855588/
131 Schellhaas B, Bernatik T, Dirks K. et al. Contrast-Enhanced Ultrasound Patterns for the Non-invasive Diagnosis of Hepatocellular Carcinoma: A Prospective Multicenter Study in Histologically Proven Liver Lesions in a Real-Life Setting Demonstrating the Benefit of Extended Late Phase Observation. Ultrasound Med Biol 2021; 47 (11) 3170-3180 https://pubmed.ncbi.nlm.nih.gov/34417066/
132 Chen X, Li M, Guo R. et al. The diagnostic performance of contrast-enhanced CT versus extracellular contrast agent-enhanced MRI in detecting hepatocellular carcinoma: direct comparison and a meta-analysis. Abdom Radiol (NY) 2022; 47 (06) 2057-2070 https://pubmed.ncbi.nlm.nih.gov/35312822/
133 Lee S, Kim Y, Shin J. et al. Liver Imaging Reporting and Data System version 2018 category 5 for diagnosing hepatocellular carcinoma: an updated meta-analysis. Eur Radiol 2024; 34 (03) 1502-1514 https://pubmed.ncbi.nlm.nih.gov/37656177/
134 CT/MRT LI-RADS® v2018. https://www.acr.org/-/media/ACR/Files/RADS/LI-RADS/Translations/LI-RADS-2018-CT-MRI-Core-German.pdf?la=en
135 Elsayes K, Kielar A, Elmohr M. et al. White paper of the Society of Abdominal Radiology hepatocellular carcinoma diagnosis disease-focused panel on LI-RADS v2018 for CT and MRI. Abdom Radiol (NY) 2018; 43 (10) 2625-2642 https://pubmed.ncbi.nlm.nih.gov/30155697/
136 Castilla-Lievre MA, Franco D, Gervais P. et al. Diagnostic value of combining (1)(1)C-choline and (1)(8)F-FDG PET/CT in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 2016; 43: 852-859 https://www.ncbi.nlm.nih.gov/pubmed/26577938
137 Chotipanich C, Kunawudhi A, Promteangtrong C. et al. Diagnosis of Hepatocellular Carcinoma Using C11 Choline PET/CT: Comparison with F18 FDG, ContrastEnhanced MRI and MDCT. Asian Pac J Cancer Prev 2016; 17: 3569-3573 https://www.ncbi.nlm.nih.gov/pubmed/27510010
138 Hong G, Suh KS, Suh SW. et al. Alpha-fetoprotein and (18)F-FDG positron emission tomography predict tumor recurrence better than Milan criteria in living donor liver transplantation. J Hepatol 2016; 64: 852-859 https://www.ncbi.nlm.nih.gov/pubmed/26658686
139 Lin CY, Liao CW, Chu LY. et al. Predictive Value of 18F-FDG PET/CT for Vascular Invasion in Patients With Hepatocellular Carcinoma Before Liver Transplantation. Clin Nucl Med 2017; 42: e183-e187 https://www.ncbi.nlm.nih.gov/pubmed/28114226
140 Khalili K, Kim TK, Jang HJ. et al. Optimization of imaging diagnosis of 1–2 cm hepatocellular carcinoma: an analysis of diagnostic performance and resource utilization. J Hepatol 2011; 54: 723-728 https://www.sciencedirect.com/science/article/pii/S0168827810008147?via%3Dihub
141 Giorgio A, Montesarchio L, Gatti P. et al. Contrast-Enhanced Ultrasound: a Simple and Effective Tool in Defining a Rapid Diagnostic Work-up for Small Nodules Detected in Cirrhotic Patients during Surveillance. J Gastrointestin Liver Dis 2016; 25: 205-211 https://www.ncbi.nlm.nih.gov/pubmed/27308652
142 Schellhaas B, Gortz RS, Pfeifer L. et al. Diagnostic accuracy of contrast-enhanced ultrasound for the differential diagnosis of hepatocellular carcinoma: ESCULAP versus CEUS-LI-RADS. Eur J Gastroenterol Hepatol 2017; 29: 1036-1044 https://www.ncbi.nlm.nih.gov/pubmed/28562394
143 Mitchell DG, Bruix J, Sherman M. et al. LI-RADS (Liver Imaging Reporting and Data System): summary, discussion, and consensus of the LI-RADS Management Working Group and future directions. Hepatology 2015; 61: 1056-1065 https://www.ncbi.nlm.nih.gov/pubmed/25041904
144 Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-338
145 Chan AC, Fan ST, Poon RT. et al. Evaluation of the seventh edition of the American Joint Committee on Cancer tumour-node-metastasis (TNM) staging system for patients undergoing curative resection of hepatocellular carcinoma: implications for the development of a refined staging system. HPB (Oxford) 2013; 15: 439-448 https://www.hpbonline.org/article/S1365-182X(15)31417-9/pdf
146 Chevret S, Trinchet JC, Mathieu D. et al. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma Groupe d’Etude et de Traitement du Carcinome Hepatocellulaire. J Hepatol 1999; 31: 133-141 https://www.journal-of-hepatology.eu/article/S0168-8278(99)80173-1/fulltext
147 Johnson PJ, Berhane S, Kagebayashi C. et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 2015; 33: 550-558 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322258/pdf/zlj550.pdf
148 Kitai S, Kudo M, Minami Y. et al. Validation of a new prognostic staging system for hepatocellular carcinoma: a comparison of the biomarker-combined Japan Integrated Staging Score, the conventional Japan Integrated Staging Score and the BALAD Score. Oncology 2008; 75 (Suppl. 01) 83-90 https://www.karger.com/Article/Abstract/173428
149 Leung TW, Tang AM, Zee B. et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 2002; 94: 1760-1769
150 Marrero JA, Fontana RJ, Barrat A. et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005; 41: 707-716 https://pubmed.ncbi.nlm.nih.gov/15795889/
151 Pinato DJ, Sharma R, Allara E. et al. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. J Hepatol 2017; 66: 338-346 https://www.journal-of-hepatology.eu/article/S0168-8278(16)30535-9/pdf
152 Vitale A, Saracino E, Boccagni P. et al. Validation of the BCLC prognostic system in surgical hepatocellular cancer patients. Transplant Proc 2009; 41: 1260-1263 https://www.sciencedirect.com/science/article/pii/S0041134509004850?via%3Dihub
153 Yau T, Tang VY, Yao TJ. et al. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology 2014; 146: 1691-1700.e3 https://www.gastrojournal.org/article/S0016-5085(14)00243-1/pdf
154 Sohn JH, Duran R, Zhao Y. et al. Validation of the Hong Kong Liver Cancer Staging System in Determining Prognosis of the North American Patients Following Intra-arterial Therapy. Clin Gastroenterol Hepatol 2017; 15: 746-755.e4 https://www.cghjournal.org/article/S1542-3565(16)31049-7/pdf
155 Yang A, Ju W, Yuan X. et al. Comparison between liver resection and liver transplantation on outcomes in patients with solitary hepatocellular carcinoma meeting UNOS criteria: a population-based study of the SEER database. Oncotarget 2017; 8: 97428-97438 https://www.oncotarget.com/article/22134/pdf/
156 Krenzien F, Schmelzle M, Struecker B. et al. Liver Transplantation and Liver Resection for Cirrhotic Patients with Hepatocellular Carcinoma: Comparison of Long-Term Survivals. J Gastrointest Surg 2018; 22: 840-848
157 Cherqui D, Laurent A, Mocellin N. et al. Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation. Ann Surg 2009; 250: 738-746
158 Eguchi S, Kanematsu T, Arii S. et al. Recurrence-free survival more than 10 years after liver resection for hepatocellular carcinoma. Br J Surg 2011; 98: 552-557
159 Sapisochin G, Goldaracena N, Laurence JM. et al. The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study. Hepatology 2016; 64: 2077-2088
160 Mazzaferro V, Battiston C, Sposito C. Pro (With Caution): Extended oncologic indications in liver transplantation. Liver Transpl 2018; 24: 98-103
161 Mazzaferro V, Regalia E, Doci R. et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699
162 Agopian VG, Harlander-Locke MP, Ruiz RM. et al. Impact of Pretransplant Bridging Locoregional Therapy for Patients With Hepatocellular Carcinoma Within Milan Criteria Undergoing Liver Transplantation: Analysis of 3601 Patients From the US Multicenter HCC Transplant Consortium. Ann Surg 2017; 266: 525-535
163 Bundesärztekammer. Richtlinien zur Organtransplantation gem § 16 TPG. Deutsches Ärzteblatt 2019;
164 von Felden J, Villanueva A. Role of Molecular Biomarkers in Liver Transplantation for Hepatocellular Carcinoma. Liver Transpl 2020; 26: 823-831
165 Yao FY, Ferrell L, Bass NM. et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394-1403
166 Mazzaferro V, Llovet JM, Miceli R. et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10: 35-43 https://www.sciencedirect.com/science/article/pii/S1470204508702845?via%3Dihub
167 Sinha J, Mehta N, Dodge JL. et al. Are There Upper Limits in Tumor Burden for Down-Staging of Hepatocellular Carcinoma to Liver Transplant? Analysis of the All-Comers Protocol. Hepatology 2019; 70: 1185-1196
168 Lai Q, Vitale A, Halazun K. et al. Identification of an Upper Limit of Tumor Burden for Downstaging in Candidates with Hepatocellular Cancer Waiting for Liver Transplantation: A West-East Collaborative Effort. Cancers (Basel) 2020; 12 https://res.mdpi.com/d_attachment/cancers/cancers-12-00452/article_deploy/cancers-12-00452-v2.pdf
169 Mehta N, Guy J, Frenette CT. et al. Excellent Outcomes of Liver Transplantation Following Down-Staging of Hepatocellular Carcinoma to Within Milan Criteria: A Multicenter Study. Clin Gastroenterol Hepatol 2018; 16: 955-964 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6053266/pdf/nihms922574.pdf
170 Otto G, Herber S, Heise M. et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 2006; 12: 1260-1267
171 Di Sandro S, Sposito C, Lauterio A. et al. Proposal of Prognostic Survival Models before and after Liver Resection for Hepatocellular Carcinoma in Potentially Transplantable Patients. J Am Coll Surg 2018; 226: 1147-1159 https://www.sciencedirect.com/science/article/abs/pii/S1072751518302199?via%3Dihub
172 Ferrer-Fàbrega J, Forner A, Liccioni A. et al. Prospective validation of ab initio liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection. Hepatology 2016; 63: 839-849
173 Scatton O, Goumard C, Cauchy F. et al. Early and resectable HCC: Definition and validation of a subgroup of patients who could avoid liver transplantation. J Surg Oncol 2015; 111: 1007-1015
174 de Haas RJ, Lim C, Bhangui P. et al. Curative salvage liver transplantation in patients with cirrhosis and hepatocellular carcinoma: An intention-to-treat analysis. Hepatology 2018; 67: 204-215
175 Bhangui P, Allard MA, Vibert E. et al. Salvage Versus Primary Liver Transplantation for Early Hepatocellular Carcinoma: Do Both Strategies Yield Similar Outcomes?. Ann Surg 2016; 264: 155-163 https://www.ingentaconnect.com/content/wk/sla/2016/00000264/00000001/art00029;jsessionid=5ees0b4oapp5t.x-ic-live-02
176 Pichlmayr R. Is there a place for liver grafting for malignancy?. Transplant Proc 1988; 20: 478-482
177 Roayaie S, Schwartz JD, Sung MW. et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl 2004; 10: 534-540
178 Shetty K, Timmins K, Brensinger C. et al. Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl 2004; 10: 911-918
179 Lee HW, Song GW, Lee SG. et al. Patient Selection by Tumor Markers in Liver Transplantation for Advanced Hepatocellular Carcinoma. Liver Transpl 2018; 24: 1243-1251
180 Berry K, Ioannou GN. Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinoma. Liver Transpl 2013; 19: 634-645
181 Vibert E, Azoulay D, Hoti E. et al. Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant 2010; 10: 129-137
182 Yao FY, Mehta N, Flemming J. et al. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology 2015; 61: 1968-1977 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4809192/pdf/nihms667031.pdf
183 Hameed B, Mehta N, Sapisochin G. et al. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transpl 2014; 20: 945-951
184 Heimbach JK, Kulik LM, Finn RS. et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018; 67: 358-380
185 500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes. Hepatology 2019; 69: 1193-1205
186 EASL Clinical Practice Guidelines: Liver transplantation. J Hepatol 2016; 64: 433-485
187 Martin P, DiMartini A, Feng S. et al. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology 2014; 59: 1144-1165
188 Adani GL, Baccarani U, Lorenzin D. et al. Elderly versus young liver transplant recipients: patient and graft survival. Transplant Proc 2009; 41: 1293-1294
189 Cross TJ, Antoniades CG, Muiesan P. et al. Liver transplantation in patients over 60 and 65 years: an evaluation of long-term outcomes and survival. Liver Transpl 2007; 13: 1382-1388
190 Grąt M, Kornasiewicz O, Grąt K. et al. Short and long-term outcomes after primary liver transplantation in elderly patients. Pol Przegl Chir 2013; 85: 581-588
191 Aduen JF, Sujay B, Dickson RC. et al. Outcomes after liver transplant in patients aged 70 years or older compared with those younger than 60 years. Mayo Clin Proc 2009; 84: 973-978 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2770908/pdf/mayoclinproc_84_11_004.pdf
192 Lipshutz GS, Hiatt J, Ghobrial RM. et al. Outcome of liver transplantation in septuagenarians: a single-center experience. Arch Surg 2007; 142: 775-781 https://jamanetwork.com/journals/jamasurgery/articlepdf/400501/spc70006_775_784.pdf
193 Oezcelik A, Dayangac M, Guler N. et al. Living Donor Liver Transplantation in Patients 70 Years or Older. Transplantation 2015; 99: 1436-1440
194 Taner CB, Ung RL, Rosser BG. et al. Age is not a contraindication for orthotopic liver transplantation: a single institution experience with recipients older than 75 years. Hepatol Int 2012; 6: 403-407
195 Huang X, Lu S. Impact of preoperative locoregional therapy on recurrence and patient survival following liver transplantation for hepatocellular carcinoma: a meta-analysis. Scand J Gastroenterol 2017; 52: 143-149
196 Kulik L, Heimbach JK, Zaiem F. et al. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis. Hepatology 2018; 67: 381-400
197 Sneiders D, Houwen T, Pengel LHM. et al. Systematic Review and Meta-Analysis of Posttransplant Hepatic Artery and Biliary Complications in Patients Treated With Transarterial Chemoembolization Before Liver Transplantation. Transplantation 2018; 102: 88-96
198 Clavien PA, Lesurtel M, Bossuyt PM. et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012; 13: e11-e22 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3417764/pdf/nihms392425.pdf
199 Beal EW, Dittmar KM, Hanje AJ. et al. Pretransplant Locoregional Therapy for Hepatocellular Carcinoma: Evaluation of Explant Pathology and Overall Survival. Front Oncol 2016; 6: 143
200 Cascales-Campos P, Martinez-Insfran LA, Ramirez P. et al. Liver Transplantation in Patients With Hepatocellular Carcinoma Outside the Milan Criteria After Downstaging: Is It Worth It?. Transplant Proc 2018; 50: 591-594 https://www.sciencedirect.com/science/article/abs/pii/S0041134517309284
201 Finkenstedt A, Vikoler A, Portenkirchner M. et al. Excellent post-transplant survival in patients with intermediate stage hepatocellular carcinoma responding to neoadjuvant therapy. Liver Int 2016; 36: 688-695
202 Györi GP, Felsenreich DM, Silberhumer GR. et al. Multimodality locoregional treatment strategies for bridging HCC patients before liver transplantation. Eur Surg 2017; 49: 236-243 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5653748/pdf/10353_2017_Article_487.pdf
203 Jianyong L, Jinjing Z, Lunan Y. et al. Preoperative adjuvant transarterial chemoembolization cannot improve the long term outcome of radical therapies for hepatocellular carcinoma. Sci Rep 2017; 7: 41624 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5290748/pdf/srep41624.pdf
204 Nicolini D, Agostini A, Montalti R. et al. Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation. World J Gastroenterol 2017; 23: 3690-3701 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5449426/pdf/WJG-23-3690.pdf
205 Gabr A, Abouchaleh N, Ali R. et al. Comparative study of post-transplant outcomes in hepatocellular carcinoma patients treated with chemoembolization or radioembolization. Eur J Radiol 2017; 93: 100-106 https://www.sciencedirect.com/science/article/abs/pii/S0720048X17302012
206 Lai Q, Vitale A, Iesari S. et al. The Intention-to-Treat Effect of Bridging Treatments in the Setting of Milan Criteria-In Patients Waiting for Liver Transplantation. Liver Transpl 2019; 25: 1023-1033
207 Oligane HC, Xing M, Kim HS. Effect of Bridging Local-Regional Therapy on Recurrence of Hepatocellular Carcinoma and Survival after Orthotopic Liver Transplantation. Radiology 2017; 282: 869-879
208 Millonig G, Graziadei IW, Freund MC. et al. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2007; 13: 272-279
209 Cucchetti A, Cescon M, Bigonzi E. et al. Priority of candidates with hepatocellular carcinoma awaiting liver transplantation can be reduced after successful bridge therapy. Liver Transpl 2011; 17: 1344-1354
210 Lai Q, Avolio AW, Graziadei I. et al. Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation. Liver Transpl 2013; 19: 1108-1118
211 Kim DJ, Clark PJ, Heimbach J. et al. Recurrence of hepatocellular carcinoma: importance of mRECIST response to chemoembolization and tumor size. Am J Transplant 2014; 14: 1383-1390
212 Riaz A, Miller FH, Kulik LM. et al. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. Jama 2010; 303: 1062-1069 https://jamanetwork.com/journals/jama/articlepdf/185545/joc05021_1062_1069.pdf
213 Wong T, Lee V, Law A. et al. Prospective Study of Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma on Waitlist for Liver Transplant. Hepatology 2021; 74 (05) 2580-2594 https://pubmed.ncbi.nlm.nih.gov/34091914/
214 Sapisochin G, Barry A, Doherty M. et al. Stereotactic body radiotherapy vs TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma An intention-to-treat analysis. J Hepatol 2017; 67 (01) 92-99 https://pubmed.ncbi.nlm.nih.gov/28257902/
215 Bush D, Volk M, Smith J. et al. Proton beam radiotherapy versus transarterial chemoembolization for hepatocellular carcinoma: Results of a randomized clinical trial. Cancer 2023; 129 (22) 3554-3563 https://pubmed.ncbi.nlm.nih.gov/37503907/
216 Degroote H, Callebout E, Iesari S. et al. Extended criteria for liver transplantation in hepatocellular carcinoma A retrospective, multicentric validation study in Belgium. Surg Oncol 2019; https://pubmed.ncbi.nlm.nih.gov/31630912/
217 Parikh ND, Waljee AK, Singal AG. Downstaging hepatocellular carcinoma: A systematic review and pooled analysis. Liver Transpl 2015; 21: 1142-1152 https://deepblue.lib.umich.edu/bitstream/handle/2027.42/113108/lt24169.pdf?sequence=1
218 Mazzaferro V, Citterio D, Bhoori S. et al. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. Lancet Oncol 2020; 21 (07) 947-956 https://pubmed.ncbi.nlm.nih.gov/32615109/
219 Chapman WC, Garcia-Aroz S, Vachharajani N. et al. Liver Transplantation for Advanced Hepatocellular Carcinoma after Downstaging Without Up-Front Stage Restrictions. J Am Coll Surg 2017; 224: 610-621 https://www.sciencedirect.com/science/article/abs/pii/S1072751516317240
220 Graziadei I, Zoller H, Fickert P. et al. Indications for liver transplantation in adults: Recommendations of the Austrian Society for Gastroenterology and Hepatology (ÖGGH) in cooperation with the Austrian Society for Transplantation, Transfusion and Genetics (ATX). Wien Klin Wochenschr 2016; 128: 679-690 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5052293/pdf/508_2016_Article_1046.pdf
221 Mazzaferro V, Sposito C, Zhou J. et al. Metroticket 20 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma. Gastroenterology 2018; 154: 128-139 https://www.gastrojournal.org/article/S0016-5085(17)36184-X/fulltext
222 Halazun KJ, Tabrizian P, Najjar M. et al. Is it Time to Abandon the Milan Criteria?: Results of a Bicoastal US Collaboration to Redefine Hepatocellular Carcinoma Liver Transplantation Selection Policies. Ann Surg 2018; 268: 690-699
223 Hong SK, Lee KW, Kim HS. et al. Living donor liver transplantation for hepatocellular carcinoma in Seoul National University. Hepatobiliary Surg Nutr 2016; 5: 453-460
224 Kornberg A, Schernhammer M, Friess H. (18)F-FDG-PET for Assessing Biological Viability and Prognosis in Liver Transplant Patients with Hepatocellular Carcinoma. J Clin Transl Hepatol 2017; 5: 224-234
225 Assalino M, Terraz S, Grat M. et al. Liver transplantation for hepatocellular carcinoma after successful treatment of macrovascular invasion – a multi-center retrospective cohort study. Transpl Int 2020; 33: 567-575
226 Parikh ND, Yopp A, Singal AG. Controversies in criteria for liver transplantation in hepatocellular carcinoma. Curr Opin Gastroenterol 2016; 32: 182-188
227 Salem R, Gordon AC, Mouli S. et al. Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma. Gastroenterology 2016; 151: 1155-1163.e2 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5124387/pdf/nihms813288.pdf
228 Ettorre GM, Levi Sandri GB, Laurenzi A. et al. Yttrium-90 Radioembolization for Hepatocellular Carcinoma Prior to Liver Transplantation. World J Surg 2017; 41: 241-249
229 Schwacha-Eipper B, Minciuna I, Banz V. et al. Immunotherapy as a downstaging therapy for liver transplantation. Hepatology 2020;
230 Golse N, Radenne S, Rode A. et al. Liver Transplantation After Neoadjuvant Sorafenib Therapy: Preliminary Experience and Literature Review. Exp Clin Transplant 2018; 16: 227-236
231 Hoffmann K, Ganten T, Gotthardtp D. et al. Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients – a prospective, randomized, double-blind, phase III trial. BMC Cancer 2015; 15: 392 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449604/pdf/12885_2015_Article_1373.pdf
232 Berenguer M, Burra P, Ghobrial M. et al. Posttransplant Management of Recipients Undergoing Liver Transplantation for Hepatocellular Carcinoma Working Group Report From the ILTS Transplant Oncology Consensus Conference. Transplantation 2020; 104: 1143-1149
233 Verna EC, Patel YA, Aggarwal A. et al. Liver transplantation for hepatocellular carcinoma: Management after the transplant. Am J Transplant 2020; 20: 333-347
234 Vivarelli M, Cucchetti A, Piscaglia F. et al. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. Liver Transpl 2005; 11: 497-503
235 Vivarelli M, Cucchetti A, La Barba G. et al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg 2008; 248: 857-862
236 Rodríguez-Perálvarez M, Tsochatzis E, Naveas MC. et al. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. J Hepatol 2013; 59: 1193-1199
237 Decaens T, Roudot-Thoraval F, Bresson-Hadni S. et al. Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: a multicenter study of 412 patients. World J Gastroenterol 2006; 12: 7319-7325 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4087490/pdf/WJG-12-7319.pdf
238 Tan PS, Muthiah MD, Koh T. et al. Asian Liver Transplant Network Clinical Guidelines on Immunosuppression in Liver Transplantation. Transplantation 2019; 103: 470-480
239 Duvoux C, Toso C. mTOR inhibitor therapy: Does it prevent HCC recurrence after liver transplantation?. Transplant Rev (Orlando) 2015; 29: 168-174
240 Tarantino G, Magistri P, Ballarin R. et al. Oncological Impact of M-Tor Inhibitor Immunosuppressive Therapy after Liver Transplantation for Hepatocellular Carcinoma: Review of the Literature. Front Pharmacol 2016; 7: 387 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5073152/pdf/fphar-07-00387.pdf
241 Teperman L, Moonka D, Sebastian A. et al. Calcineurin inhibitor-free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial. Liver Transpl 2013; 19: 675-689
242 De Simone P, Metselaar HJ, Fischer L. et al. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial. Liver Transpl 2009; 15: 1262-1269
243 Fischer L, Saliba F, Kaiser GM. et al. Three-year Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus: Follow-Up Results From a Randomized, Multicenter Study. Transplantation 2015; 99: 1455-1462
244 Geissler EK, Schnitzbauer AA, Zülke C. et al. Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation 2016; 100: 116-125
245 Schnitzbauer A, Filmann N, Adam R. et al. mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors. Ann Surg 2020; 272 (05) 855-862 https://pubmed.ncbi.nlm.nih.gov/32889867/
246 Trevisani F, Frigerio M, Santi V. et al. Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal. Dig Liver Dis 2010; 42: 341-347
247 Paradis V, Zalinski S, Chelbi E. et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 2009; 49: 851-859
248 Piscaglia F, Svegliati-Baroni G, Barchetti A. et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. Hepatology 2016; 63: 827-838
249 Ertle J, Dechêne A, Sowa JP. et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 2011; 128: 2436-2443
250 Zhou Y, Lei X, Wu L. et al. Outcomes of hepatectomy for noncirrhotic hepatocellular carcinoma: a systematic review. Surg Oncol 2014; 23: 236-242
251 Faber W, Sharafi S, Stockmann M. et al. Long-term results of liver resection for hepatocellular carcinoma in noncirrhotic liver. Surgery 2013; 153: 510-517
252 Cauchy F, Zalinski S, Dokmak S. et al. Surgical treatment of hepatocellular carcinoma associated with the metabolic syndrome. Br J Surg 2013; 100: 113-121
253 Dasari BV, Kamarajah SK, Hodson J. et al. Development and validation of a risk score to predict the overall survival following surgical resection of hepatocellular carcinoma in non-cirrhotic liver. HPB (Oxford) 2020; 22: 383-390 https://www.sciencedirect.com/science/article/abs/pii/S1365182X19306215?via%3Dihub
254 Ju M, Yopp AC. The Utility of Anatomical Liver Resection in Hepatocellular Carcinoma: Associated with Improved Outcomes or Lack of Supportive Evidence?. Cancers (Basel) 2019; 11 https://res.mdpi.com/d_attachment/cancers/cancers-11-01441/article_deploy/cancers-11-01441.pdf
255 Moris D, Tsilimigras DI, Kostakis ID. et al. Anatomic versus non-anatomic resection for hepatocellular carcinoma: A systematic review and meta-analysis. Eur J Surg Oncol 2018; 44: 927-938 https://www.sciencedirect.com/science/article/abs/pii/S0748798318310242?via%3Dihub
256 Arnaoutakis DJ, Mavros MN, Shen F. et al. Recurrence patterns and prognostic factors in patients with hepatocellular carcinoma in noncirrhotic liver: a multi-institutional analysis. Ann Surg Oncol 2014; 21: 147-154
257 Lang H, Sotiropoulos GC, Brokalaki EI. et al. Survival and recurrence rates after resection for hepatocellular carcinoma in noncirrhotic livers. J Am Coll Surg 2007; 205: 27-36
258 Bège T, Le Treut YP, Hardwigsen J. et al. Prognostic factors after resection for hepatocellular carcinoma in nonfibrotic or moderately fibrotic liver A 116-case European series. J Gastrointest Surg 2007; 11: 619-625
259 Teegen EM, Mogl MT, Pratschke J. et al. Adrenal Metastasis of Hepatocellular Carcinoma in Patients following Liver Resection or Liver Transplantation: Experience from a Tertiary Referral Center. Int J Surg Oncol 2018; 2018: 4195076 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6087597/pdf/IJSO2018-4195076.pdf
260 Wang YY, Zhao XH, Ma L. et al. Comparison of the ability of Child-Pugh score, MELD score, and ICG-R15 to assess preoperative hepatic functional reserve in patients with hepatocellular carcinoma. J Surg Oncol 2018; 118: 440-445
261 Rubin TM, Heyne K, Luchterhand A. et al. Kinetic validation of the LiMAx test during 10000 intravenous (13)C-methacetin breath tests. J Breath Res 2017; 12: 016005
262 Stockmann M, Lock JF, Riecke B. et al. Prediction of postoperative outcome after hepatectomy with a new bedside test for maximal liver function capacity. Ann Surg 2009; 250: 119-125
263 Huang Z, Huang J, Zhou T. et al. Prognostic value of liver stiffness measurement for the liver-related surgical outcomes of patients under hepatic resection: A meta-analysis. PLoS One 2018; 13: e0190512 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5764309/pdf/pone.0190512.pdf
264 Simonetto DA, Liu M, Kamath PS. Portal Hypertension and Related Complications: Diagnosis and Management. Mayo Clin Proc 2019; 94: 714-726 https://www.sciencedirect.com/science/article/abs/pii/S0025619618310085?via%3Dihub
265 Roayaie S, Jibara G, Tabrizian P. et al. The role of hepatic resection in the treatment of hepatocellular cancer. Hepatology 2015; 62: 440-451
266 Ishizawa T, Hasegawa K, Aoki T. et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 2008; 134: 1908-1916 https://www.sciencedirect.com/science/article/pii/S0016508508004277?via%3Dihub
267 Torzilli G, Belghiti J, Kokudo N. et al. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations?: an observational study of the HCC East-West study group. Ann Surg 2013; 257: 929-937
268 Koh YX, Tan HL, Lye WK. et al. Systematic review of the outcomes of surgical resection for intermediate and advanced Barcelona Clinic Liver Cancer stage hepatocellular carcinoma: A critical appraisal of the evidence. World J Hepatol 2018; 10: 433-447 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033716/pdf/WJH-10-433.pdf
269 Zaydfudim VM, Vachharajani N, Klintmalm GB. et al. Liver Resection and Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria. Ann Surg 2016; 264: 650-658 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5279918/pdf/nihms-835604.pdf
270 Tsilimigras DI, Bagante F, Moris D. et al. Recurrence Patterns and Outcomes after Resection of Hepatocellular Carcinoma within and beyond the Barcelona Clinic Liver Cancer Criteria. Ann Surg Oncol 2020; 27: 2321-2331
271 Pang TC, Lam VW. Surgical management of hepatocellular carcinoma. World J Hepatol 2015; 7: 245-252 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342606/pdf/WJH-7-245.pdf
272 Feng X, Su Y, Zheng S. et al. A double blinded prospective randomized trial comparing the effect of anatomic versus non-anatomic resection on hepatocellular carcinoma recurrence. HPB (Oxford) 2017; 19: 667-674
273 Wakabayashi G, Cherqui D, Geller DA. et al. Recommendations for laparoscopic liver resection: a report from the second international consensus conference held in Morioka. Ann Surg 2015; 261: 619-629
274 Cherqui D, Soubrane O. Laparoscopic Liver Resection: An Ongoing Revolution. Ann Surg 2017; 265: 864-865 https://www.ingentaconnect.com/content/wk/sla/2017/00000265/00000005/art00019
275 Andreou A, Struecker B, Raschzok N. et al. Minimal-invasive versus open hepatectomy for hepatocellular carcinoma: Comparison of postoperative outcomes and long-term survivals using propensity score matching analysis. Surg Oncol 2018; 27: 751-758 https://www.sciencedirect.com/science/article/abs/pii/S0960740418302512?via%3Dihub
276 Haber PK, Wabitsch S, Krenzien F. et al. Laparoscopic liver surgery in cirrhosis – Addressing lesions in posterosuperior segments. Surg Oncol 2019; 28: 140-144 https://www.sciencedirect.com/science/article/abs/pii/S0960740418304614?via%3Dihub
277 Levi Sandri GB, Ettorre GM, Aldrighetti L. et al. Laparoscopic liver resection of hepatocellular carcinoma located in unfavorable segments: a propensity score-matched analysis from the I Go MILS (Italian Group of Minimally Invasive Liver Surgery) Registry. Surg Endosc 2019; 33: 1451-1458
278 Felli E, Cillo U, Pinna AD. et al. Salvage liver transplantation after laparoscopic resection for hepatocellular carcinoma: a multicenter experience. Updates Surg 2015; 67: 215-222
279 Chen MS, Li JQ, Zheng Y. et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006; 243: 321-328 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1448947/pdf/20060300s00006p321.pdf
280 Feng K, Yan J, Li X. et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol 2012; 57: 794-802 https://www.sciencedirect.com/science/article/pii/S0168827812003613?via%3Dihub
281 Huang J, Yan L, Cheng Z. et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg 2010; 252: 903-912
282 Ng KKC, Chok KSH, Chan ACY. et al. Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma. Br J Surg 2017; 104: 1775-1784
283 Yin L, Li H, Li AJ. et al. Partial hepatectomy vs transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT. J Hepatol 2014; 61: 82-88 https://www.sciencedirect.com/science/article/pii/S0168827814001561?via%3Dihub
284 Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60
285 Wahab MA, Shehta A, Hamed H. et al. Predictors of recurrence in hepatitis C virus related hepatocellular carcinoma after hepatic resection: a retrospective cohort study. Eurasian J Med 2014; 46: 36-41 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4261437/pdf/eajm-46-1-36.pdf
286 Ramacciato G, Mercantini P, Nigri GR. et al. Univariate and multivariate analysis of prognostic factors in the surgical treatment of hepatocellular carcinoma in cirrhotic patients. Hepatogastroenterology 2006; 53: 898-903
287 Di Costanzo GG, Tortora R, D’Adamo G. et al. Radiofrequency ablation versus laser ablation for the treatment of small hepatocellular carcinoma in cirrhosis: a randomized trial. J Gastroenterol Hepatol 2015; 30: 559-565
288 Cucchetti A, Piscaglia F, Cescon M. et al. An explorative data-analysis to support the choice between hepatic resection and radiofrequency ablation in the treatment of hepatocellular carcinoma. Dig Liver Dis 2014; 46: 257-263
289 Nishikawa H, Inuzuka T, Takeda H. et al. Comparison of percutaneous radiofrequency thermal ablation and surgical resection for small hepatocellular carcinoma. BMC Gastroenterol 2011; 11: 143 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3260104/pdf/1471-230X-11-143.pdf
290 Uhlig J, Sellers CM, Stein SM. et al. Radiofrequency ablation versus surgical resection of hepatocellular carcinoma: contemporary treatment trends and outcomes from the United States National Cancer Database. Eur Radiol 2019; 29: 2679-2689
291 Salmi A, Turrini R, Lanzani G. et al. Radiofrequency ablation of hepatocellular carcinoma in patients with and without cirrhosis. J Ultrasound 2009; 12: 118-124 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3552707/pdf/main.pdf
292 Mohanty S, Rajaram R, Bilimoria KY. et al. Assessment of non-surgical versus surgical therapy for localized hepatocellular carcinoma. J Surg Oncol 2016; 113: 175-180
293 Yamauchi R, Takata K, Shinagawa Y. et al. Hepatocellular Carcinoma Arising in a Non-cirrhotic Liver with Secondary Hemochromatosis. Intern Med 2019; 58: 661-665 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443541/pdf/1349-7235-58-0661.pdf
294 Livraghi T, Goldberg SN, Lazzaroni S. et al. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 1999; 210: 655-661
295 Lencioni RA, Allgaier HP, Cioni D. et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003; 228: 235-240
296 or =4 cm. Gastroenterology 2004; 127: 1714-1723 https://www.sciencedirect.com/science/article/abs/pii/S0016508504015720?via%3Dihub
297 Bruix J, Sherman M, Llovet JM. et al. Clinical management of hepatocellular carcinoma Conclusions of the Barcelona-2000 EASL conference European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430
298 Shiina S, Teratani T, Obi S. et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005; 129: 122-130 https://www.sciencedirect.com/science/article/abs/pii/S0016508505006918?via%3Dihub
299 Brunello F, Veltri A, Carucci P. et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: A randomized controlled trial. Scand J Gastroenterol 2008; 43: 727-735
300 Lin SM, Lin CJ, Lin CC. et al. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005; 54: 1151-1156 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1774888/pdf/gut05401151.pdf
301 Shiina S, Teratani T, Obi S. et al. Nonsurgical treatment of hepatocellular carcinoma: from percutaneous ethanol injection therapy and percutaneous microwave coagulation therapy to radiofrequency ablation. Oncology 2002; 62 (Suppl. 01) 64-68 https://www.karger.com/Article/Pdf/48278
302 Hara K, Takeda A, Tsurugai Y. et al. Radiotherapy for Hepatocellular Carcinoma Results in Comparable Survival to Radiofrequency Ablation: A Propensity Score Analysis. Hepatology 2019; 69: 2533-2545
303 Peng ZW, Zhang YJ, Chen MS. et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol 2013; 31: 426-432
304 Liu H, Wang ZG, Fu SY. et al. Randomized clinical trial of chemoembolization plus radiofrequency ablation versus partial hepatectomy for hepatocellular carcinoma within the Milan criteria. Br J Surg 2016; 103: 348-356
305 Endo K, Kuroda H, Oikawa T. et al. Efficacy of combination therapy with transcatheter arterial chemoembolization and radiofrequency ablation for intermediate-stage hepatocellular carcinoma. Scand J Gastroenterol 2018; 53: 1575-1583
306 Fukutomi S, Nomura Y, Nakashima O. et al. Evaluation of hepatocellular carcinoma spread via the portal system by 3-dimensional mapping. HPB (Oxford) 2017; 19: 1119-1125
307 Hendriks P, Sudiono D, Schaapman J. et al. Thermal ablation combined with transarterial chemoembolization for hepatocellular carcinoma: What is the right treatment sequence?. Eur J Radiol 2021; 144: 110006 https://pubmed.ncbi.nlm.nih.gov/34717187/
308 Smolock AR, Cristescu MM, Hinshaw A. et al. Combination transarterial chemoembolization and microwave ablation improves local tumor control for 3- to 5-cm hepatocellular carcinoma when compared with transarterial chemoembolization alone. Abdom Radiol (NY) 2018; 43: 2497-2504
309 Bonomo G, Della Vigna P, Monfardini L. et al. Combined therapies for the treatment of technically unresectable liver malignancies: bland embolization and radiofrequency thermal ablation within the same session. Cardiovasc Intervent Radiol 2012; 35: 1372-1379
310 Lo CM, Ngan H, Tso WK. et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-1171
311 Lammer J, Malagari K, Vogl T. et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33: 41-52 https://www.zora.uzh.ch/id/eprint/24207/1/Lammer_CardiovascInterventRadiol_2010_V.pdf
312 Golfieri R, Giampalma E, Renzulli M. et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer 2014; 111: 255-264 https://iris.unito.it/retrieve/handle/2318/149077/25760/art%20Doxorubicina-Tace%202014.pdf
313 Yamada R, Bassaco B, Bracewell S. et al. Long-term follow-up after conventional transarterial chemoembolization (c-TACE) with mitomycin for hepatocellular carcinoma (HCC). J Gastrointest Oncol 2019; 10: 348-353
314 Llovet JM, Real MI, Montana X. et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-1739 https://www.sciencedirect.com/science/article/pii/S014067360208649X?via%3Dihub
315 Abdel-Rahman O, Elsayed Z. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2020; 1: Cd011313
316 Yang J, Wang J, Zhou H. et al. Efficacy and safety of endoscopic radiofrequency ablation for unresectable extrahepatic cholangiocarcinoma: a randomized trial. Endoscopy 2018; 50: 751-760
317 Ludwig JM, Zhang D, Xing M. et al. Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus (90)Y-radioembolization for hepatocellular carcinoma. Eur Radiol 2017; 27: 2031-2041 https://link.springer.com/content/pdf/10.1007%2Fs00330-016-4548-3.pdf
318 Casadei Gardini A, Tamburini E, Inarrairaegui M. et al. Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials. Onco Targets Ther 2018; 11: 7315-7321 https://www.dovepress.com/getfile.php?fileID=45631
319 Kolligs FT, Bilbao JI, Jakobs T. et al. Pilot randomized trial of selective internal radiation therapy vs chemoembolization in unresectable hepatocellular carcinoma. Liver Int 2015; 35: 1715-1721
320 Katsanos K, Kitrou P, Spiliopoulos S. et al. Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials. PLoS One 2017; 12: e0184597 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5608206/pdf/pone.0184597.pdf
321 Pitton MB, Kloeckner R, Ruckes C. et al. Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol 2015; 38: 352-360 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355443/pdf/270_2014_Article_1012.pdf
322 Lobo L, Yakoub D, Picado O. et al. Unresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis. Cardiovasc Intervent Radiol 2016; 39: 1580-1588
323 Salem R, Gilbertsen M, Butt Z. et al. Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol 2013; 11: 1358-1365.e1 https://www.sciencedirect.com/science/article/abs/pii/S1542356513005971?via%3Dihub
324 Sangro B, Maini CL, Ettorre GM. et al. Radioembolisation in patients with hepatocellular carcinoma that have previously received liver-directed therapies. Eur J Nucl Med Mol Imaging 2018; 45: 1721-1730 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097757/pdf/259_2018_Article_3968.pdf
325 Johnson GE, Monsky WL, Valji K. et al. Yttrium-90 Radioembolization as a Salvage Treatment following Chemoembolization for Hepatocellular Carcinoma. J Vasc Interv Radiol 2016; 27: 1123-1129
326 Hilgard P, Hamami M, Fouly AE. et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 2010; 52: 1741-1749
327 Sangro B, Carpanese L, Cianni R. et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 2011; 54: 868-878
328 Kulik LM, Carr BI, Mulcahy MF. et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008; 47: 71-81
329 Mazzaferro V, Sposito C, Bhoori S. et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology 2013; 57: 1826-1837
330 Salem R, Lewandowski RJ, Mulcahy MF. et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010; 138: 52-64
331 Rim CH, Kim CY, Yang DS. et al. Comparison of radiation therapy modalities for hepatocellular carcinoma with portal vein thrombosis: A meta-analysis and systematic review. Radiother Oncol 2018; 129: 112-122 https://www.sciencedirect.com/science/article/abs/pii/S0167814017327305?via%3Dihub
332 Salem R, Padia S, Lam M. et al. Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group. Eur J Nucl Med Mol Imaging 2019; 46 (08) 1695-1704 https://pubmed.ncbi.nlm.nih.gov/31098749/
333 Levillain H, Bagni O, Deroose C. et al. International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres. Eur J Nucl Med Mol Imaging 2021; 48 (05) 1570-1584 https://pubmed.ncbi.nlm.nih.gov/33433699/
334 Garin E, Tselikas L, Guiu B. et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol 2021; 6 (01) 17-29 https://pubmed.ncbi.nlm.nih.gov/33166497/
335 Salem R, Johnson G, Kim E. et al. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study. Hepatology 2021; 74 (05) 2342-2352 https://pubmed.ncbi.nlm.nih.gov/33739462/
336 Vilgrain V, Pereira H, Assenat E. et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. The Lancet Oncology 2017; 18: 1624-1636
337 Chow PKH, Gandhi M, Tan SB. et al. SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. J Clin Oncol 2018; 36: 1913-1921 https://www.ncbi.nlm.nih.gov/pubmed/29498924
338 Sapir E, Tao Y, Schipper MJ. et al. Stereotactic Body Radiation Therapy as an Alternative to Transarterial Chemoembolization for Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys 2018; 100: 122-130 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818982/pdf/nihms942371.pdf
339 Eriguchi T, Takeda A, Tateishi Y. et al. Comparison of stereotactic body radiotherapy and radiofrequency ablation for hepatocellular carcinoma: Systematic review and meta-analysis of propensity score studies. Hepatol Res 2021; 51 (07) 813-822 https://pubmed.ncbi.nlm.nih.gov/33856722/
340 Rim C, Lee J, Kim S. et al. Comparison of radiofrequency ablation and ablative external radiotherapy for the treatment of intrahepatic malignancies: A hybrid meta-analysis. JHEP Rep 2023; 5 (01) 100594 https://pubmed.ncbi.nlm.nih.gov/36561128/
341 Craig T, Xiao Y, McNulty S. et al. Insights From Image Guided Radiation Therapy Credentialing for the NRG Oncology RTOG 1112 Liver Stereotactic Body Radiation Therapy Trial. Pract Radiat Oncol 2022; https://pubmed.ncbi.nlm.nih.gov/36581199/
342 Rim C, Kim H, Seong J. Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. Radiother Oncol 2019; 131: 135-144 https://pubmed.ncbi.nlm.nih.gov/30773180/
343 Brunner T, Bettinger D, Schultheiss M. et al. Efficacy of Stereotactic Body Radiotherapy in Patients With Hepatocellular Carcinoma Not Suitable for Transarterial Chemoembolization (HERACLES: HEpatocellular Carcinoma Stereotactic RAdiotherapy CLinical Efficacy Study). Front Oncol 2021; 11: 653141 https://pubmed.ncbi.nlm.nih.gov/33816309/
344 Omata M, Cheng A, Kokudo N. et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 2017; 11 (04) 317-370 https://pubmed.ncbi.nlm.nih.gov/28620797/
345 Vogel A, Cervantes A, Chau I. et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29: iv238-iv255
346 Guckenberger M, Baus W, Blanck O. et al. Definition and quality requirements for stereotactic radiotherapy: consensus statement from the DEGRO/DGMP Working Group Stereotactic Radiotherapy and Radiosurgery. Strahlenther Onkol 2020; 196 (05) 417-420 https://pubmed.ncbi.nlm.nih.gov/32211940/
347 Mizumoto M, Tokuuye K, Sugahara S. et al. Proton beam therapy for hepatocellular carcinoma adjacent to the porta hepatis. Int J Radiat Oncol Biol Phys 2008; 71: 462-467
348 Fukumitsu N, Sugahara S, Nakayama H. et al. A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2009; 74: 831-836
349 Sugahara S, Oshiro Y, Nakayama H. et al. Proton beam therapy for large hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2010; 76: 460-466
350 Kim T, Park J, Kim Y. et al. Phase I dose-escalation study of proton beam therapy for inoperable hepatocellular carcinoma. Cancer Res Treat 2015; 47 (01) 34-45 https://pubmed.ncbi.nlm.nih.gov/25381830/
351 Nakayama H, Sugahara S, Fukuda K. et al. Proton beam therapy for hepatocellular carcinoma located adjacent to the alimentary tract. Int J Radiat Oncol Biol Phys 2011; 80: 992-995
352 Bush DA, Smith JC, Slater JD. et al. Randomized Clinical Trial Comparing Proton Beam Radiation Therapy with Transarterial Chemoembolization for Hepatocellular Carcinoma: Results of an Interim Analysis. Int J Radiat Oncol Biol Phys 2016; 95: 477-482
353 Hong TS, Wo JY, Yeap BY. et al. Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Clin Oncol 2016; 34: 460-468 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872014/pdf/JCO642710.pdf
354 Mizumoto M, Oshiro Y, Okumura T. et al. Proton Beam Therapy for Hepatocellular Carcinoma: A Review of the University of Tsukuba Experience. Int J Part Ther 2016; 2 (04) 570-578 https://pubmed.ncbi.nlm.nih.gov/31772968/
355 Mohnike K, Wieners G, Schwartz F. et al. Computed tomography-guided high-dose-rate brachytherapy in hepatocellular carcinoma: safety, efficacy, and effect on survival. Int J Radiat Oncol Biol Phys 2010; 78: 172-179
356 Mohnike K, Steffen IG, Seidensticker M. et al. Radioablation by Image-Guided (HDR) Brachytherapy and Transarterial Chemoembolization in Hepatocellular Carcinoma: A Randomized Phase II Trial. Cardiovasc Intervent Radiol 2019; 42: 239-249
357 Collettini F, Schreiber N, Schnapauff D. et al. CT-guided high-dose-rate brachytherapy of unresectable hepatocellular carcinoma. Strahlenther Onkol 2015; 191: 405-412
358 Comito T, Loi M, Franzese C. et al. Stereotactic Radiotherapy after Incomplete Transarterial (Chemo-) Embolization (TAE\TACE) versus Exclusive TAE or TACE for Treatment of Inoperable HCC: A Phase III Trial (NCT02323360). Curr Oncol 2022; 29 (11) 8802-8813 https://pubmed.ncbi.nlm.nih.gov/36421345/
359 Buckstein M, Kim E, Özbek U. et al. Combination Transarterial Chemoembolization and Stereotactic Body Radiation Therapy for Unresectable Single Large Hepatocellular Carcinoma: Results From a Prospective Phase 2 Trial. Int J Radiat Oncol Biol Phys 2022; 114 (02) 221-230 https://pubmed.ncbi.nlm.nih.gov/35643250/
360 Yoon S, Ryoo B, Lee S. et al. Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial. JAMA Oncol 2018; 4 (05) 661-669 https://pubmed.ncbi.nlm.nih.gov/29543938/
361 Huo Y, Eslick G. Transcatheter Arterial Chemoembolization Plus Radiotherapy Compared With Chemoembolization Alone for Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. JAMA Oncol 2015; 1 (06) 756-765 https://pubmed.ncbi.nlm.nih.gov/26182200/
362 Bargellini I, Bozzi E, Campani D. et al. Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT-pathologic correlation in 178 liver explants. Eur J Radiol 2013; 82 (05) e212-e218 https://pubmed.ncbi.nlm.nih.gov/23332890/
363 Yu H, Bai Y, Xie X. et al. RECIST 11 versus mRECIST for assessment of tumour response to molecular targeted therapies and disease outcomes in patients with hepatocellular carcinoma: a systematic review and meta-analysis. BMJ Open 2022; 12 (06) e052294 https://pubmed.ncbi.nlm.nih.gov/35649603/
364 Kim D, Kim B, Choi J. et al. LI-RADS Treatment Response versus Modified RECIST for Diagnosing Viable Hepatocellular Carcinoma after Locoregional Therapy: A Systematic Review and Meta-Analysis of Comparative Studies. Taehan Yongsang Uihakhoe Chi 2022; 83 (02) 331-343 https://pubmed.ncbi.nlm.nih.gov/36237934/
365 Santillan C, Chernyak V, Sirlin C. LI-RADS categories: concepts, definitions, and criteria. Abdom Radiol (NY) 2018; 43: 101-110
366 Santillan C, Fowler K, Kono Y. et al. LI-RADS major features: CT, MRI with extracellular agents, and MRI with hepatobiliary agents. Abdom Radiol (NY) 2018; 43: 75-81
367 Takahashi S, Kudo M, Chung H. et al. Initial treatment response is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy. Oncology 2007; 72 (Suppl. 01) 98-103 https://www.karger.com/Article/Pdf/111714
368 Guglielmi A, Ruzzenente A, Pachera S. et al. Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response. Am J Gastroenterol 2008; 103: 597-604
369 Yoon JH, Lee EJ, Cha SS. et al. Comparison of gadoxetic acid-enhanced MR imaging versus four-phase multi-detector row computed tomography in assessing tumor regression after radiofrequency ablation in subjects with hepatocellular carcinomas. J Vasc Interv Radiol 2010; 21: 348-356
370 Vauthey JN, Dixon E, Abdalla EK. et al. Pretreatment assessment of hepatocellular carcinoma: expert consensus statement. HPB (Oxford) 2010; 12: 289-299 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2951814/pdf/hpb0012-0289.pdf
371 Schima W, Ba-Ssalamah A, Kurtaran A. et al. Post-treatment imaging of liver tumours. Cancer Imaging 2007; 7 Spec No A: S28-S36 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727978/pdf/ci079047.pdf
372 Frieser M, Kiesel J, Lindner A. et al. Efficacy of contrast-enhanced US versus CT or MRI for the therapeutic control of percutaneous radiofrequency ablation in the case of hepatic malignancies. Ultraschall Med 2011; 32: 148-153
373 Schacherer D, Girlich C, Jung ME. et al. Transabdominal ultrasound with echoenhancement by contrast media in the diagnosis of hepatocellular carcinoma. Dig Dis 2009; 27: 109-113 https://www.karger.com/Article/Pdf/218342
374 Lencioni R, Piscaglia F, Bolondi L. Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma. J Hepatol 2008; 48: 848-857 https://www.sciencedirect.com/science/article/pii/S0168827808001244?via%3Dihub
375 Crocetti L, de Baere T, Lencioni R. Quality improvement guidelines for radiofrequency ablation of liver tumours. Cardiovasc Intervent Radiol 2010; 33: 11-17 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2816824/pdf/270_2009_Article_9736.pdf
376 Tsai MC, Wang JH, Hung CH. et al. Favorable alpha-fetoprotein decrease as a prognostic surrogate in patients with hepatocellular carcinoma after radiofrequency ablation. J Gastroenterol Hepatol 2010; 25: 605-612
377 Lencioni R. New data supporting modified RECIST (mRECIST) for Hepatocellular Carcinoma. Clin Cancer Res 2013; 19: 1312-1314 https://clincancerres.aacrjournals.org/content/clincanres/19/6/1312.full.pdf
378 Vincenzi B, Di Maio M, Silletta M. et al. Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis. PLoS One 2015; 10: e0133488 https://iris.unito.it/retrieve/handle/2318/1572009/162002/pone.0133488.pdf
379 Finn RS, Qin S, Ikeda M. et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 2020; 382: 1894-1905
380 Cheng AL, Kang YK, Chen Z. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34 https://www.sciencedirect.com/science/article/pii/S1470204508702857?via%3Dihub
381 Kudo M, Finn RS, Qin S. et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. The Lancet 2018; 391: 1163-1173
382 Bruix J, Qin S, Merle P. et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 2017; 389: 56-66
383 Abou-Alfa GK, Meyer T, Cheng AL. et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med 2018; 379: 54-63
384 Zhu AX, Kang YK, Yen CJ. et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019; 20: 282-296
385 Facciorusso A, Tartaglia N, Villani R. et al. Lenvatinib versus sorafenib as first-line therapy of advanced hepatocellular carcinoma: a systematic review and meta-analysis. Am J Transl Res 2021; 13 (04) 2379-2387 https://pubmed.ncbi.nlm.nih.gov/34017396/
386 Abou-Alfa Ghassan K, Lau G, Kudo M. et al. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. NEJM Evidence 2022; 1: EVIDoa2100070
387 Llovet JM, Ricci S, Mazzaferro V. et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390
388 Zhu AX, Kang Y, Yen C. et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology 2019; 20: 282-296
389 Cheng A, Qin S, Ikeda M. et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs sorafenib for unresectable hepatocellular carcinoma. J Hepatol 2022; 76 (04) 862-873 https://pubmed.ncbi.nlm.nih.gov/34902530/
390 Galle P, Finn R, Qin S. et al. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. Lancet Oncol 2021; 22 (07) 991-1001 https://pubmed.ncbi.nlm.nih.gov/34051880/
391 Yau T, Park J, Finn R. et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 2022; 23 (01) 77-90 https://pubmed.ncbi.nlm.nih.gov/34914889/
392 Qin S, Kudo M, Meyer T. et al. Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial. JAMA Oncol 2023; 9 (12) 1651-1659 https://pubmed.ncbi.nlm.nih.gov/37796513/
393 Cainap C, Qin S, Huang WT. et al. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol 2015; 33: 172-179 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4279237/pdf/zlj172.pdf
394 Johnson PJ, Qin S, Park JW. et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol 2013; 31: 3517-3524
395 Zhu AX, Rosmorduc O, Evans TR. et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2015; 33: 559-566 http://diposit.ub.edu/dspace/bitstream/2445/117402/1/649304.pdf
396 Cheng AL, Kang YK, Lin DY. et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol 2013; 31: 4067-4075
397 Llovet J, Kudo M, Merle P. et al. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Lancet Oncol 2023; 24 (12) 1399-1410 https://pubmed.ncbi.nlm.nih.gov/38039993/
398 Marrero JA, Kudo M, Venook AP. et al. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study. J Hepatol 2016; 65: 1140-1147 https://www.journal-of-hepatology.eu/article/S0168-8278(16)30346-4/pdf
399 Ganten TM, Stauber RE, Schott E. et al. Sorafenib in Patients with Hepatocellular Carcinoma-Results of the Observational INSIGHT Study. Clin Cancer Res 2017; 23: 5720-5728 https://clincancerres.aacrjournals.org/content/clincanres/23/19/5720.full.pdf
400 Leal CRG, Magalhães C, Barbosa D. et al. Survival and tolerance to sorafenib in Child-Pugh B patients with hepatocellular carcinoma: a prospective study. Invest New Drugs 2018; 36: 911-918
401 Pressiani T, Boni C, Rimassa L. et al. Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis. Ann Oncol 2013; 24: 406-411 https://www.annalsofoncology.org/article/S0923-7534(19)36863-2/pdf
402 Ogasawara S, Chiba T, Ooka Y. et al. Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors. Invest New Drugs 2015; 33: 729-739 https://link.springer.com/article/10.1007%2Fs10637-015-0237-3
403 Rimini M, Persano M, Tada T. et al. Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients. J Cancer Res Clin Oncol 2023; 149 (10) 7565-7577 https://pubmed.ncbi.nlm.nih.gov/36976353/
404 Kudo M, Matilla A, Santoro A. et al. CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. J Hepatol 2021; 75 (03) 600-609 https://pubmed.ncbi.nlm.nih.gov/34051329/
405 El-Khoueiry A, Meyer T, Cheng A. et al. Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child-Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial. BMC Cancer 2022; 22 (01) 377 https://pubmed.ncbi.nlm.nih.gov/35397508/
406 Huynh J, Cho M, Kim E. et al. Lenvatinib in patients with unresectable hepatocellular carcinoma who progressed to Child-Pugh B liver function. Ther Adv Med Oncol 2022; 14 https://pubmed.ncbi.nlm.nih.gov/36051472/
407 Xie E, Yeo Y, Scheiner B. et al. Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. JAMA Oncol 2023; 9 (10) 1423-1431 https://pubmed.ncbi.nlm.nih.gov/37615958/
408 D’Alessio A, Fulgenzi C, Nishida N. et al. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study. Hepatology 2022; 76 (04) 1000-1012 https://pubmed.ncbi.nlm.nih.gov/35313048/
409 Jost-Brinkmann F, Demir M, Wree A. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from a German real-world cohort. Aliment Pharmacol Ther 2023; 57 (11) 1313-1325 https://pubmed.ncbi.nlm.nih.gov/36883351/
410 de Castro T, Jochheim L, Bathon M. et al. Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience. Ther Adv Med Oncol 2022; 14 https://pubmed.ncbi.nlm.nih.gov/35251317/
411 Vilgrain V, Pereira H, Assenat E. et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol 2017; 18: 1624-1636 https://www.sciencedirect.com/science/article/abs/pii/S1470204517306836
412 Lencioni R, Llovet JM, Han G. et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. J Hepatol 2016; 64: 1090-1098 https://www.ncbi.nlm.nih.gov/pubmed/26809111
413 Meyer T, Fox R, Ma YT. et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol 2017; 2: 565-575 https://www.thelancet.com/pdfs/journals/langas/PIIS2468-1253(17)30156-5.pdf
414 Cai R, Song R, Pang P. et al. Transcatheter arterial chemoembolization plus sorafenib versus transcatheter arterial chemoembolization alone to treat advanced hepatocellular carcinoma: a meta-analysis. BMC Cancer 2017; 17 (01) 714 https://pubmed.ncbi.nlm.nih.gov/29110700/
415 Dai Y, Jiang H, Jiang H. et al. Optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis. Transl Oncol 2021; 14 (12) 101238 https://pubmed.ncbi.nlm.nih.gov/34628285/
416 Duan R, Gong F, Wang Y. et al. Transarterial chemoembolization (TACE) plus tyrosine kinase inhibitors versus TACE in patients with hepatocellular carcinoma: a systematic review and meta-analysis. World J Surg Oncol 2023; 21 (01) 120 https://pubmed.ncbi.nlm.nih.gov/37004052/
417 Zhao S, Zhang T, Dou W. et al. A comparison of transcatheter arterial chemoembolization used with and without apatinib for intermediate- to advanced-stage hepatocellular carcinoma: a systematic review and meta-analysis. Ann Transl Med 2020; 8 (08) 542 https://pubmed.ncbi.nlm.nih.gov/32411765/
418 Gu H, Li J, You N. et al. Efficacy and safety of apatinib combined with transarterial chemoembolization (TACE) in treating patients with recurrent hepatocellular carcinoma. Ann Transl Med 2020; 8 (24) 1677 https://pubmed.ncbi.nlm.nih.gov/33490189/
419 Kudo M, Ueshima K, Ikeda M. et al. Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma. Liver Cancer 2022; 11 (04) 354-367 https://pubmed.ncbi.nlm.nih.gov/35978604/
420 Kudo M, Ueshima K, Ikeda M. et al. Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma. Liver Cancer 2022; 11 (04) 354-367 https://pubmed.ncbi.nlm.nih.gov/35978604/
421 Ding X, Sun W, Li W. et al. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study. Cancer 2021; 127 (20) 3782-3793 https://pubmed.ncbi.nlm.nih.gov/34237154/
422 Cai M, Huang W, Huang J. et al. Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study. Front Immunol 2022; 13: 848387 https://pubmed.ncbi.nlm.nih.gov/35300325/
423 Marinelli B, Kim E, D’Alessio A. et al. Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study. J Immunother Cancer 2022; 10 (06) https://pubmed.ncbi.nlm.nih.gov/35710293/
424 Fan W, Zhu B, Yue S. et al. Idarubicin-Loaded DEB-TACE plus Lenvatinib versus Lenvatinib for patients with advanced hepatocellular carcinoma: A propensity score-matching analysis. Cancer Med 2023; 12 (01) 61-72 https://pubmed.ncbi.nlm.nih.gov/35698292/
425 Ricke J, Klümpen HJ, Amthauer H. et al. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol 2019; 71: 1164-1174 https://www.journal-of-hepatology.eu/article/S0168-8278(19)30472-6/fulltext
426 Kudo M, Ueshima K, Ikeda M. et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut 2020; 69: 1492-1501 https://www.ncbi.nlm.nih.gov/pubmed/31801872
427 Kudo M, Ikeda M, Ueshima K. et al. Response Evaluation Criteria in Cancer of the Liver version 5 (RECICL 2019 revised version). Hepatol Res 2019; 49: 981-989 https://www.ncbi.nlm.nih.gov/pubmed/31231916
428 Kudo M, Ueshima K, Ikeda M. et al. TACTICS: Final overall survival (OS) data from a randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients (pts) with hepatocellular carcinoma (HCC). Journal of Clinical Oncology 2021; 39: 270-270
429 Bruix J, Qin S, Merle P. et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 389: 56-66 https://www.sciencedirect.com/science/article/pii/S0140673616324539?via%3Dihub
430 Finn R, Ryoo B, Merle P. et al. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. J Clin Oncol 2020; 38 (03) 193-202 https://pubmed.ncbi.nlm.nih.gov/31790344/
431 Rao Q, Li M, Xu W. et al. Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis. Hepatol Int 2020; 14 (05) 765-775 https://pubmed.ncbi.nlm.nih.gov/32572818/
432 Parikh N, Marshall A, Betts K. et al. Network meta-analysis of nivolumab plus ipilimumab in the second-line setting for advanced hepatocellular carcinoma. J Comp Eff Res 2021; 10 (05) 343-352 https://pubmed.ncbi.nlm.nih.gov/33442996/
433 He S, Jiang W, Fan K. et al. The Efficacy and Safety of Programmed Death-1 and Programmed Death Ligand 1 Inhibitors for the Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Front Oncol 2021; 11: 626984 https://pubmed.ncbi.nlm.nih.gov/33833987/
434 Kudo M, Finn R, Edeline J. et al. Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. Eur J Cancer 2022; 167: 1-12 https://pubmed.ncbi.nlm.nih.gov/35364421/
435 Yau T, Kang Y, Kim T. et al. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial. JAMA Oncol 2020; 6 (11) e204564 https://pubmed.ncbi.nlm.nih.gov/33001135/
436 El-Khoueiry AB, Sangro B, Yau T. et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017; 389: 2492-2502 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539326/pdf/nihms-1623792.pdf
437 Zhu AX, Finn RS, Edeline J. et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 2018; 19: 940-952 https://www.ncbi.nlm.nih.gov/pubmed/29875066
438 Finn RS, Ryoo BY, Merle P. et al. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. J Clin Oncol 2020; 38: 193-202 https://www.ncbi.nlm.nih.gov/pubmed/31790344
439 Qin S, Chen Z, Fang W. et al. Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study. Journal of Clinical Oncology 2022; 40: 383
440 Dinh T, Utria A, Barry K. et al. A framework for fibrolamellar carcinoma research and clinical trials. Nat Rev Gastroenterol Hepatol 2022; 19 (05) 328-342 https://pubmed.ncbi.nlm.nih.gov/35190728/
441 Honeyman J, Simon E, Robine N. et al. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science 2014; 343: 1010-1014 https://pubmed.ncbi.nlm.nih.gov/24578576/
442 Ramai D, Ofosu A, Lai J. et al. Fibrolamellar Hepatocellular Carcinoma: A Population-Based Observational Study. Dig Dis Sci 2021; 66 (01) 308-314 https://pubmed.ncbi.nlm.nih.gov/32052215/
443 Rimassa L, Personeni N, Czauderna C. et al. Systemic treatment of HCC in special populations. J Hepatol 2021; 74 (04) 931-943 https://pubmed.ncbi.nlm.nih.gov/33248171/
444 Wege H, Schulze K, von Felden J. et al. Rare variants of primary liver cancer: Fibrolamellar, combined, and sarcomatoid hepatocellular carcinomas. Eur J Med Genet 2021; 64 (11) 104313 https://pubmed.ncbi.nlm.nih.gov/34418585/
445 Da Fonseca L, Yamamoto V, Trinconi Cunha M. et al. Treatment Outcomes in Patients with Advanced Fibrolamellar Hepatocellular Carcinoma Under Systemic Treatment: Analysis of Clinical Characteristics, Management, and Radiomics. J Hepatocell Carcinoma 2023; 10: 1923-1933 https://pubmed.ncbi.nlm.nih.gov/37933267/
446 Chakrabarti S, Tella S, Kommalapati A. et al. Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma. J Gastrointest Oncol 2019; 10 (03) 554-561 https://pubmed.ncbi.nlm.nih.gov/31183207/
447 Gras P, Truant S, Boige V. et al. Prolonged Complete Response after GEMOX Chemotherapy in a Patient with Advanced Fibrolamellar Hepatocellular Carcinoma. Case Rep Oncol 2012; 5 (01) 169-172 https://pubmed.ncbi.nlm.nih.gov/22666208/
448 Patt Y, Hassan M, Lozano R. et al. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol 2003; 21 (03) 421-427 https://pubmed.ncbi.nlm.nih.gov/12560429/
449 Kim A, Gani F, Layman A. et al. Multiple Immune-Suppressive Mechanisms in Fibrolamellar Carcinoma. Cancer Immunol Res 2019; 7 (05) 805-812 https://pubmed.ncbi.nlm.nih.gov/30902819/
450 Chen K, Popovic A, Hsiehchen D. et al. Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors. Cancers (Basel) 2022; 14 (21) 5347 https://pubmed.ncbi.nlm.nih.gov/36358766/
451 Berger R, Dinstag G, Tirosh O. et al. Fibrolamellar carcinoma transcriptomic-based treatment prediction: complete response after nivolumab and ipilimumab. J Immunother Cancer 2022; 10 (12) e005620 https://pubmed.ncbi.nlm.nih.gov/36600603/
452 De Toni E, Roessler D. Using dual checkpoint blockade to treat fibrolamellar hepatocellular carcinoma. Gut 2020; 69 (11) 2056-2058 https://pubmed.ncbi.nlm.nih.gov/32051207/
453 Kang S, Magliocca J, Sellers M. et al. Successful Liver Transplantation of Recurrent Fibrolamellar Carcinoma following Clinical and Pathologic Complete Response to Triple Immunochemotherapy: A Case Report. Oncol Res Treat 2022; 45 (07) 430-437 https://pubmed.ncbi.nlm.nih.gov/35537414/
454 Gottlieb S, O’Grady C, Gliksberg A. et al. Early Experiences with Triple Immunochemotherapy in Adolescents and Young Adults with High-Risk Fibrolamellar Carcinoma. Oncology 2021; 99 (05) 310-317 https://pubmed.ncbi.nlm.nih.gov/33690232/
455 Bauer J, Köhler N, Maringer Y. et al. The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma. Nat Commun 2022; 13 (01) 6401 https://pubmed.ncbi.nlm.nih.gov/36302754/
456 Nagtegaal I, Odze R, Klimstra D. et al. The 2019 WHO classification of tumours of the digestive system. Histopathology 2020; 76 (02) 182-188 https://pubmed.ncbi.nlm.nih.gov/31433515/
457 Eschrich J, Kobus Z, Geisel D. et al. The Diagnostic Approach towards Combined Hepatocellular-Cholangiocarcinoma-State of the Art and Future Perspectives. Cancers (Basel) 2023; 15 (01) 301 https://pubmed.ncbi.nlm.nih.gov/36612297/
458 Gigante E, Paradis V, Ronot M. et al. New insights into the pathophysiology and clinical care of rare primary liver cancers. JHEP Rep 2021; 3 (01) 100174 https://pubmed.ncbi.nlm.nih.gov/33205035/
459 Xue R, Chen L, Zhang C. et al. Genomic and Transcriptomic Profiling of Combined Hepatocellular and Intrahepatic Cholangiocarcinoma Reveals Distinct Molecular Subtypes. Cancer Cell 2019; 35 (06) 932-947.e8 https://pubmed.ncbi.nlm.nih.gov/31130341/
460 Gigante E, Hobeika C, Le Bail B. et al. Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic Hepatocholangiocarcinoma. Liver Cancer 2022; 11 (05) 460-473 https://pubmed.ncbi.nlm.nih.gov/36158591/
461 Pomej K, Balcar L, Shmanko K. et al. Clinical characteristics and outcome of patients with combined hepatocellular-cholangiocarcinoma-a European multicenter cohort. ESMO Open 2023; 8 (01) 100783 https://pubmed.ncbi.nlm.nih.gov/36753993/
462 Jang Y, Kim E, Kim H. et al. Clinical outcomes of immune checkpoint inhibitors in unresectable or metastatic combined hepatocellular-cholangiocarcinoma. J Cancer Res Clin Oncol 2023; 149 (10) 7547-7555 https://pubmed.ncbi.nlm.nih.gov/36971796/
463 Rizell M, Åberg F, Perman M. et al. Checkpoint Inhibition Causing Complete Remission of Metastatic Combined Hepatocellular-Cholangiocarcinoma after Hepatic Resection. Case Rep Oncol 2020; 13 (01) 478-484 https://pubmed.ncbi.nlm.nih.gov/32508620/
464 Satake T, Shibuki T, Watanabe K. et al. Case Report: Atezolizumab plus bevacizumab for combined hepatocellular-cholangiocarcinoma. Front Oncol 2023; 13: 1234113 https://pubmed.ncbi.nlm.nih.gov/37546425/
465 Kim E, Yoo C, Kang H. et al. Clinical outcomes of systemic therapy in patients with unresectable or metastatic combined hepatocellular-cholangiocarcinoma. Liver Int 2021; 41 (06) 1398-1408 https://pubmed.ncbi.nlm.nih.gov/33548073/
466 Kobayashi S, Terashima T, Shiba S. et al. Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma. Cancer Sci 2018; 109 (08) 2549-2557 https://pubmed.ncbi.nlm.nih.gov/29856900/
467 Rogers J, Bolonesi R, Rashid A. et al. Systemic therapy for unresectable, mixed hepatocellular-cholangiocarcinoma: treatment of a rare malignancy. J Gastrointest Oncol 2017; 8 (02) 347-351 https://pubmed.ncbi.nlm.nih.gov/28480073/
468 Trikalinos N, Zhou A, Doyle M. et al. Systemic Therapy for Combined Hepatocellular-Cholangiocarcinoma: A Single-Institution Experience. J Natl Compr Canc Netw 2018; 16 (10) 1193-1199 https://pubmed.ncbi.nlm.nih.gov/30323089/
469 Salimon M, Prieux-Klotz C, Tougeron D. et al. Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study. Br J Cancer 2018; 118 (03) 325-330 https://pubmed.ncbi.nlm.nih.gov/29169182/
470 Qin S, Chen M, Cheng A. et al. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet 2023; 402: 1835-1847 https://pubmed.ncbi.nlm.nih.gov/37871608/
471 Bruix J, Takayama T, Mazzaferro V. et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 2015; 16: 1344-1354 https://www.sciencedirect.com/science/article/pii/S1470204515001989?via%3Dihub
472 Vogel A, Grant R, Meyer T. et al. Adjuvant and neoadjuvant therapies for hepatocellular carcinoma. Hepatology 2023; https://pubmed.ncbi.nlm.nih.gov/38108634/
473 Ho W, Zhu Q, Durham J. et al. Neoadjuvant Cabozantinib and Nivolumab Converts Locally Advanced HCC into Resectable Disease with Enhanced Antitumor Immunity. Nat Cancer 2021; 2 (09) 891-903 https://pubmed.ncbi.nlm.nih.gov/34796337/
474 Kaseb A, Hasanov E, Cao H. et al. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol 2022; 7 (03) 208-218 https://pubmed.ncbi.nlm.nih.gov/35065057/
475 Marron T, Fiel M, Hamon P. et al. Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. Lancet Gastroenterol Hepatol 2022; 7 (03) 219-229 https://pubmed.ncbi.nlm.nih.gov/35065058/
476 Xia Y, Tang W, Qian X. et al. Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial. J Immunother Cancer 2022; 10 (04) e004656 https://pubmed.ncbi.nlm.nih.gov/35379737/
477 Katzenstein HM, Krailo MD, Malogolowkin MH. et al. Hepatocellular carcinoma in children and adolescents: results from the Pediatric Oncology Group and the Children’s Cancer Group intergroup study. J Clin Oncol 2002; 20: 2789-2797
478 Czauderna P, Mackinlay G, Perilongo G. et al. Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology group. J Clin Oncol 2002; 20: 2798-2804 https://www.ncbi.nlm.nih.gov/pubmed/12065556
479 Schmid I, von Schweinitz D. Pediatric hepatocellular carcinoma: challenges and solutions. J Hepatocell Carcinoma 2017; 4: 15-21 https://pubmed.ncbi.nlm.nih.gov/28144610/
480 Schmid I, Häberle B, Albert MH. et al. Sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma. Pediatr Blood Cancer 2012; 58: 539-544
481 Villani A, Davidson S, Kanwar N. et al. The clinical utility of integrative genomics in childhood cancer extends beyond targetable mutations. Nat Cancer 2023; 4 (02) 203-221 https://pubmed.ncbi.nlm.nih.gov/36585449/
482 Schroeder C, Faust U, Krauße L. et al. Clinical trio genome sequencing facilitates the interpretation of variants in cancer predisposition genes in paediatric tumour patients. Eur J Hum Genet 2023; 31 (10) 1139-1146 https://pubmed.ncbi.nlm.nih.gov/37507557/
483 Cohen-Gogo S, Denburg A, Villani A. et al. Precision oncology for children: A primer for paediatricians. Paediatr Child Health 2023; 28 (05) 278-284 https://pubmed.ncbi.nlm.nih.gov/37484033/
484 Parsons D, Roy A, Yang Y. et al. Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors. JAMA Oncol 2016; 2 (05) 616-624 https://pubmed.ncbi.nlm.nih.gov/26822237/
485 Atchison EA, Gridley G, Carreon JD. et al. Risk of cancer in a large cohort of US veterans with diabetes. Int J Cancer 2011; 128: 635-643
486 de Valle MB, Björnsson E, Lindkvist B. Mortality and cancer risk related to primary sclerosing cholangitis in a Swedish population-based cohort. Liver Int 2012; 32: 441-448
487 El-Serag HB, Engels EA, Landgren O. et al. Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of US veterans. Hepatology 2009; 49: 116-123
488 Huang Y, You L, Xie W. et al. Smoking and risk of cholangiocarcinoma: a systematic review and meta-analysis. Oncotarget 2017; 8: 100570-100581 https://www.oncotarget.com/article/20141/pdf/
489 Jing W, Jin G, Zhou X. et al. Diabetes mellitus and increased risk of cholangiocarcinoma: a meta-analysis. Eur J Cancer Prev 2012; 21: 24-31
490 Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol 2012; 57: 69-76 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3804834/pdf/nihms363811.pdf
491 Wongjarupong N, Assavapongpaiboon B, Susantitaphong P. et al. Non-alcoholic fatty liver disease as a risk factor for cholangiocarcinoma: a systematic review and meta-analysis. BMC Gastroenterol 2017; 17: 149 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721586/pdf/12876_2017_Article_696.pdf
492 Park JY, Hong SP, Kim YJ. et al. Long-term follow up of gallbladder polyps. J Gastroenterol Hepatol 2009; 24: 219-222
493 Nagaraja V, Eslick GD. Systematic review with meta-analysis: the relationship between chronic Salmonella typhi carrier status and gall-bladder cancer. Aliment Pharmacol Ther 2014; 39: 745-750
494 Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet 2014; 383: 2168-2179 https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(13)61903-0.pdf
495 Rizvi S, Khan SA, Hallemeier CL. et al. Cholangiocarcinoma – evolving concepts and therapeutic strategies. Nat Rev Clin Oncol 2018; 15: 95-111
496 Valle JW, Borbath I, Khan SA. et al. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27: v28-v37 https://pubmed.ncbi.nlm.nih.gov/27664259/
497 Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology 2013; 145: 1215-1229 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3862291/pdf/nihms535439.pdf
498 Kamsa-ard S, Kamsa-ard S, Luvira V. et al. Risk Factors for Cholangiocarcinoma in Thailand: A Systematic Review and Meta-Analysis. Asian Pac J Cancer Prev 2018; 19: 605-614 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980830/pdf/APJCP-19-605.pdf
499 Qian MB, Utzinger J, Keiser J. et al. Clonorchiasis. Lancet 2016; 387: 800-810
500 Qian MB, Zhou XN. Global burden of cancers attributable to liver flukes. Lancet Glob Health 2017; 5: e139
501 You MS, Lee SH, Kang J. et al. Natural Course and Risk of Cholangiocarcinoma in Patients with Recurrent Pyogenic Cholangitis: A Retrospective Cohort Study. Gut Liver 2019; 13: 373-379 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6529165/pdf/gnl-13-373.pdf
502 Ten Hove A, de Meijer VE, Hulscher JBF. et al. Meta-analysis of risk of developing malignancy in congenital choledochal malformation. Br J Surg 2018; 105: 482-490 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5900735/pdf/BJS-105-482.pdf
503 Fahrner R, Dennler SG, Inderbitzin D. Risk of malignancy in Caroli disease and syndrome: A systematic review. World J Gastroenterol 2020; 26: 4718-4728 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445861/pdf/WJG-26-4718.pdf
504 Claessen MM, Vleggaar FP, Tytgat KM. et al. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol 2009; 50: 158-164
505 Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology 2011; 54: 173-184
506 McGee EE, Jackson SS, Petrick JL. et al. Smoking, Alcohol, and Biliary Tract Cancer Risk: A Pooling Project of 26 Prospective Studies. J Natl Cancer Inst 2019; 111: 1263-1278 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6910180/pdf/djz103.pdf
507 Clements O, Eliahoo J, Kim JU. et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis. J Hepatol 2020; 72: 95-103
508 Schmidt MA, Marcano-Bonilla L, Roberts LR. Gallbladder cancer: epidemiology and genetic risk associations. Chin Clin Oncol 2019; 8: 31 http://cco.amegroups.com/article/view/28517/25064
509 Rawla P, Sunkara T, Thandra KC. et al. Epidemiology of gallbladder cancer. Clin Exp Hepatol 2019; 5: 93-102 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6728871/pdf/CEH-5-36699.pdf
510 Kratzer W, Schmid A, Akinli AS. et al. [Gallbladder polyps: prevalence and risk factors]. Ultraschall Med 2011; 32 (Suppl. 01) S68-S73 https://www.thieme-connect.com/products/ejournals/pdf/10.1055/s-0029-1245265.pdf
511 Schnelldorfer T. Porcelain gallbladder: a benign process or concern for malignancy?. J Gastrointest Surg 2013; 17: 1161-1168
512 DesJardins H, Duy L, Scheirey C. et al. Porcelain Gallbladder: Is Observation a Safe Option in Select Populations?. J Am Coll Surg 2018; 226: 1064-1069 https://www.sciencedirect.com/science/article/abs/pii/S1072751518301571?via%3Dihub
513 Patel S, Roa JC, Tapia O. et al. Hyalinizing cholecystitis and associated carcinomas: clinicopathologic analysis of a distinctive variant of cholecystitis with porcelain-like features and accompanying diagnostically challenging carcinomas. Am J Surg Pathol 2011; 35: 1104-1113
514 Gutt C, Jenssen C, Barreiros AP. et al. [Updated S3-Guideline for Prophylaxis, Diagnosis and Treatment of Gallstones German Society for Digestive and Metabolic Diseases (DGVS) and German Society for Surgery of the Alimentary Tract (DGAV) – AWMF Registry 021/008]. Z Gastroenterol 2018; 56: 912-966
515 Eaton JE, Thackeray EW, Lindor KD. Likelihood of malignancy in gallbladder polyps and outcomes following cholecystectomy in primary sclerosing cholangitis. Am J Gastroenterol 2012; 107: 431-439
516 [Practice guideline autoimmune liver diseases – AWMF-Reg No 021-27]. Z Gastroenterol 2017; 55: 1135-1226 10.1055/s-0043-120199
517 Wiles R, Thoeni RF, Barbu ST. et al. Management and follow-up of gallbladder polyps: Joint guidelines between the European Society of Gastrointestinal and Abdominal Radiology (ESGAR), European Association for Endoscopic Surgery and other Interventional Techniques (EAES), International Society of Digestive Surgery - European Federation (EFISDS) and European Society of Gastrointestinal Endoscopy (ESGE). Eur Radiol 2017; 27: 3856-3866 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5544788/pdf/330_2017_Article_4742.pdf
518 Fung BM, Lindor KD, Tabibian JH. Cancer risk in primary sclerosing cholangitis: Epidemiology, prevention, and surveillance strategies. World J Gastroenterol 2019; 25: 659-671 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378537/pdf/WJG-25-659.pdf
519 Charatcharoenwitthaya P, Enders FB, Halling KC. et al. Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology 2008; 48: 1106-1117
520 Naitoh I, Nakazawa T, Kato A. et al. Predictive factors for positive diagnosis of malignant biliary strictures by transpapillary brush cytology and forceps biopsy. J Dig Dis 2016; 17: 44-51
521 Navaneethan U, Njei B, Lourdusamy V. et al. Comparative effectiveness of biliary brush cytology and intraductal biopsy for detection of malignant biliary strictures: a systematic review and meta-analysis. Gastrointest Endosc 2015; 81: 168-176 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824293/pdf/nihms773255.pdf
522 Klimstra DS LA. Tumors of the gallbladder and extrahepatic bile ducts. In: WHO Classification of Tumours Editorial Board WHO-Classification of Tumours (5th ed.) Digestive System Tumours. International Agency for Research on Cancer. Lyon: 2019: 265-294
523 Moeini A, Sia D, Zhang Z. et al. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity. J Hepatol 2017; 66: 952-961
524 Paradis V SP. Other tumours of the digestive system. In: WHO Classification of Tumours Editorial Board WHO-Classification of Tumours (5th ed.) Digestive System Tumours. International Agency for Research on Cancer. Lyon: 2019: 499-510
525 C W. TNM-Klassifikation maligner Tumoren (8 Auflage, korrigierter Nachdruck). Weinheim: Wiley-VCH; 2020
526 Wagner G HP. Organspezifische Tumordokumentation – Prinzipien und Verschlüsselungsanweisungen für Klinik und Praxis. Online-version: deutsche Krebsgesellschaft. Frankfurt (Main).: 1995
527 Khuntikeo N, Chamadol N, Yongvanit P. et al. Cohort profile: cholangiocarcinoma screening and care program (CASCAP). BMC Cancer 2015; 15: 459 https://www.ncbi.nlm.nih.gov/pubmed/26054405
528 Li R, Zhang X, Ma KS. et al. Dynamic enhancing vascular pattern of intrahepatic peripheral cholangiocarcinoma on contrast-enhanced ultrasound: the influence of chronic hepatitis and cirrhosis. Abdom Imaging 2013; 38: 112-119 https://link.springer.com/content/pdf/10.1007%2Fs00261-012-9854-x.pdf
529 Xu HX, Chen LD, Liu LN. et al. Contrast-enhanced ultrasound of intrahepatic cholangiocarcinoma: correlation with pathological examination. Br J Radiol 2012; 85: 1029-1037 https://www.ncbi.nlm.nih.gov/pubmed/22374276
530 Wildner D, Bernatik T, Greis C. et al. CEUS in hepatocellular carcinoma and intrahepatic cholangiocellular carcinoma in 320 patients – early or late washout matters: a subanalysis of the DEGUM multicenter trial. Ultraschall Med 2015; 36: 132-139
531 Bach AM, Hann LE, Brown KT. et al. Portal vein evaluation with US: comparison to angiography combined with CT arterial portography. Radiology 1996; 201: 149-154 https://www.ncbi.nlm.nih.gov/pubmed/8816536
532 Wennmacker SZ, Lamberts MP, Di Martino M. et al. Transabdominal ultrasound and endoscopic ultrasound for diagnosis of gallbladder polyps. Cochrane Database Syst Rev 2018; 8: CD012233 https://www.ncbi.nlm.nih.gov/pubmed/30109701
533 Zhang Y, Uchida M, Abe T. et al. Intrahepatic peripheral cholangiocarcinoma: comparison of dynamic CT and dynamic MRI. J Comput Assist Tomogr 1999; 23: 670-677 https://www.ncbi.nlm.nih.gov/pubmed/10524843
534 Johnson PT, Fishman EK. Routine use of precontrast and delayed acquisitions in abdominal CT: time for change. Abdom Imaging 2013; 38: 215-223 https://www.ncbi.nlm.nih.gov/pubmed/23132390
535 Fabrega-Foster K, Ghasabeh MA, Pawlik TM. et al. Multimodality imaging of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr 2017; 6: 67-78 https://www.ncbi.nlm.nih.gov/pubmed/28503554
536 Valls C, Guma A, Puig I. et al. Intrahepatic peripheral cholangiocarcinoma: CT evaluation. Abdom Imaging 2000; 25: 490-496 https://www.ncbi.nlm.nih.gov/pubmed/10931983
537 Kim JH, Won HJ, Shin YM. et al. Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma. Am J Roentgenol 2011; 196: W205-W209
538 Bridgewater J, Galle PR, Khan SA. et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol 2014; 60: 1268-1289 https://www.ncbi.nlm.nih.gov/pubmed/24681130
539 Jhaveri KS, Hosseini-Nik H. MRI of cholangiocarcinoma. J Magn Reson Imaging 2015; 42: 1165-1179 https://www.ncbi.nlm.nih.gov/pubmed/25447417
540 Murakami T, Nakamura H, Tsuda K. et al. Contrast-enhanced MR imaging of intrahepatic cholangiocarcinoma: pathologic correlation study. J Magn Reson Imaging 1995; 5: 165-170 https://www.ncbi.nlm.nih.gov/pubmed/7766977
541 Hamrick-Turner J, Abbitt PL, Ros PR. Intrahepatic cholangiocarcinoma: MR appearance. Am J Roentgenol 1992; 158: 77-79 https://www.ncbi.nlm.nih.gov/pubmed/1309221
542 Fan ZM, Yamashita Y, Harada M. et al. Intrahepatic cholangiocarcinoma: spin-echo and contrast-enhanced dynamic MR imaging. Am J Roentgenol 1993; 161: 313-317 https://www.ncbi.nlm.nih.gov/pubmed/8392787
543 https://www.ncbi.nlm.nih.gov/pubmed/24559750
544 Chung YE, Kim MJ, Park YN. et al. Varying appearances of cholangiocarcinoma: radiologic-pathologic correlation. Radiographics 2009; 29: 683-700 https://www.ncbi.nlm.nih.gov/pubmed/19448110
545 Park HJ, Kim YK, Park MJ. et al. Small intrahepatic mass-forming cholangiocarcinoma: target sign on diffusion-weighted imaging for differentiation from hepatocellular carcinoma. Abdom Imaging 2013; 38: 793-801 https://www.ncbi.nlm.nih.gov/pubmed/22829097
546 Fattach HE, Dohan A, Guerrache Y. et al. Intrahepatic and hilar mass-forming cholangiocarcinoma: Qualitative and quantitative evaluation with diffusion-weighted MR imaging. Eur J Radiol 2015; 84: 1444-1451 https://www.ncbi.nlm.nih.gov/pubmed/26022518
547 Navaneethan U, Njei B, Venkatesh PG. et al. Endoscopic ultrasound in the diagnosis of cholangiocarcinoma as the etiology of biliary strictures: a systematic review and meta-analysis. Gastroenterol Rep (Oxf) 2015; 3: 209-215 https://www.ncbi.nlm.nih.gov/pubmed/25169922
548 Pahade JK, Juice D, Staib L. et al. Is there an added value of a hepatobiliary phase with gadoxetate disodium following conventional MRI with an extracellular gadolinium agent in a single imaging session for detection of primary hepatic malignancies?. Abdom Radiol (NY) 2016; 41: 1270-1284 https://link.springer.com/content/pdf/10.1007%2Fs00261-016-0635-9.pdf
549 Park HJ, Kim SH, Jang KM. et al. The role of diffusion-weighted MR imaging for differentiating benign from malignant bile duct strictures. Eur Radiol 2014; 24: 947-958 https://www.ncbi.nlm.nih.gov/pubmed/24487774
550 Lee J, Kim SH, Kang TW. et al. Mass-forming Intrahepatic Cholangiocarcinoma: Diffusion-weighted Imaging as a Preoperative Prognostic Marker. Radiology 2016; 281: 119-128 https://www.ncbi.nlm.nih.gov/pubmed/27115053
551 Rupp C, Hippchen T, Bruckner T. et al. Effect of scheduled endoscopic dilatation of dominant strictures on outcome in patients with primary sclerosing cholangitis. Gut 2019; 68: 2170-2178 https://www.ncbi.nlm.nih.gov/pubmed/30910856
552 Zhang H, Zhu J, Ke F. et al. Radiological Imaging for Assessing the Respectability of Hilar Cholangiocarcinoma: A Systematic Review and Meta-Analysis. Biomed Res Int 2015; 2015: 497942 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4569758/pdf/BMRI2015-497942.pdf
553 Lamarca A, Barriuso J, Chander A. et al. 18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) for patients with biliary tract cancer: Systematic review and meta-analysis. J Hepatol 2019; 71 (01) 115-129 https://pubmed.ncbi.nlm.nih.gov/30797051/
554 Feng ST, Wu L, Cai H. et al. Cholangiocarcinoma: spectrum of appearances on Gd-EOB-DTPA-enhanced MR imaging and the effect of biliary function on signal intensity. BMC Cancer 2015; 15: 38 https://www.ncbi.nlm.nih.gov/pubmed/25655565
555 Kim SH, Lee CH, Kim BH. et al. Typical and atypical imaging findings of intrahepatic cholangiocarcinoma using gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging. J Comput Assist Tomogr 2012; 36: 704-709 https://www.ncbi.nlm.nih.gov/pubmed/23192208
556 Kiefer LS, Sekler J, Gückel B. et al. Impact of 18F-FDG-PET/CT on Clinical Management in Patients with Cholangiocellular Carcinoma. BJR|Open 2021; 3: 20210008
557 De Moura DTH, Moura EGH, Bernardo WM. et al. Endoscopic retrograde cholangiopancreatography versus endoscopic ultrasound for tissue diagnosis of malignant biliary stricture: Systematic review and meta-analysis. Endosc Ultrasound 2018; 7: 10-19 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838722/pdf/EUS-7-10.pdf
558 Heimbach JK, Sanchez W, Rosen CB. et al. Trans-peritoneal fine needle aspiration biopsy of hilar cholangiocarcinoma is associated with disease dissemination. HPB (Oxford) 2011; 13: 356-360 https://www.ncbi.nlm.nih.gov/pubmed/21492336
559 El Chafic AH, Dewitt J, Leblanc JK. et al. Impact of preoperative endoscopic ultrasound-guided fine needle aspiration on postoperative recurrence and survival in cholangiocarcinoma patients. Endoscopy 2013; 45: 883-889 https://www.ncbi.nlm.nih.gov/pubmed/24165813
560 Korc P, Sherman S. ERCP tissue sampling. Gastrointest Endosc 2016; 84: 557-571 https://www.ncbi.nlm.nih.gov/pubmed/27156656
561 Fogel EL, deBellis M, McHenry L. et al. Effectiveness of a new long cytology brush in the evaluation of malignant biliary obstruction: a prospective study. Gastrointest Endosc 2006; 63: 71-77 https://www.ncbi.nlm.nih.gov/pubmed/16377319
562 Shieh FK, Luong-Player A, Khara HS. et al. Improved endoscopic retrograde cholangiopancreatography brush increases diagnostic yield of malignant biliary strictures. World J Gastrointest Endosc 2014; 6: 312-317 https://www.ncbi.nlm.nih.gov/pubmed/25031790
563 Glasbrenner B, Ardan M, Boeck W. et al. Prospective evaluation of brush cytology of biliary strictures during endoscopic retrograde cholangiopancreatography. Endoscopy 1999; 31: 712-717 https://www.ncbi.nlm.nih.gov/pubmed/10604612
564 Macken E, Drijkoningen M, Van Aken E. et al. Brush cytology of ductal strictures during ERCP. Acta Gastroenterol Belg 2000; 63: 254-259 https://www.ncbi.nlm.nih.gov/pubmed/11189981
565 Mansfield JC, Griffin SM, Wadehra V. et al. A prospective evaluation of cytology from biliary strictures. Gut 1997; 40: 671-677 https://www.ncbi.nlm.nih.gov/pubmed/9203949
566 Trikudanathan G, Navaneethan U, Njei B. et al. Diagnostic yield of bile duct brushings for cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis. Gastrointest Endosc 2014; 79: 783-789 https://www.ncbi.nlm.nih.gov/pubmed/24140129
567 Draganov PV, Chauhan S, Wagh MS. et al. Diagnostic accuracy of conventional and cholangioscopy-guided sampling of indeterminate biliary lesions at the time of ERCP: a prospective, long-term follow-up study. Gastrointest Endosc 2012; 75: 347-353 https://www.ncbi.nlm.nih.gov/pubmed/22248602
568 Sugiyama M, Atomi Y, Wada N. et al. Endoscopic transpapillary bile duct biopsy without sphincterotomy for diagnosing biliary strictures: a prospective comparative study with bile and brush cytology. Am J Gastroenterol 1996; 91: 465-467 https://www.ncbi.nlm.nih.gov/pubmed/8633492
569 Jailwala J, Fogel EL, Sherman S. et al. Triple-tissue sampling at ERCP in malignant biliary obstruction. Gastrointest Endosc 2000; 51: 383-390 https://www.ncbi.nlm.nih.gov/pubmed/10744806
570 Hartman DJ, Slivka A, Giusto DA. et al. Tissue yield and diagnostic efficacy of fluoroscopic and cholangioscopic techniques to assess indeterminate biliary strictures. Clin Gastroenterol Hepatol 2012; 10: 1042-1046 https://www.ncbi.nlm.nih.gov/pubmed/22677575
571 Pugliese V, Conio M, Nicolo G. et al. Endoscopic retrograde forceps biopsy and brush cytology of biliary strictures: a prospective study. Gastrointest Endosc 1995; 42: 520-526 https://www.ncbi.nlm.nih.gov/pubmed/8674921
572 Kitajima Y, Ohara H, Nakazawa T. et al. Usefulness of transpapillary bile duct brushing cytology and forceps biopsy for improved diagnosis in patients with biliary strictures. J Gastroenterol Hepatol 2007; 22: 1615-1620 https://www.ncbi.nlm.nih.gov/pubmed/17573833
573 Navaneethan U, Hasan MK, Lourdusamy V. et al. Single-operator cholangioscopy and targeted biopsies in the diagnosis of indeterminate biliary strictures: a systematic review. Gastrointest Endosc 2015; 82: 608-614 e2 https://www.ncbi.nlm.nih.gov/pubmed/26071061
574 Gerges C, Beyna T, Tang RSY. et al. Digital single-operator peroral cholangioscopy-guided biopsy versus ERCP-guided brushing for indeterminate biliary strictures: a prospective, randomized multicenter trial (with video). Gastrointest Endosc 2019; https://www.ncbi.nlm.nih.gov/pubmed/31778656
575 Aabakken L, Karlsen TH, Albert J. et al. Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. Endoscopy 2017; 49: 588-608
576 Bagante F, Spolverato G, Weiss M. et al. Assessment of the Lymph Node Status in Patients Undergoing Liver Resection for Intrahepatic Cholangiocarcinoma: the New Eighth Edition AJCC Staging System. J Gastrointest Surg 2018; 22: 52-59
577 Bagante F, Spolverato G, Weiss M. et al. Surgical Management of Intrahepatic Cholangiocarcinoma in Patients with Cirrhosis: Impact of Lymphadenectomy on Peri-Operative Outcomes. World J Surg 2018; 42: 2551-2560
578 Ebata T, Mizuno T, Yokoyama Y. et al. Surgical resection for Bismuth type IV perihilar cholangiocarcinoma. Br J Surg 2018; 105: 829-838
579 El-Diwany R, Pawlik TM, Ejaz A. Intrahepatic Cholangiocarcinoma. Surg Oncol Clin N Am 2019; 28: 587-599 https://www.sciencedirect.com/science/article/abs/pii/S1055320719300444?via%3Dihub
580 Lang H, Sotiropoulos GC, Sgourakis G. et al. Operations for intrahepatic cholangiocarcinoma: single-institution experience of 158 patients. J Am Coll Surg 2009; 208: 218-228
581 Schnitzbauer AA, Eberhard J, Bartsch F. et al. The MEGNA Score and Preoperative Anemia are Major Prognostic Factors After Resection in the German Intrahepatic Cholangiocarcinoma Cohort. Ann Surg Oncol 2020; 27: 1147-1155
582 Zhang XF, Bagante F, Chakedis J. et al. Perioperative and Long-Term Outcome for Intrahepatic Cholangiocarcinoma: Impact of Major Versus Minor Hepatectomy. J Gastrointest Surg 2017; 21: 1841-1850 10.1007/s11605-017-3499-6
583 Bartsch F, Tripke V, Baumgart J. et al. Extended resection of intrahepatic cholangiocarcinoma: A retrospective single-center cohort study. Int J Surg 2019; 67: 62-69 https://www.sciencedirect.com/science/article/abs/pii/S1743919119301116?via%3Dihub
584 Mizuno T, Ebata T, Nagino M. Advanced hilar cholangiocarcinoma: An aggressive surgical approach for the treatment of advanced hilar cholangiocarcinoma: Perioperative management, extended procedures, and multidisciplinary approaches. Surg Oncol 2020; 33: 201-206 https://www.sciencedirect.com/science/article/abs/pii/S0960740419302439?via%3Dihub
585 Rassam F, Roos E, van Lienden KP. et al. Modern work-up and extended resection in perihilar cholangiocarcinoma: the AMC experience. Langenbecks Arch Surg 2018; 403: 289-307 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5986829/pdf/423_2018_Article_1649.pdf
586 Primrose JN, Fox RP, Palmer DH. et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol 2019; 20: 663-673 https://www.sciencedirect.com/science/article/abs/pii/S147020451830915X?via%3Dihub
587 Le RoyB, Gelli M, Pittau G. et al. Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma. Br J Surg 2018; 105: 839-847
588 Chang Y, Li Q, Wu Q. et al. Impact of surgical strategies on the survival of gallbladder cancer patients: analysis of 715 cases. World J Surg Oncol 2020; 18: 142 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320575/pdf/12957_2020_Article_1915.pdf
589 Coimbra FJF, Torres OJM, Alikhanov R. et al. BRAZILIAN CONSENSUS ON INCIDENTAL GALLBLADDER CARCINOMA. Arq Bras Cir Dig 2020; 33: e1496 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357549/pdf/0102-6720-abcd-33-01-e1496.pdf
590 Sikora SS, Singh RK. Surgical strategies in patients with gallbladder cancer: nihilism to optimism. J Surg Oncol 2006; 93: 670-681
591 Søreide K, Guest RV, Harrison EM. et al. Systematic review of management of incidental gallbladder cancer after cholecystectomy. Br J Surg 2019; 106: 32-45
592 Benson AB, Abrams TA, Ben-Josef E. et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw 2009; 7: 350-391 https://jnccn.org/downloadpdf/journals/jnccn/7/4/article-p350.pdf
593 Yuza K, Sakata J, Prasoon P. et al. Long-term outcomes of surgical resection for T1b gallbladder cancer: an institutional evaluation. BMC Cancer 2020; 20: 20 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945689/pdf/12885_2019_Article_6507.pdf
594 Lee SE, Jang JY, Kim SW. et al. Surgical strategy for T1 gallbladder cancer: a nationwide multicenter survey in South Korea. Ann Surg Oncol 2014; 21: 3654-3660
595 Bartsch F, Paschold M, Baumgart J. et al. Surgical Resection for Recurrent Intrahepatic Cholangiocarcinoma. World J Surg 2019; 43: 1105-1116
596 Spolverato G, Kim Y, Alexandrescu S. et al. Management and Outcomes of Patients with Recurrent Intrahepatic Cholangiocarcinoma Following Previous Curative-Intent Surgical Resection. Ann Surg Oncol 2016; 23: 235-243
597 Seidensticker R, Seidensticker M, Doegen K. et al. Extensive Use of Interventional Therapies Improves Survival in Unresectable or Recurrent Intrahepatic Cholangiocarcinoma. Gastroenterol Res Pract 2016; 2016: 8732521 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4758109/pdf/GRP2016-8732521.pdf
598 Xu C, Li L, Xu W. et al. Ultrasound-guided percutaneous microwave ablation versus surgical resection for recurrent intrahepatic cholangiocarcinoma: intermediate-term results. Int J Hyperthermia 2019; 36: 351-358
599 Zhang SJ, Hu P, Wang N. et al. Thermal ablation versus repeated hepatic resection for recurrent intrahepatic cholangiocarcinoma. Ann Surg Oncol 2013; 20: 3596-3602
600 Amini N, Ejaz A, Spolverato G. et al. Temporal trends in liver-directed therapy of patients with intrahepatic cholangiocarcinoma in the United States: a population-based analysis. J Surg Oncol 2014; 110: 163-170 https://www.ncbi.nlm.nih.gov/pubmed/24676600
601 Butros SR, Shenoy-Bhangle A, Mueller PR. et al. Radiofrequency ablation of intrahepatic cholangiocarcinoma: feasability, local tumor control, and long-term outcome. Clin Imaging 2014; 38: 490-494 https://www.clinicalimaging.org/article/S0899-7071(14)00040-0/fulltext
602 Fu Y, Yang W, Wu W. et al. Radiofrequency ablation in the management of unresectable intrahepatic cholangiocarcinoma. J Vasc Interv Radiol 2012; 23: 642-649 https://www.jvir.org/article/S1051-0443(12)00208-4/fulltext
603 Han K, Ko HK, Kim KW. et al. Radiofrequency ablation in the treatment of unresectable intrahepatic cholangiocarcinoma: systematic review and meta-analysis. J Vasc Interv Radiol 2015; 26: 943-948 https://www.jvir.org/article/S1051-0443(15)00250-X/fulltext
604 Kolarich AR, Shah JL, George TJ. et al. Non-surgical management of patients with intrahepatic cholangiocarcinoma in the United States, 2004-2015: an NCDB analysis. J Gastrointest Oncol 2018; 9: 536-545 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6006029/pdf/jgo-09-03-536.pdf
605 Takahashi EA, Kinsman KA, Schmit GD. et al. Thermal ablation of intrahepatic cholangiocarcinoma: Safety, efficacy, and factors affecting local tumor progression. Abdom Radiol (NY) 2018; 43: 3487-3492
606 Kim JH, Won HJ, Shin YM. et al. Radiofrequency ablation for recurrent intrahepatic cholangiocarcinoma after curative resection. Eur J Radiol 2011; 80: e221-e225 https://www.ejradiology.com/article/S0720-048X(10)00476-6/fulltext
607 Goldaracena N, Gorgen A, Sapisochin G. Current status of liver transplantation for cholangiocarcinoma. Liver Transpl 2018; 24: 294-303
608 Facciuto ME, Singh MK, Lubezky N. et al. Tumors with intrahepatic bile duct differentiation in cirrhosis: implications on outcomes after liver transplantation. Transplantation 2015; 99: 151-157
609 Vilchez V, Shah MB, Daily MF. et al. Long-term outcome of patients undergoing liver transplantation for mixed hepatocellular carcinoma and cholangiocarcinoma: an analysis of the UNOS database. HPB (Oxford) 2016; 18: 29-34 https://www.hpbonline.org/article/S1365-182X(15)00002-7/pdf
610 Sapisochin G, de Lope CR, Gastaca M. et al. Intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma in patients undergoing liver transplantation: a Spanish matched cohort multicenter study. Ann Surg 2014; 259: 944-952
611 Sapisochin G, Facciuto M, Rubbia-Brandt L. et al. Liver transplantation for “very early” intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment. Hepatology 2016; 64: 1178-1188
612 Lunsford KE, Javle M, Heyne K. et al. Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series. Lancet Gastroenterol Hepatol 2018; 3: 337-348 https://www.thelancet.com/journals/langas/article/PIIS2468-1253(18)30045-1/fulltext
613 Becker NS, Rodriguez JA, Barshes NR. et al. Outcomes analysis for 280 patients with cholangiocarcinoma treated with liver transplantation over an 18-year period. J Gastrointest Surg 2008; 12: 117-122
614 Darwish Murad S, Kim WR, Harnois DM. et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 2012; 143: 88-98.e3 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3846443/pdf/nihms507180.pdf
615 Rosen CB, Heimbach JK, Gores GJ. Surgery for cholangiocarcinoma: the role of liver transplantation. HPB (Oxford) 2008; 10: 186-189 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2504373/pdf/MHPB10-186.pdf
616 Gulamhusein AF, Sanchez W. Liver transplantation in the management of perihilar cholangiocarcinoma. Hepat Oncol 2015; 2: 409-421 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095165/pdf/hep-02-409.pdf
617 Ethun CG, Lopez-Aguiar AG, Anderson DJ. et al. Transplantation Versus Resection for Hilar Cholangiocarcinoma: An Argument for Shifting Treatment Paradigms for Resectable Disease. Ann Surg 2018; 267: 797-805 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6002861/pdf/nihms955692.pdf
618 Mantel HT, Westerkamp AC, Adam R. et al. Strict Selection Alone of Patients Undergoing Liver Transplantation for Hilar Cholangiocarcinoma Is Associated with Improved Survival. PLoS One 2016; 11: e0156127 https://air.unimi.it/retrieve/handle/2434/465540/799026/journal.pone.0156127.PDF
619 Weber SM, Ribero D, O’Reilly EM. et al. Intrahepatic cholangiocarcinoma: expert consensus statement. HPB (Oxford) 2015; 17: 669-680
620 NCCN Guidelines® for Hepatobiliary Cancers Version 3. 2019.
621 Ray CE, Edwards A, Smith MT. et al. Metaanalysis of survival, complications, and imaging response following chemotherapy-based transarterial therapy in patients with unresectable intrahepatic cholangiocarcinoma. J Vasc Interv Radiol 2013; 24: 1218-1226
622 Koch C, Franzke C, Bechstein WO. et al. Poor Prognosis of Advanced Cholangiocarcinoma: Real-World Data from a Tertiary Referral Center. Digestion 2019; 1-8
623 Gusani NJ, Balaa FK, Steel JL. et al. Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experience. J Gastrointest Surg 2008; 12: 129-137
624 Boehm LM, Jayakrishnan TT, Miura JT. et al. Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. J Surg Oncol 2015; 111: 213-220
625 Kiefer MV, Albert M, McNally M. et al. Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2-center study. Cancer 2011; 117: 1498-1505
626 Vogl TJ, Naguib NN, Nour-Eldin NE. et al. Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: Results and prognostic factors governing treatment success. Int J Cancer 2012; 131: 733-740
627 Cucchetti A, Cappelli A, Mosconi C. et al. Improving patient selection for selective internal radiation therapy of intra-hepatic cholangiocarcinoma: A meta-regression study. Liver Int 2017; 37: 1056-1064
628 Gangi A, Shah J, Hatfield N. et al. Intrahepatic Cholangiocarcinoma Treated with Transarterial Yttrium-90 Glass Microsphere Radioembolization: Results of a Single Institution Retrospective Study. J Vasc Interv Radiol 2018; 29: 1101-1108 https://www.sciencedirect.com/science/article/pii/S1051044318310868?via%3Dihub
629 Manceau V, Palard X, Rolland Y. et al. A MAA-based dosimetric study in patients with intrahepatic cholangiocarcinoma treated with a combination of chemotherapy and (90)Y-loaded glass microsphere selective internal radiation therapy. Eur J Nucl Med Mol Imaging 2018; 45: 1731-1741 https://link.springer.com/content/pdf/10.1007%2Fs00259-018-3990-7.pdf
630 Reimer P, Virarkar MK, Binnenhei M. et al. Prognostic Factors in Overall Survival of Patients with Unresectable Intrahepatic Cholangiocarcinoma Treated by Means of Yttrium-90 Radioembolization: Results in Therapy-Naïve Patients. Cardiovasc Intervent Radiol 2018; 41: 744-752
631 Yang L, Shan J, Shan L. et al. Trans-arterial embolisation therapies for unresectable intrahepatic cholangiocarcinoma: a systematic review. J Gastrointest Oncol 2015; 6: 570-588 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570915/pdf/jgo-06-05-570.pdf
632 Zhen Y, Liu B, Chang Z. et al. A pooled analysis of transarterial radioembolization with yttrium-90 microspheres for the treatment of unresectable intrahepatic cholangiocarcinoma. Onco Targets Ther 2019; 12: 4489-4498 https://pubmed.ncbi.nlm.nih.gov/31239717/
633 Mosconi C, Solaini L, Vara G. et al. Transarterial Chemoembolization and Radioembolization for Unresectable Intrahepatic Cholangiocarcinoma-a Systemic Review and Meta-Analysis. Cardiovasc Intervent Radiol 2021; 44 (05) 728-738 https://pubmed.ncbi.nlm.nih.gov/33709272/
634 Hyder O, Marsh JW, Salem R. et al. Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis. Ann Surg Oncol 2013; 20: 3779-3786
635 Marquardt S, Kirstein MM, Brüning R. et al. Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival. Eur Radiol 2019; 29: 1882-1892
636 Edeline J, Touchefeu Y, Guiu B. et al. Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol 2019; 6: 51-59 https://jamanetwork.com/journals/jamaoncology/articlepdf/2753557/jamaoncology_edeline_2019_oi_190074.pdf
637 Konstantinidis IT, Groot Koerkamp B, Do RK. et al. Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. Cancer 2016; 122: 758-765
638 Al-Adra DP, Gill RS, Axford SJ. et al. Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis. Eur J Surg Oncol 2015; 41: 120-127
639 Wronka KM, Grąt M, Stypułkowski J. et al. Relevance of Preoperative Hyperbilirubinemia in Patients Undergoing Hepatobiliary Resection for Hilar Cholangiocarcinoma. J Clin Med 2019; 8: 458 https://res.mdpi.com/d_attachment/jcm/jcm-08-00458/article_deploy/jcm-08-00458.pdf
640 Al Mahjoub A, Menahem B, Fohlen A. et al. Preoperative Biliary Drainage in Patients with Resectable Perihilar Cholangiocarcinoma: Is Percutaneous Transhepatic Biliary Drainage Safer and More Effective than Endoscopic Biliary Drainage? A Meta-Analysis. J Vasc Interv Radiol 2017; 28: 576-582
641 Hameed A, Pang T, Chiou J. et al. Percutaneous vs endoscopic pre-operative biliary drainage in hilar cholangiocarcinoma – a systematic review and meta-analysis. HPB (Oxford) 2016; 18: 400-410 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4857062/pdf/main.pdf
642 Coelen RJS, Roos E, Wiggers JK. et al. Endoscopic versus percutaneous biliary drainage in patients with resectable perihilar cholangiocarcinoma: a multicentre, randomised controlled trial. Lancet Gastroenterol Hepatol 2018; 3: 681-690 https://www.sciencedirect.com/science/article/abs/pii/S2468125318302346?via%3Dihub
643 Ba Y, Yue P, Leung JW. et al. Percutaneous transhepatic biliary drainage may be the preferred preoperative drainage method in hilar cholangiocarcinoma. Endosc Int Open 2020; 8: E203-E210
644 Maeda T, Ebata T, Yokoyama Y. et al. Preoperative course of patients undergoing endoscopic nasobiliary drainage during the management of resectable perihilar cholangiocarcinoma. J Hepatobiliary Pancreat Sci 2019; 26: 341-347
645 Nakai Y, Yamamoto R, Matsuyama M. et al. Multicenter study of endoscopic preoperative biliary drainage for malignant hilar biliary obstruction: E-POD hilar study. J Gastroenterol Hepatol 2018; 33: 1146-1153
646 Komaya K, Ebata T, Yokoyama Y. et al. Verification of the oncologic inferiority of percutaneous biliary drainage to endoscopic drainage: A propensity score matching analysis of resectable perihilar cholangiocarcinoma. Surgery 2017; 161: 394-404
647 Kim KM, Park JW, Lee JK. et al. A Comparison of Preoperative Biliary Drainage Methods for Perihilar Cholangiocarcinoma: Endoscopic versus Percutaneous Transhepatic Biliary Drainage. Gut Liver 2015; 9: 791-799 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4625710/pdf/gnl-09-791.pdf
648 Kennedy TJ, Yopp A, Qin Y. et al. Role of preoperative biliary drainage of liver remnant prior to extended liver resection for hilar cholangiocarcinoma. HPB (Oxford) 2009; 11: 445-451 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2742615/pdf/hpb0011-0445.pdf
649 Miura S, Kanno A, Fukase K. et al. Preoperative biliary drainage of the hepatic lobe to be resected does not affect liver hypertrophy after percutaneous transhepatic portal vein embolization. Surg Endosc 2020; 34: 667-674
650 Hintze RE, Abou-Rebyeh H, Adler A. et al. Magnetic resonance cholangiopancreatography-guided unilateral endoscopic stent placement for Klatskin tumors. Gastrointest Endosc 2001; 53: 40-46
651 Abraham NS, Barkun JS, Barkun AN. Palliation of malignant biliary obstruction: a prospective trial examining impact on quality of life. Gastrointest Endosc 2002; 56: 835-841
652 Paik WH, Park YS, Hwang JH. et al. Palliative treatment with self-expandable metallic stents in patients with advanced type III or IV hilar cholangiocarcinoma: a percutaneous versus endoscopic approach. Gastrointest Endosc 2009; 69: 55-62
653 Saluja SS, Gulati M, Garg PK. et al. Endoscopic or percutaneous biliary drainage for gallbladder cancer: a randomized trial and quality of life assessment. Clin Gastroenterol Hepatol 2008; 6: 944-950.e3 https://www.sciencedirect.com/science/article/abs/pii/S1542356508003418?via%3Dihub
654 Schima W, Prokesch R, Osterreicher C. et al. Biliary Wallstent endoprosthesis in malignant hilar obstruction: long-term results with regard to the type of obstruction. Clin Radiol 1997; 52: 213-219
655 Uberoi R, Das N, Moss J. et al. British Society of Interventional Radiology: Biliary Drainage and Stenting Registry (BDSR). Cardiovasc Intervent Radiol 2012; 35: 127-138
656 Smith AC, Dowsett JF, Russell RC. et al. Randomised trial of endoscopic stenting versus surgical bypass in malignant low bileduct obstruction. Lancet 1994; 344: 1655-1660
657 Speer AG, Cotton PB, Russell RC. et al. Randomised trial of endoscopic versus percutaneous stent insertion in malignant obstructive jaundice. Lancet 1987; 2: 57-62
658 Almadi MA, Barkun A, Martel M. Plastic vs Self-Expandable Metal Stents for Palliation in Malignant Biliary Obstruction: A Series of Meta-Analyses. Am J Gastroenterol 2017; 112: 260-273
659 Lee TH, Moon JH, Choi JH. et al. Prospective comparison of endoscopic bilateral stent-in-stent versus stent-by-stent deployment for inoperable advanced malignant hilar biliary stricture. Gastrointest Endosc 2019; 90: 222-230 https://www.sciencedirect.com/science/article/abs/pii/S0016510719301737?via%3Dihub
660 Sharaiha RZ, Kumta NA, Desai AP. et al. Endoscopic ultrasound-guided biliary drainage versus percutaneous transhepatic biliary drainage: predictors of successful outcome in patients who fail endoscopic retrograde cholangiopancreatography. Surg Endosc 2016; 30: 5500-5505
661 Paik WH, Lee TH, Park DH. et al. EUS-Guided Biliary Drainage Versus ERCP for the Primary Palliation of Malignant Biliary Obstruction: A Multicenter Randomized Clinical Trial. Am J Gastroenterol 2018; 113: 987-997
662 Bang JY, Navaneethan U, Hasan M. et al. Stent placement by EUS or ERCP for primary biliary decompression in pancreatic cancer: a randomized trial (with videos). Gastrointest Endosc 2018; 88: 9-17
663 Dumonceau JM, Tringali A, Papanikolaou IS. et al. Endoscopic biliary stenting: indications, choice of stents, and results: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline – Updated October 2017. Endoscopy 2018; 50: 910-930
664 Moole H, Dharmapuri S, Duvvuri A. et al. Endoscopic versus Percutaneous Biliary Drainage in Palliation of Advanced Malignant Hilar Obstruction: A Meta-Analysis and Systematic Review. Can J Gastroenterol Hepatol 2016; 2016: 4726078 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5014937/pdf/CJGH2016-4726078.pdf
665 Zhao XQ, Dong JH, Jiang K. et al. Comparison of percutaneous transhepatic biliary drainage and endoscopic biliary drainage in the management of malignant biliary tract obstruction: a meta-analysis. Dig Endosc 2015; 27: 137-145
666 Born P, Rösch T, Triptrap A. et al. Long-term results of percutaneous transhepatic biliary drainage for benign and malignant bile duct strictures. Scand J Gastroenterol 1998; 33: 544-549
667 De Palma GD, Galloro G, Siciliano S. et al. Unilateral versus bilateral endoscopic hepatic duct drainage in patients with malignant hilar biliary obstruction: results of a prospective, randomized, and controlled study. Gastrointest Endosc 2001; 53: 547-553
668 Chang WH, Kortan P, Haber GB. Outcome in patients with bifurcation tumors who undergo unilateral versus bilateral hepatic duct drainage. Gastrointest Endosc 1998; 47: 354-362
669 Bulajic M, Panic N, Radunovic M. et al. Clinical outcome in patients with hilar malignant strictures type II Bismuth-Corlette treated by minimally invasive unilateral versus bilateral endoscopic biliary drainage. Hepatobiliary Pancreat Dis Int 2012; 11: 209-214
670 Cheng JL, Bruno MJ, Bergman JJ. et al. Endoscopic palliation of patients with biliary obstruction caused by nonresectable hilar cholangiocarcinoma: efficacy of self-expandable metallic Wallstents. Gastrointest Endosc 2002; 56: 33-39
671 Vienne A, Hobeika E, Gouya H. et al. Prediction of drainage effectiveness during endoscopic stenting of malignant hilar strictures: the role of liver volume assessment. Gastrointest Endosc 2010; 72: 728-735
672 Rees J, Mytton J, Evison F. et al. The outcomes of biliary drainage by percutaneous transhepatic cholangiography for the palliation of malignant biliary obstruction in England between 2001 and 2014: a retrospective cohort study. BMJ Open 2020; 10: e033576 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045186/pdf/bmjopen-2019-033576.pdf
673 Harvey PR, Baldwin S, Mytton J. et al. Higher volume providers are associated with improved outcomes following ERCP for the palliation of malignant biliary obstruction. EClinicalMedicine 2020; 18: 100212 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6948226/pdf/main.pdf
674 Tal AO, Vermehren J, Friedrich-Rust M. et al. Intraductal endoscopic radiofrequency ablation for the treatment of hilar non-resectable malignant bile duct obstruction. World J Gastrointest Endosc 2014; 6: 13-19 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3921441/pdf/WJGE-6-13.pdf
675 Moole H, Tathireddy H, Dharmapuri S. et al. Success of photodynamic therapy in palliating patients with nonresectable cholangiocarcinoma: A systematic review and meta-analysis. World J Gastroenterol 2017; 23: 1278-1288 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5323453/pdf/WJG-23-1278.pdf
676 Zoepf T, Jakobs R, Rosenbaum A. et al. Photodynamic therapy with 5-aminolevulinic acid is not effective in bile duct cancer. Gastrointest Endosc 2001; 54: 763-766
677 Ortner ME, Caca K, Berr F. et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 2003; 125: 1355-1363 https://www.sciencedirect.com/science/article/abs/pii/S0016508503013623?via%3Dihub
678 Zoepf T, Jakobs R, Arnold JC. et al. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am J Gastroenterol 2005; 100: 2426-2430
679 Pereira SP, Jitlal M, Duggan M. et al. PHOTOSTENT-02: porfimer sodium photodynamic therapy plus stenting versus stenting alone in patients with locally advanced or metastatic biliary tract cancer. ESMO Open 2018; 3: e000379 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6069917/pdf/esmoopen-2018-000379.pdf
680 Gonzalez-Carmona MA, Bolch M, Jansen C. et al. Combined photodynamic therapy with systemic chemotherapy for unresectable cholangiocarcinoma. Aliment Pharmacol Ther 2019; 49: 437-447
681 Wentrup R, Winkelmann N, Mitroshkin A. et al. Photodynamic Therapy Plus Chemotherapy Compared with Photodynamic Therapy Alone in Hilar Nonresectable Cholangiocarcinoma. Gut Liver 2016; 10: 470-475 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4849702/pdf/gnl-10-470.pdf
682 Strand DS, Cosgrove ND, Patrie JT. et al. ERCP-directed radiofrequency ablation and photodynamic therapy are associated with comparable survival in the treatment of unresectable cholangiocarcinoma. Gastrointest Endosc 2014; 80: 794-804
683 Dolak W, Schwaighofer H, Hellmich B. et al. Photodynamic therapy with polyhematoporphyrin for malignant biliary obstruction: A nationwide retrospective study of 150 consecutive applications. United European Gastroenterol J 2017; 5: 104-110 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5384559/pdf/10.1177_2050640616654037.pdf
684 Kahaleh M, Mishra R, Shami VM. et al. Unresectable cholangiocarcinoma: comparison of survival in biliary stenting alone versus stenting with photodynamic therapy. Clin Gastroenterol Hepatol 2008; 6: 290-297 https://www.sciencedirect.com/science/article/abs/pii/S1542356507011469?via%3Dihub
685 Ben-Josef E, Normolle D, Ensminger WD. et al. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol 2005; 23: 8739-8747
686 Brunner TB, Blanck O, Lewitzki V. et al. Stereotactic body radiotherapy dose and its impact on local control and overall survival of patients for locally advanced intrahepatic and extrahepatic cholangiocarcinoma. Radiother Oncol 2019; 132: 42-47 https://www.sciencedirect.com/science/article/abs/pii/S0167814018336089?via%3Dihub
687 Tao R, Krishnan S, Bhosale PR. et al. Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis. J Clin Oncol 2016; 34: 219-226 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980564/pdf/JCO613778.pdf
688 Lee J, Yoon WS, Koom WS. et al. Efficacy of stereotactic body radiotherapy for unresectable or recurrent cholangiocarcinoma: a meta-analysis and systematic review. Strahlenther Onkol 2019; 195: 93-102
689 Frakulli R, Buwenge M, Macchia G. et al. Stereotactic body radiation therapy in cholangiocarcinoma: a systematic review. Br J Radiol 2019; 92: 20180688 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580923/pdf/bjr.20180688.pdf
690 Barney BM, Olivier KR, Miller RC. et al. Clinical outcomes and toxicity using stereotactic body radiotherapy (SBRT) for advanced cholangiocarcinoma. Radiat Oncol 2012; 7: 67 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3464963/pdf/1748-717X-7-67.pdf
691 Tse RV, Hawkins M, Lockwood G. et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2008; 26: 657-664
692 Weiner AA, Olsen J, Ma D. et al. Stereotactic body radiotherapy for primary hepatic malignancies – Report of a phase I/II institutional study. Radiother Oncol 2016; 121: 79-85 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5543719/pdf/nihms872134.pdf
693 Kopek N, Holt MI, Hansen AT. et al. Stereotactic body radiotherapy for unresectable cholangiocarcinoma. Radiother Oncol 2010; 94: 47-52
694 Schnapauff D, Denecke T, Grieser C. et al. Computed tomography-guided interstitial HDR brachytherapy (CT-HDRBT) of the liver in patients with irresectable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol 2012; 35: 581-587
695 Jeong H, Kim K, Jeong J. et al. Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial. Hepatology 2023; 77 (05) 1540-1549 https://pubmed.ncbi.nlm.nih.gov/37070950/
696 Vogel A, Wege H, Caca K. et al. The diagnosis and treatment of cholangiocarcinoma. Dtsch Arztebl Int 2014; 111: 748-754 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4239580/pdf/Dtsch_Arztebl_Int-111-0748.pdf
697 Horgan AM, Amir E, Walter T. et al. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol 2012; 30: 1934-1940
698 Bridgewater J, Fletcher P, Palmer D. et al. Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study. J Clin Oncol 2022; 40 (18) 2048-2057 https://pubmed.ncbi.nlm.nih.gov/35316080/
699 Edeline J, Bonnetain F, Phelip JM. et al. Gemox versus surveillance following surgery of localized biliary tract cancer: Results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial. Journal of Clinical Oncology 2017; 35: 225-225
700 Edeline J, Hirano S, Bertaut A. et al. Individual patient data meta-analysis of adjuvant gemcitabine-based chemotherapy for biliary tract cancer: combined analysis of the BCAT and PRODIGE-12 studies. Eur J Cancer 2022; 164: 80-87 https://pubmed.ncbi.nlm.nih.gov/35182925/
701 Luvira V, Satitkarnmanee E, Pugkhem A. et al. Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma. Cochrane Database Syst Rev 2021; 9 (09) CD012814 https://pubmed.ncbi.nlm.nih.gov/34515993/
702 Oh D, Ruth He A, Qin S. et al. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evidence 2022; 1: EVIDoa2200015
703 Valle J, Wasan H, Palmer DH. et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362: 1273-1281
704 Okusaka T, Nakachi K, Fukutomi A. et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 2010; 103: 469-474 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2939781/pdf/6605779a.pdf
705 Valle JW, Furuse J, Jitlal M. et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol 2014; 25: 391-398
706 Park JO, Oh DY, Hsu C. et al. Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review. Cancer Res Treat 2015; 47: 343-361 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4509359/pdf/crt-2014-308.pdf
707 Markussen A, Jensen L, Diness L. et al. Treatment of Patients with Advanced Biliary Tract Cancer with Either Oxaliplatin, Gemcitabine, and Capecitabine or Cisplatin and Gemcitabine-A Randomized Phase II Trial. Cancers (Basel) 2020; 12 (07) 1975 https://pubmed.ncbi.nlm.nih.gov/32698410/
708 Valle JW, Borbath I, Khan SA. et al. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27: v28-v37 https://www.ncbi.nlm.nih.gov/pubmed/27664259
709 Kelley R, Ueno M, Yoo C. et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023; 401: 1853-1865 https://pubmed.ncbi.nlm.nih.gov/37075781/
710 Abou-Alfa GK, Macarulla T, Javle MM. et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. The Lancet Oncology 2020; 21: 796-807
711 Abou-Alfa GK, Sahai V, Hollebecque A. et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. The Lancet Oncology 2020; 21: 671-684
712 Lamarca A, Palmer DH, Wasan HS. et al. ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced/metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy. Journal of Clinical Oncology 2019; 37: 4003-4003
713 Goyal L, Meric-Bernstam F, Hollebecque A. et al. Futibatinib for. N Engl J Med 2023; 388 (03) 228-239 https://pubmed.ncbi.nlm.nih.gov/36652354/
714 Valle JW, Lamarca A, Goyal L. et al. New Horizons for Precision Medicine in Biliary Tract Cancers. Cancer Discov 2017; 7: 943-962 https://cancerdiscovery.aacrjournals.org/content/candisc/7/9/943.full.pdf
715 Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol 2018; 15: 731-747 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419506/pdf/nihms-1016874.pdf
716 Solomon JP, Linkov I, Rosado A. et al. NTRK fusion detection across multiple assays and 33997 cases: diagnostic implications and pitfalls. Mod Pathol 2019; 33: 38-46 https://www.ncbi.nlm.nih.gov/pubmed/31375766
717 Ross JS, Wang K, Gay L. et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist 2014; 19: 235-242 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3958461/pdf/theoncologist_13352.pdf
718 Drilon A, Laetsch TW, Kummar S. et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 2018; 378: 731-739
719 Oh DY, Bang YJ. HER2-targeted therapies – a role beyond breast cancer. Nat Rev Clin Oncol 2019; https://www.ncbi.nlm.nih.gov/pubmed/31548601
720 Javle M, Borad M, Azad N. et al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol 2021; 22 (09) 1290-1300 https://pubmed.ncbi.nlm.nih.gov/34339623/
721 Nakamura Y, Mizuno N, Sunakawa Y. et al. Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study. J Clin Oncol 2023; 41 (36) 5569-5578 https://pubmed.ncbi.nlm.nih.gov/37751561/
722 Meric-Bernstam F, Makker V, Oaknin A. et al. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial. J Clin Oncol 2024; 42 (01) 47-58 https://pubmed.ncbi.nlm.nih.gov/37870536/
723 Harding J, Piha-Paul S, Shah R. et al. Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers. Nat Commun 2023; 14 (01) 630 https://pubmed.ncbi.nlm.nih.gov/36746967/
724 Hyman DM, Puzanov I, Subbiah V. et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med 2015; 373: 726-736
725 Salama AKS, Li SL, Macrae ER. et al. Dabrafenib and trametinib in patients with tumors with BRAF V600E/K mutations: Results from the molecular analysis for therapy choice (MATCH) Arm H. Journal of Clinical Oncology 2019; 37
726 Lavingia V, Fakih M. Impressive response to dual BRAF and MEK inhibition in patients with BRAF mutant intrahepatic cholangiocarcinoma-2 case reports and a brief review. J Gastrointest Oncol 2016; 7: E98-E102 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5177579/pdf/jgo-07-06-E98.pdf
727 Kocsis J, Árokszállási A, András C. et al. Combined dabrafenib and trametinib treatment in a case of chemotherapy-refractory extrahepatic BRAF V600E mutant cholangiocarcinoma: dramatic clinical and radiological response with a confusing synchronic new liver lesion. J Gastrointest Oncol 2017; 8: E32-E38 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5401859/pdf/jgo-08-02-E32.pdf
728 Bunyatov T, Zhao A, Kovalenko J. et al. Personalised approach in combined treatment of cholangiocarcinoma: a case report of healing from cholangiocellular carcinoma at stage IV. J Gastrointest Oncol 2019; 10: 815-820 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657318/pdf/jgo-10-04-815.pdf
729 Subbiah V, Lassen U, Élez E. et al. Dabrafenib plus trametinib in patients with BRAF. Lancet Oncol 2020; 21 (09) 1234-1243 https://pubmed.ncbi.nlm.nih.gov/32818466/
730 Abou-Alfa G, Sahai V, Hollebecque A. et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol 2020; 21 (05) 671-684 https://pubmed.ncbi.nlm.nih.gov/32203698/
731 Wu Q, Ellis H, Siravegna G. et al. Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma. Clin Cancer Res 2024; 30 (01) 198-208 https://pubmed.ncbi.nlm.nih.gov/37843855/
732 Rengan A, Denlinger C. Robust Response to Futibatinib in a Patient With Metastatic FGFR-Addicted Cholangiocarcinoma Previously Treated Using Pemigatinib. J Natl Compr Canc Netw 2022; 20 (05) 430-435 https://pubmed.ncbi.nlm.nih.gov/35378504/
733 Meric-Bernstam F, Bahleda R, Hierro C. et al. Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring. Cancer Discov 2022; 12 (02) 402-415 https://pubmed.ncbi.nlm.nih.gov/34551969/
734 Mazzaferro V, El-Rayes BF, Droz Dit Busset M. et al. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. Br J Cancer 2019; 120: 165-171 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6342954/pdf/41416_2018_Article_334.pdf
735 Bahleda R, Italiano A, Hierro C. et al. Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors. Clin Cancer Res 2019; 25: 4888-4897 https://clincancerres.aacrjournals.org/content/clincanres/25/16/4888.full.pdf
736 Subbiah V, Sahai V, Maglic D. et al. RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations. Cancer Discov 2023; 13 (09) 2012-2031 https://pubmed.ncbi.nlm.nih.gov/37270847/
737 Cleary J, Raghavan S, Wu Q. et al. FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma. Cancer Discov 2021; 11 (10) 2488-2505 https://pubmed.ncbi.nlm.nih.gov/33926920/
738 Katoh M. Fibroblast growth factor receptors as treatment targets in clinical oncology. Nat Rev Clin Oncol 2018; 16: 105-122 https://www.ncbi.nlm.nih.gov/pubmed/30367139
739 Maio M, Ascierto P, Manzyuk L. et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol 2022; 33 (09) 929-938 https://pubmed.ncbi.nlm.nih.gov/35680043/
740 Lamarca A, Palmer D, Wasan H. et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol 2021; 22 (05) 690-701 https://pubmed.ncbi.nlm.nih.gov/33798493/
741 Marabelle A, Le DT, Ascierto PA. et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. Journal of Clinical Oncology 2020;
742 Le DT, Durham JN, Smith KN. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017; 357: 409-413 https://science.sciencemag.org/content/sci/357/6349/409.full.pdf
743 Le DT, Uram JN, Wang H. et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 2015; 372: 2509-2520
744 Goeppert B, Roessler S, Renner M. et al. Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma. Br J Cancer 2019; 120: 109-114 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325153/pdf/41416_2018_Article_199.pdf
745 Cloyd J, Chun Y, Ikoma N. et al. Clinical and Genetic Implications of DNA Mismatch Repair Deficiency in Biliary Tract Cancers Associated with Lynch Syndrome. J Gastrointest Cancer 2018; 49 (01) 93-96 https://pubmed.ncbi.nlm.nih.gov/29238914/
746 Zalevskaja K, Mecklin J, Seppälä T. Clinical characteristics of pancreatic and biliary tract cancers in Lynch syndrome: A retrospective analysis from the Finnish National Lynch Syndrome Research Registry. Front Oncol 2023; 13: 1123901 https://pubmed.ncbi.nlm.nih.gov/36816932/
747 Zhu A, Macarulla T, Javle M. et al. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial. JAMA Oncol 2021; 7 (11) 1669-1677 https://pubmed.ncbi.nlm.nih.gov/34554208/
748 Choi I, Kim K, Lee J. et al. A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy. Eur J Cancer 2021; 154: 288-295 https://pubmed.ncbi.nlm.nih.gov/34303267/
749 Yoo C, Kim K, Jeong J. et al. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study. Lancet Oncol 2021; 22: 1560-1572 https://pubmed.ncbi.nlm.nih.gov/34656226/
750 Zheng Y, Tu X, Zhao P. et al. A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin. Br J Cancer 2018; 119 (03) 291-295 https://pubmed.ncbi.nlm.nih.gov/29955136/
751 Vogel A, Wenzel P, Folprecht G. et al. 53MO Nal-IRI and 5-FU/LV compared to 5-FU/LV in patients with cholangio- and gallbladder carcinoma previously treated with gemcitabine-based therapies (NALIRICC – AIO-HEP-0116). Annals of Oncology 2022; 33: S563
752 Ramaswamy A, Ostwal V, Sharma A. et al. Efficacy of Capecitabine Plus Irinotecan vs Irinotecan Monotherapy as Second-line Treatment in Patients With Advanced Gallbladder Cancer: A Multicenter Phase 2 Randomized Clinical Trial (GB-SELECT). JAMA Oncol 2021; 7 (03) 436-439 https://pubmed.ncbi.nlm.nih.gov/33270098/
753 Schütte K, Tippelt B, Schulz C. et al. Malnutrition is a prognostic factor in patients with hepatocellular carcinoma (HCC). Clin Nutr 2015; 34: 1122-1127
754 Huang TH, Hsieh CC, Kuo LM. et al. Malnutrition associated with an increased risk of postoperative complications following hepatectomy in patients with hepatocellular carcinoma. HPB (Oxford) 2019; 21: 1150-1155
755 Arends J, Bachmann P, Baracos V. et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr 2017; 36: 11-48
756 Ciuni R, Biondi A, Grosso G. et al. Nutritional aspects in patient undergoing liver resection. Updates Surg 2011; 63: 249-252
757 Cederholm T, Jensen GL, Correia M. et al. GLIM criteria for the diagnosis of malnutrition – A consensus report from the global clinical nutrition community. J Cachexia Sarcopenia Muscle 2019; 10: 207-217 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438340/pdf/JCSM-10-207.pdf
758 Badran H, Elsabaawy MM, Ragab A. et al. Baseline Sarcopenia is Associated with Lack of Response to Therapy, Liver Decompensation and High Mortality in Hepatocellular Carcinoma Patients. Asian Pac J Cancer Prev 2020; 21: 3285-3290 http://journal.waocp.org/article_89349_cc643ce4770cf7eeca5890c5d5c453d5.pdf
759 Fujiwara N, Nakagawa H, Kudo Y. et al. Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma. J Hepatol 2015; 63: 131-140
760 Kim N, Yu JI, Park HC. et al. Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab. Cancer Immunol Immunother 2020;
761 Mardian Y, Yano Y, Ratnasari N. et al. “Sarcopenia and intramuscular fat deposition are associated with poor survival in Indonesian patients with hepatocellular carcinoma: a retrospective study”. BMC Gastroenterol 2019; 19: 229 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937974/pdf/12876_2019_Article_1152.pdf
762 Voron T, Tselikas L, Pietrasz D. et al. Sarcopenia Impacts on Short- and Long-term Results of Hepatectomy for Hepatocellular Carcinoma. Ann Surg 2015; 261: 1173-1183
763 Plauth M, Bernal W, Dasarathy S. et al. ESPEN guideline on clinical nutrition in liver disease. Clin Nutr 2019; 38: 485-521 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6686849/pdf/nihms-1529826.pdf
764 Haun MW, Estel S, Rucker G. et al. Early palliative care for adults with advanced cancer. Cochrane Database Syst Rev 2017; 6: CD011129 http://www.ncbi.nlm.nih.gov/pubmed/28603881
765 Adler K, Schlieper D, Kindgen-Milles D. et al. [Integration of palliative care into intensive care: Systematic review]. Anaesthesist 2017; 66: 660-666 http://www.ncbi.nlm.nih.gov/pubmed/28589374
766 Dalgaard KM, Bergenholtz H, Nielsen ME. et al. Early integration of palliative care in hospitals: A systematic review on methods, barriers, and outcome. Palliat Support Care 2014; 12: 495-513 http://www.ncbi.nlm.nih.gov/pubmed/24621947
767 Davis MP, Temel JS, Balboni T. et al. A review of the trials which examine early integration of outpatient and home palliative care for patients with serious illnesses. Ann Palliat Med 2015; 4: 99-121 http://www.ncbi.nlm.nih.gov/pubmed/26231807
768 Hui D, Kim YJ, Park JC. et al. Integration of oncology and palliative care: a systematic review. Oncologist 2015; 20: 77-83 http://www.ncbi.nlm.nih.gov/pubmed/25480826
769 Hui D, Meng YC, Bruera S. et al. Referral Criteria for Outpatient Palliative Cancer Care: A Systematic Review. Oncologist 2016; 21: 895-901 http://www.ncbi.nlm.nih.gov/pubmed/27185614
770 Tassinari D, Drudi F, Monterubbianesi MC. et al. Early Palliative Care in Advanced Oncologic and Non-Oncologic Chronic Diseases: A Systematic Review of Literature. Rev Recent Clin Trials 2016; 11: 63-71 http://www.ncbi.nlm.nih.gov/pubmed/26464077
771 Gärtner U, Braun GD, Held K. et al. [Physical complaints, stress and quality of life of oncologic patients Effects and patient assessment in inpatient rehabilitation]. Med Klin (Munich) 1996; 91: 501-508
772 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK. Palliativmedizin für Patienten mit einer nicht-heilbaren Krebserkrankung. Version 2.2. 2020. https://www.leitlinienprogramm-onkologie.de/leitlinien/palliativmedizin/
773 Hamano J, Morita T, Inoue S. et al. Surprise Questions for Survival Prediction in Patients With Advanced Cancer: A Multicenter Prospective Cohort Study. Oncologist 2015; 20: 839-844 http://www.ncbi.nlm.nih.gov/pubmed/26054631
774 Moroni M, Zocchi D, Bolognesi D. et al. The “surprise” question in advanced cancer patients: A prospective study among general practitioners. Palliat Med 2014; 28: 959-964 http://www.ncbi.nlm.nih.gov/pubmed/24662237
775 Moss AH, Lunney JR, Culp S. et al. Prognostic significance of the “surprise” question in cancer patients. J Palliat Med 2010; 13: 837-840 http://www.ncbi.nlm.nih.gov/pubmed/20636154
776 Murray S, Boyd K. Using the “surprise question” can identify people with advanced heart failure and COPD who would benefit from a palliative care approach. Palliat Med 2011; 25: 382 http://www.ncbi.nlm.nih.gov/pubmed/21610113
777 Kremer AE, Beuers U, Oude-Elferink RP. et al. Pathogenesis and treatment of pruritus in cholestasis. Drugs 2008; 68: 2163-2182 http://www.ncbi.nlm.nih.gov/pubmed/18840005
778 Stander S, Raap U, Weisshaar E. et al. Pathogenesis of pruritus. J Dtsch Dermatol Ges 2011; 9: 456-463 http://www.ncbi.nlm.nih.gov/pubmed/21208378
779 Stander S, Zeidler C, Augustin M. et al. S2k-Leitlinie zur Diagnostik und Therapie des chronischen Pruritus – Update – Kurzversion. J Dtsch Dermatol Ges 2017; 15: 860-873 http://www.ncbi.nlm.nih.gov/pubmed/28763608
780 Bachs L, Pares A, Elena M. et al. Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet 1989; 1: 574-576 http://www.ncbi.nlm.nih.gov/pubmed/2564110
781 Ghent CN, Carruthers SG. Treatment of pruritus in primary biliary cirrhosis with rifampin Results of a double-blind, crossover, randomized trial. Gastroenterology 1988; 94: 488-493 http://www.ncbi.nlm.nih.gov/pubmed/3275568
782 Terg R, Coronel E, Sorda J. et al. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol 2002; 37: 717-722 http://www.ncbi.nlm.nih.gov/pubmed/12445410
783 Bergasa NV, Talbot TL, Alling DW. et al. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology 1992; 102: 544-549 http://www.ncbi.nlm.nih.gov/pubmed/1732125
784 Mayo MJ, Handem I, Saldana S. et al. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology 2007; 45: 666-674 http://www.ncbi.nlm.nih.gov/pubmed/17326161
785 Lindor KD. Ursodiol for primary sclerosing cholangitis Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997; 336: 691-695 http://www.ncbi.nlm.nih.gov/pubmed/9041099
786 Talwalkar JA, Souto E, Jorgensen RA. et al. Natural history of pruritus in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2003; 1: 297-302 http://www.ncbi.nlm.nih.gov/pubmed/15017671
787 Zapata R, Sandoval L, Palma J. et al. Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy A 12-year experience. Liver Int 2005; 25: 548-554 http://www.ncbi.nlm.nih.gov/pubmed/15910492
788 Lemyze M, Dharancy S, Nevière R. et al. Aerobic capacity in patients with chronic liver disease: Very modest effect of liver transplantation. Presse Med 2010; 39: e174-e181
789 Epstein SK, Freeman RB, Khayat A. et al. Aerobic capacity is associated with 100-day outcome after hepatic transplantation. Liver Transpl 2004; 10: 418-424
790 van Ginneken BT, van den Berg-Emons RJ, Kazemier G. et al. Physical fitness, fatigue, and quality of life after liver transplantation. Eur J Appl Physiol 2007; 100: 345-353 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1914221/pdf/421_2007_Article_435.pdf
791 van den Berg-Emons R, van Ginneken B, Wijffels M. et al. Fatigue is a major problem after liver transplantation. Liver Transpl 2006; 12: 928-933
792 van Ginneken BT, van den Berg-Emons HJ, Metselaar HJ. et al. Effects of a rehabilitation programme on daily functioning, participation, health-related quality of life, anxiety and depression in liver transplant recipients. Disabil Rehabil 2010; 32: 2107-2112
793 Schwibbe G. [Changes in quality of life in oncological patients in the course of an inpatient after-care program]. Rehabilitation (Stuttg) 1991; 30: 55-62
794 Fan SY, Eiser C, Ho MC. et al. Health-related quality of life in patients with hepatocellular carcinoma: the mediation effects of illness perceptions and coping. Psychooncology 2013; 22: 1353-1360
795 Fan SY, Eiser C, Ho MC. Health-related quality of life in patients with hepatocellular carcinoma: a systematic review. Clin Gastroenterol Hepatol 2010; 8: 559-564.e1-10 https://www.sciencedirect.com/science/article/abs/pii/S1542356510002533?via%3Dihub
796 Qiao CX, Zhai XF, Ling CQ. et al. Health-related quality of life evaluated by tumor node metastasis staging system in patients with hepatocellular carcinoma. World J Gastroenterol 2012; 18: 2689-2694 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3370007/pdf/WJG-18-2689.pdf
797 Steel JL, Geller DA, Gamblin TC. et al. Depression, immunity, and survival in patients with hepatobiliary carcinoma. J Clin Oncol 2007; 25: 2397-2405
798 Lee HH, Chiu CC, Lin JJ. et al. Impact of preoperative anxiety and depression on quality of life before and after resection of hepatocellular carcinoma. J Affect Disord 2019; 246: 361-367 https://www.sciencedirect.com/science/article/abs/pii/S0165032718318639?via%3Dihub
799 Huang TW, Lin CC. The mediating effects of depression on sleep disturbance and fatigue: symptom clusters in patients with hepatocellular carcinoma. Cancer Nurs 2009; 32: 398-403
800 Ahn MH, Park S, Lee HB. et al. Suicide in cancer patients within the first year of diagnosis. Psychooncology 2015; 24: 601-607
801 Chiu CC, Lee KT, Wang JJ. et al. Health-Related Quality of Life before and after Surgical Resection of Hepatocellular Carcinoma: A Prospective Study. Asian Pac J Cancer Prev 2018; 19: 65-72 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844638/pdf/APJCP-19-65.pdf
802 Shun SC, Chen CH, Sheu JC. et al. Quality of life and its associated factors in patients with hepatocellular carcinoma receiving one course of transarterial chemoembolization treatment: a longitudinal study. Oncologist 2012; 17: 732-739 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3360913/pdf/onc732.pdf
803 Shun SC, Lai YH, Hung H. et al. The Role of Age in Change in Unmet Supportive Care Needs in Hepatocellular Carcinoma Patients During Transition From Hospital to Home. Cancer Nurs 2017; 40: 245-254
804 Wang ZX, Liu SL, Sun CH. et al. Psychological intervention reduces postembolization pain during hepatic arterial chemoembolization therapy: a complementary approach to drug analgesia. World J Gastroenterol 2008; 14: 931-935 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687062/pdf/WJG-14-931.pdf
805 Sanson-Fisher R, Girgis A, Boyes A. et al. The unmet supportive care needs of patients with cancer Supportive Care Review Group. Cancer 2000; 88: 226-237
806 Kleeberg UR, Tews JT, Ruprecht T. et al. Patient satisfaction and quality of life in cancer outpatients: results of the PASQOC study. Support Care Cancer 2005; 13: 303-310
807 Fallowfield L, Jenkins V. Communicating sad, bad, and difficult news in medicine. Lancet 2004; 363: 312-319
808 de Haes H, Teunissen S. Communication in palliative care: a review of recent literature. Curr Opin Oncol 2005; 17: 345-350
809 Ong LM, Visser MR, Lammes FB. et al. Doctor-patient communication and cancer patients’ quality of life and satisfaction. Patient Educ Couns 2000; 41: 145-156
810 Fukui S, Ogawa K, Ohtsuka M. et al. A randomized study assessing the efficacy of communication skill training on patients’ psychologic distress and coping: nurses’ communication with patients just after being diagnosed with cancer. Cancer 2008; 113: 1462-1470
811 Lienard A, Merckaert I, Libert Y. et al. Factors that influence cancer patients’ and relatives’ anxiety following a three-person medical consultation: impact of a communication skills training program for physicians. Psychooncology 2008; 17: 488-496
812 Razavi D, Merckaert I, Marchal S. et al. How to optimize physicians’ communication skills in cancer care: results of a randomized study assessing the usefulness of posttraining consolidation workshops. J Clin Oncol 2003; 21: 3141-3149
813 Butow P, Juraskova I, Chang S. et al. Shared decision making coding systems: how do they compare in the oncology context?. Patient Educ Couns 2010; 78: 261-268
814 Edwards A, Elwyn G. Inside the black box of shared decision making: distinguishing between the process of involvement and who makes the decision. Health Expect 2006; 9: 307-320 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5060371/pdf/HEX-9-307.pdf
815 Gordon EJ, Bergeron A, McNatt G. et al. Are informed consent forms for organ transplantation and donation too difficult to read?. Clin Transplant 2012; 26: 275-283
816 Rodrigue JR, Hanto DW, Curry MP. Patients’ expectations and success criteria for liver transplantation. Liver Transpl 2011; 17: 1309-1317
817 Volk ML, Tocco RS, Pelletier SJ. et al. Patient decision making about organ quality in liver transplantation. Liver Transpl 2011; 17: 1387-1393 https://deepblue.lib.umich.edu/bitstream/handle/2027.42/88081/22437_ftp.pdf?sequence=1
818 Butow PN, Tattersall MH, Goldstein D. Communication with cancer patients in culturally diverse societies. Ann N Y Acad Sci 1997; 809: 317-329
819 Dowsett SM, Saul JL, Butow PN. et al. Communication styles in the cancer consultation: preferences for a patient-centred approach. Psychooncology 2000; 9: 147-156
820 Epstein RM. Making communication research matter: what do patients notice, what do patients want, and what do patients need?. Patient Educ Couns 2006; 60: 272-278
821 Zachariae R, Pedersen CG, Jensen AB. et al. Association of perceived physician communication style with patient satisfaction, distress, cancer-related self-efficacy, and perceived control over the disease. Br J Cancer 2003; 88: 658-665 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376357/pdf/88-6600798a.pdf
822 Fogarty LA, Curbow BA, Wingard JR. et al. Can 40 seconds of compassion reduce patient anxiety?. J Clin Oncol 1999; 17: 371-379
823 Strasser F, Palmer JL, Willey J. et al. Impact of physician sitting versus standing during inpatient oncology consultations: patients’ preference and perception of compassion and duration A randomized controlled trial. J Pain Symptom Manage 2005; 29: 489-497
824 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK. Entwicklung von leitlinienbasierten Qualitätsindikatoren Methodenpapier für das Leitlinienprogramm Onkologie, Version 21. 2017. https://www.leitlinienprogramm-onkologie.de/methodik/grundlegende-informationen-zur-methodik
825 Ashoori N, Bamberg F, Paprottka P. et al. Multimodality treatment for early-stage hepatocellular carcinoma: a bridging therapy for liver transplantation. Digestion 2012; 86: 338-348
826 Boteon A, Boteon YL, Vinuela EF. et al. The impact of transarterial chemoembolization induced complications on outcomes after liver transplantation: A propensity-matched study. Clin Transplant 2018; 32: e13255
827 Habibollahi P, Shamchi SP, Choi JM. et al. Association of Complete Radiologic and Pathologic Response following Locoregional Therapy before Liver Transplantation with Long-Term Outcomes of Hepatocellular Carcinoma: A Retrospective Study. J Vasc Interv Radiol 2019; 30: 323-329 https://www.sciencedirect.com/science/article/pii/S105104431831741X?via%3Dihub
828 Lu DS, Yu NC, Raman SS. et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology 2005; 41: 1130-1137
829 Nicolini A, Martinetti L, Crespi S. et al. Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma. J Vasc Interv Radiol 2010; 21: 327-332
830 Sandow T, Pavlus J, Field D. et al. Bridging Hepatocellular Carcinoma to Transplant: Transarterial Chemoembolization Response, Tumor Biology, and Recurrence after Transplantation in a 12-Year Transplant Cohort. J Vasc Interv Radiol 2019; 30: 995-1003
831 Tan CHN, Yu Y, Tan YRN. et al. Bridging therapies to liver transplantation for hepatocellular carcinoma: A bridge to nowhere?. Ann Hepatobiliary Pancreat Surg 2018; 22: 27-35
832 Werner JD, Frangakis C, Ruck JM. et al. Neoadjuvant Transarterial Chemoembolization Improves Survival After Liver Transplant in Patients With Hepatocellular Carcinoma. Exp Clin Transplant 2019; 17: 638-643
833 Sapisochin G, Barry A, Doherty M. et al. Stereotactic body radiotherapy vs TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma An intention-to-treat analysis. J Hepatol 2017; 67: 92-99
834 Wang JH, Wang CC, Hung CH. et al. Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma. J Hepatol 2012; 56: 412-418 https://www.journal-of-hepatology.eu/article/S0168-8278(11)00524-1/fulltext
835 Peng ZW, Lin XJ, Zhang YJ. et al. Radiofrequency ablation versus hepatic resection for the treatment of hepatocellular carcinomas 2 cm or smaller: a retrospective comparative study. Radiology 2012; 262: 1022-1033
836 Hasegawa K, Kokudo N, Makuuchi M. et al. Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey. J Hepatol 2013; 58: 724-729 https://www.sciencedirect.com/science/article/pii/S016882781200877X?via%3Dihub
837 Fang Y, Chen W, Liang X. et al. Comparison of long-term effectiveness and complications of radiofrequency ablation with hepatectomy for small hepatocellular carcinoma. J Gastroenterol Hepatol 2014; 29: 193-200
838 Miura JT, Johnston FM, Tsai S. et al. Surgical resection versus ablation for hepatocellular carcinoma ≤ 3 cm: a population-based analysis. HPB (Oxford) 2015; 17: 896-901 https://www.hpbonline.org/article/S1365-182X(15)31122-9/pdf
839 Zhang M, Ma H, Zhang J. et al. Comparison of microwave ablation and hepatic resection for hepatocellular carcinoma: a meta-analysis. Onco Targets Ther 2017; 10: 4829-4839 https://pubmed.ncbi.nlm.nih.gov/29042794/
840 Zhang QB, Zhang XG, Jiang RD. et al. Microwave ablation versus hepatic resection for the treatment of hepatocellular carcinoma and oesophageal variceal bleeding in cirrhotic patients. Int J Hyperthermia 2017; 33: 255-262
841 Liu PH, Hsu CY, Hsia CY. et al. Surgical Resection Versus Radiofrequency Ablation for Single Hepatocellular Carcinoma ≤ 2 cm in a Propensity Score Model. Ann Surg 2016; 263: 538-545 https://www.ingentaconnect.com/content/wk/sla/2016/00000263/00000003/art00040;jsessionid=1n53m5b4ljd7b.x-ic-live-01
842 Takayasu K, Arii S, Sakamoto M. et al. Impact of resection and ablation for single hypovascular hepatocellular carcinoma ≤2 cm analysed with propensity score weighting. Liver Int 2018; 38: 484-493
843 Hung HH, Chiou YY, Hsia CY. et al. Survival rates are comparable after radiofrequency ablation or surgery in patients with small hepatocellular carcinomas. Clin Gastroenterol Hepatol 2011; 9: 79-86 https://www.cghjournal.org/article/S1542-3565(10)00847-5/pdf
844 Ogihara M, Wong LL, Machi J. Radiofrequency ablation versus surgical resection for single nodule hepatocellular carcinoma: long-term outcomes. HPB (Oxford) 2005; 7: 214-221
845 Lü MD, Kuang M, Liang LJ. et al. [Surgical resection versus percutaneous thermal ablation for early-stage hepatocellular carcinoma: a randomized clinical trial]. Zhonghua Yi Xue Za Zhi 2006; 86: 801-805
846 Lupo L, Panzera P, Giannelli G. et al. Single hepatocellular carcinoma ranging from 3 to 5 cm: radiofrequency ablation or resection?. HPB (Oxford) 2007; 9: 429-434
847 Abu-Hilal M, Primrose JN, Casaril A. et al. Surgical resection versus radiofrequency ablation in the treatment of small unifocal hepatocellular carcinoma. J Gastrointest Surg 2008; 12: 1521-1526
848 Tashiro H, Aikata H, Waki K. et al. Treatment strategy for early hepatocellular carcinomas: comparison of radiofrequency ablation with or without transcatheter arterial chemoembolization and surgical resection. J Surg Oncol 2011; 104: 3-9
849 Kim JW, Shin SS, Kim JK. et al. Radiofrequency ablation combined with transcatheter arterial chemoembolization for the treatment of single hepatocellular carcinoma of 2 to 5 cm in diameter: comparison with surgical resection. Korean J Radiol 2013; 14: 626-635
850 Tang C, Shen J, Feng W. et al. Combination Therapy of Radiofrequency Ablation and Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Retrospective Study. Medicine (Baltimore) 2016; 95: e3754 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902444/pdf/medi-95-e3754.pdf
851 Bholee AK, Peng K, Zhou Z. et al. Radiofrequency ablation combined with transarterial chemoembolization versus hepatectomy for patients with hepatocellular carcinoma within Milan criteria: a retrospective case-control study. Clin Transl Oncol 2017; 19: 844-852
852 Pan T, Mu LW, Wu C. et al. Comparison of Combined Transcatheter Arterial Chemoembolization and CT-guided Radiofrequency Ablation with Surgical Resection in Patients with Hepatocellular Carcinoma within the Up-to-seven Criteria: A Multicenter Case-matched Study. J Cancer 2017; 8: 3506-3513 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687165/pdf/jcav08p3506.pdf
853 Zhang R, Shen L, Zhao L. et al. Combined transarterial chemoembolization and microwave ablation versus transarterial chemoembolization in BCLC stage B hepatocellular carcinoma. Diagn Interv Radiol 2018; 24: 219-224 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6045511/pdf/dir-24-4-219.pdf
854 Lin DY, Liaw YF, Lee TY. et al. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma--a randomized controlled trial. Gastroenterology 1988; 94: 453-456 https://www.sciencedirect.com/science/article/abs/pii/0016508588904362?via%3Dihub
855 Pelletier G, Roche A, Ink O. et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990; 11: 181-184
856 A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995; 332: 1256-1261
857 Bruix J, Llovet JM, Castells A. et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998; 27: 1578-1583
858 Pelletier G, Ducreux M, Gay F. et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial Groupe CHC. J Hepatol 1998; 29: 129-134
859 Stefanini GF, Amorati P, Biselli M. et al. Efficacy of transarterial targeted treatments on survival of patients with hepatocellular carcinoma An Italian experience. Cancer 1995; 75: 2427-2434
860 Bronowicki JP, Vetter D, Dumas F. et al. Transcatheter oily chemoembolization for hepatocellular carcinoma A 4-year study of 127 French patients. Cancer 1994; 74: 16-24
861 Kim JH, Yoon HK, Kim SY. et al. Transcatheter arterial chemoembolization vs chemoinfusion for unresectable hepatocellular carcinoma in patients with major portal vein thrombosis. Aliment Pharmacol Ther 2009; 29: 1291-1298
862 Herber S, Otto G, Schneider J. et al. Transarterial chemoembolization (TACE) for inoperable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol 2007; 30: 1156-1165
863 Chung GE, Lee JH, Kim HY. et al. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology 2011; 258: 627-634
864 Georgiades CS, Hong K, D’Angelo M. et al. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2005; 16: 1653-1659 https://www.sciencedirect.com/science/article/pii/S1051044307607933?via%3Dihub
865 Okazaki M, Higashihara H, Koganemaru H. et al. Transcatheter arterial embolization for inoperable hepatocellular carcinoma. Jpn J Clin Radiol 1991; 36: 535-539
866 Sacco R, Bargellini I, Bertini M. et al. Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol 2011; 22: 1545-1552
867 van Malenstein H, Maleux G, Vandecaveye V. et al. A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma. Onkologie 2011; 34: 368-376 https://www.karger.com/Article/Pdf/329602
868 Dhanasekaran R, Kooby DA, Staley CA. et al. Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC). J Surg Oncol 2010; 101: 476-480
869 Ferrer Puchol MD, la Parra C, Esteban E. et al. [Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma]. Radiologia 2011; 53: 246-253 https://www.sciencedirect.com/science/article/abs/pii/S0033833810003449?via%3Dihub
870 Wiggermann P, Sieron D, Brosche C. et al. Transarterial Chemoembolization of Child-A hepatocellular carcinoma: drug-eluting bead TACE (DEB TACE) vs TACE with cisplatin/lipiodol (cTACE). Med Sci Monit 2011; 17: Cr189-Cr195 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539521/pdf/medscimonit-17-4-cr189.pdf
871 Song MJ, Chun HJ, Song DS. et al. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol 2012; 57: 1244-1250
872 Megías Vericat JE, García Marcos R, López Briz E. et al. Trans-arterial chemoembolization with doxorubicin-eluting particles versus conventional trans-arterial chemoembolization in unresectable hepatocellular carcinoma: A study of effectiveness, safety and costs. Radiologia 2015; 57: 496-504 https://www.sciencedirect.com/science/article/abs/pii/S0033833815000764?via%3Dihub
873 Kloeckner R, Weinmann A, Prinz F. et al. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma. BMC Cancer 2015; 15: 465 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4460638/pdf/12885_2015_Article_1480.pdf
874 Facciorusso A, Mariani L, Sposito C. et al. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Gastroenterol Hepatol 2016; 31: 645-653
875 Baur J, Ritter CO, Germer CT. et al. Transarterial chemoembolization with drug-eluting beads versus conventional transarterial chemoembolization in locally advanced hepatocellular carcinoma. Hepat Med 2016; 8: 69-74 https://pubmed.ncbi.nlm.nih.gov/27382341/
876 Gao S, Yang Z, Zheng Z. et al. Doxorubicin-eluting bead versus conventional TACE for unresectable hepatocellular carcinoma: a meta-analysis. Hepatogastroenterology 2013; 60: 813-820
877 Huang K, Zhou Q, Wang R. et al. Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 2014; 29: 920-925
878 Zhou X, Tang Z, Wang J. et al. Doxorubicin-eluting beads versus conventional transarterialchemoembolization for the treatment of hepatocellular carcinoma: a meta-analysis. Int J Clin Exp Med 2014; 7: 3892-3903
879 Zou JH, Zhang L, Ren ZG. et al. Efficacy and safety of cTACE versus DEB-TACE in patients with hepatocellular carcinoma: a meta-analysis. J Dig Dis 2016; 17: 510-517
880 Facciorusso A, Di Maso M, Muscatiello N. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: A meta-analysis. Dig Liver Dis 2016; 48: 571-577
881 Chiesa C, Maccauro M, Romito R. et al. Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with (90)Y microspheres: the experience of the National Tumor Institute of Milan. Q J Nucl Med Mol Imaging 2011; 55 (02) 168-197 https://pubmed.ncbi.nlm.nih.gov/21386789/
882 Garin E, Lenoir L, Rolland Y. et al. Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results. J Nucl Med 2012; 53 (02) 255-263 https://pubmed.ncbi.nlm.nih.gov/22302962/
883 Garin E, Rolland Y, Pracht M. et al. High impact of macroaggregated albumin-based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with. Liver Int 2017; 37 (01) 101-110 https://pubmed.ncbi.nlm.nih.gov/27514012/
884 Kappadath S, Mikell J, Balagopal A. et al. Hepatocellular Carcinoma Tumor Dose Response After. Int J Radiat Oncol Biol Phys 2018; 102 (02) 451-461 https://pubmed.ncbi.nlm.nih.gov/30191875/
885 Chan K, Alessio A, Johnson G. et al. Prospective Trial Using Internal Pair-Production Positron Emission Tomography to Establish the Yttrium-90 Radioembolization Dose Required for Response of Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys 2018; 101 (02) 358-365 https://pubmed.ncbi.nlm.nih.gov/29559288/
886 d’Abadie P, Walrand S, Hesse M. et al. Prediction of tumor response and patient outcome after radioembolization of hepatocellular carcinoma using 90Y-PET-computed tomography dosimetry. Nucl Med Commun 2021; 42 (07) 747-754 https://pubmed.ncbi.nlm.nih.gov/33741864/
887 Nodari G, Popoff R, Riedinger J. et al. Impact of contouring methods on pre-treatment and post-treatment dosimetry for the prediction of tumor control and survival in HCC patients treated with selective internal radiation therapy. EJNMMI Res 2021; 11 (01) 24 https://pubmed.ncbi.nlm.nih.gov/33687596/
888 Allimant C, Kafrouni M, Delicque J. et al. Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma. J Vasc Interv Radiol 2018; 29 (12) 1662-1670.e4 https://pubmed.ncbi.nlm.nih.gov/30217745/
889 Hermann A, Dieudonné A, Ronot M. et al. Relationship of Tumor Radiation-absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with. Radiology 2020; 296 (03) 673-684 https://pubmed.ncbi.nlm.nih.gov/32602828/
890 Son M, Ha L, Bang M. et al. Diagnostic and prognostic value of. Sci Rep 2021; 11 (01) 3207 https://pubmed.ncbi.nlm.nih.gov/33547398/
891 Celotti A, Solaini L, Montori G. et al. Preoperative biliary drainage in hilar cholangiocarcinoma: Systematic review and meta-analysis. Eur J Surg Oncol 2017; 43: 1628-1635
892 Ramanathan R, Borrebach J, Tohme S. et al. Preoperative Biliary Drainage Is Associated with Increased Complications After Liver Resection for Proximal Cholangiocarcinoma. J Gastrointest Surg 2018; 22: 1950-1957
893 Cai Y, Tang Q, Xiong X. et al. Preoperative biliary drainage versus direct surgery for perihilar cholangiocarcinoma: A retrospective study at a single center. Biosci Trends 2017; 11: 319-325 https://www.jstage.jst.go.jp/article/bst/11/3/11_2017.01107/_pdf
894 Farges O, Regimbeau JM, Fuks D. et al. Multicentre European study of preoperative biliary drainage for hilar cholangiocarcinoma. Br J Surg 2013; 100: 274-283
895 Xiong JJ, Nunes QM, Huang W. et al. Preoperative biliary drainage in patients with hilar cholangiocarcinoma undergoing major hepatectomy. World J Gastroenterol 2013; 19: 8731-8739 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3870521/pdf/WJG-19-8731.pdf
896 Wang L, Lin N, Xin F. et al. A systematic review of the comparison of the incidence of seeding metastasis between endoscopic biliary drainage and percutaneous transhepatic biliary drainage for resectable malignant biliary obstruction. World J Surg Oncol 2019; 17: 116 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6612106/pdf/12957_2019_Article_1656.pdf
897 Kishi Y, Shimada K, Nara S. et al. The type of preoperative biliary drainage predicts short-term outcome after major hepatectomy. Langenbecks Arch Surg 2016; 401: 503-511
898 Sangchan A, Kongkasame W, Pugkhem A. et al. Efficacy of metal and plastic stents in unresectable complex hilar cholangiocarcinoma: a randomized controlled trial. Gastrointest Endosc 2012; 76: 93-99